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Abstract 
Alzheimer’s disease (AD) is a progressive neurodegenerative disease, characterised by memory loss 
and cognitive decline. No cure has been found for the disease yet, therefore the development of 
disease-modifying therapeutics (DMTs), which can target the underlying mechanisms of AD, is 
necessary. Glycogen synthase kinase 3 (GSK-3) has become a promising CNS target, since GSK-3 
dysregulation has been shown to play a central role in the multifactorial neuropathogenesis of AD. 
In this project, a proposed library of structurally-related, irreversible GSK-3β inhibitors was modelled, 
synthesised, characterised and biologically tested as potential AD drug candidates. The library 
contained two sets of 1-aryl-3-(4-methoxybenzyl)ureas wherein the incorporated aryl group was a 
benzothiazole or benzimidazole scaffold, respectively. Different electrophilic warheads were 
incorporated onto the scaffolds, with the potential to form a covalent, irreversible bond with 
nucleophilic Cys199 in the GSK-3 ATP pocket. Targeting of Cys199 was suggested to provide increased 
GSK-3 selectivity, since Cys199 is exchanged with other amino acids in structurally-related enzymes. 
A library of 10 covalent inhibitors containing the nitrile, halomethylketone (HMK), vinyl ketone, 
ethynyl ketone and acrylamide electrophilic warheads was successfully synthesised, as well as the 
reference GSK-3 inhibitor, AR-A014418 (AstraZeneca). The synthetic route commenced with the 
preparation of the 6-substituted 2-aminobenzothiazoles and 6-substituted 2-aminobenzimidazoles in 
good yields. Thereafter, the scaffolds were coupled to 4-methoxybenzylamine through 
carbonyldiimidazole-mediated urea formation, which afforded excellent yields for the benzothiazoles 
and moderate yields for the benzimidazoles, proposedly due to tautomeric effects in the latter. These 
ureas were further modified in position 6 of the benzazole scaffolds, to incorporate the respective 
electrophilic warheads. 
The GSK-3β inhibitory activity results were promising, with high activities measured for the nitrile-
substituted ureas and the HMK-substituted benzimidazole urea. In comparison to the reference GSK-3 
inhibitor, which displayed an IC50 value of 0.072 ± 0.043 μM in the assay, the best IC50 value obtained 
in the library was 0.086 ± 0.023 μM, observed for 1-(6-cyano-1H-benzo[d]imidazol-2-yl)-3-(4-
methoxybenzyl)urea. In general, the benzimidazole series displayed better IC50 values than the 
equivalent inhibitors in the benzothiazole series. Although an initial assay was carried out to ascertain 
whether the newly synthesised inhibitors were in fact irreversible inhibitors, the results remain 
ambiguous and further study is required to confirm this hypothesis. 
In conclusion, highly active GSK-3β inhibitors were successfully developed and may potentially 
contribute to future AD drug development. 
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Uittreksel 
Alzheimersiekte (AD) is ‘n progressiewe neurodegenerasiesiekte, gekenmerk deur geheueverlies en 
kognitiewe kwyning. Daar is tans geen geneesmiddel beskikbaar vir die siekte nie, daarom is die 
ontwikkeling van siekte-wysigingsmiddels, wat instaat is om die onderliggende siekteverwekkende 
meganismes van AD te teiken, noodsaaklik. Die glikogeen sintase kinase 3 (GSK-3) ensiem is ‘n 
belowende teiken in die sentrale senuweestelsel, aangesien daar getoon is dat abnormale GSK-3 
vlakke bydra tot veelvoudige faktore in die neuropatogenese van AD. 
In hierdie projek is ‘n versameling van struktuurverwante, onomkeerbare GSK-3β inhibeerders 
voorgestel, waarna dit gemoduleer, gesintetiseer en biologies getoets is as potentiële AD 
geneesmiddelkandidate. Die versameling het bestaan uit twee stelle 1-ariel-3-(4-
metoksibensiel)ureumverbindings, waarin die arielgroep onderskeidelik ‘n bensotiasool- of 
bensimidasool-struktuur verteenwoordig het. Hierdie sentrale strukture is elk aangepas met ‘n 
verskillende elektrofiliese reaktiewe groep, aangesien hierdie substituent potensieel ‘n kovalente, 
onomkeerbare binding met sisteïen 199 (Cys199) in die ATP bindingsetel van GSK-3 kan vorm. Cys199 
word vervang met ander aminosure in struktuurverwante ensieme, daarom kan ‘n kovalente binding 
met Cys199 moontlik die selektiwiteit van die GSK-3 inhibeerders verbeter. 
‘n Versameling van 10 kovalente inhibeerders, met onderskeidelik die nitriel, halometielketoon 
(HMK), vinielketoon, etenielketoon en akrielamied elektrofiliese reaktiewe groepe, is suksesvol 
gesintetiseer, asook die kontrole GSK-3 inhibeerder, AR-A014418 (AstraZeneca). Die sintesepad het ‘n 
aanvang geneem met bereiding van die 6-gesubstitueerde 2-aminobensotiasool- en 
6-gesubstitueerde 2-aminobensimidasool-verbindings, met goeie opbrengste. Hierdie verbindings is
daarna gekoppel aan 4-metoksibensielamien met behulp van karbonieldiimidasool, om die 
bensotiasool-ureumverbindings te vorm met puik opbrengste. Die opbrengste van die bensimidasool-
ureumverbindings was gematig, moontlik a.g.v. toutomeriese effekte. Die ureumverbindings is verder 
aangepas by posisie 6 van die bensasool-basisstruktuur, om sodoende die relevante elektrofiliese 
reaktiewe groepe te koppel. 
GSK-3β inhiberingsaktiwiteit resultate was belowend en die beste aktiwiteit is gemeet vir die nitriel-
gesubstitueerde ureumverbindings en die HMK-gesubstitueerde bensimidasool-ureumverbinding. Die 
aktiefste inhibeerder was 1-(6-siano-1H-benso[d]imidasol-2-iel)-3-(4-metoksibensiel)ureum, met ‘n 
IC50 waarde van 0.086 ± 0.023 μM. Hierdie waarde het ook goed vergelyk met die aktiwiteit van die 
kontrole GSK-3 inhibeerder (IC50 waarde = 0.072 ± 0.043 μM). Die bensimidasool reeks het oor die 
algemeen better IC50 waardes vertoon as ooreenstemmende inhibeerders in die bensotiasool reeks. 
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Alhoewel ‘n aanvanklike ensiemtoets uitgevoer is om die onomkeerbare bindingsmeganisme van die 
nuut-gesintetiseerde inhibeerders te bevestig, was die resultate van die kontrole GSK-3 inhibeerder 
onverklaarbaar en word verdere navorsing benodig om hierdie hipotese te bevestig. 
Ten slotte, hoogs aktiewe GSK-3β inhibeerders is suksevol ontwerp en kan potensieel bydra tot 
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Chapter 1: The pathogenesis of Alzheimer’s disease and the search for 
drug therapies 
1.1 Introduction: Alzheimer’s Disease 
Alzheimer’s disease (AD) is the most prevalent form of dementia and has been proposed to contribute 
to 60 – 70% of dementia cases.1 Other forms of dementia include frontotemporal dementia, dementia 
with Lewy bodies, vascular dementia and dementia due to Parkinson’s disease.2 Dementia is a 
syndrome caused by chronic or progressive disease in the brain, which impairs memory, as well as one 
or more domains of cognitive functioning, such as comprehension, language, judgement, personality 
and orientation. These impairments are often accompanied by a decline in emotional and behavioural 
control. As a result, a patient’s level of functioning and ability to perform daily activities are 
decreased.2,3 
As the predominant form of dementia, AD is thus defined as a progressive neurodegenerative disease 
with clinical symptoms of memory loss and cognitive decline, which is characterised at the molecular 
level by deposits of intracellular neurofibrillary tangles (NFTs) and extracellular β-amyloid (Aβ) plaques 
(insoluble proteins) in the brain.4 The pathogenesis of the disease results in a loss of neurons and 
neuronal processes in, primarily, the cortical regions of the brain, which results in a decreased brain 
volume.5,6 Within only a few years, AD patients can no longer function independently, creating great 
challenges and suffering for the AD individuals, as well as their families. 
AD is a global challenge in terms of health care and is associated with enormous societal costs. The 
global impact of dementia was analysed by Alzheimer’s Disease International in the World Alzheimer 
Report of 2015.7 In 2015, 46.8 million people were estimated to live with dementia globally, of which 
4 million people were living in Africa. The total economic cost of dementia worldwide was estimated 
to amount to US $818 billion. Currently there is no cure for AD and other forms of dementia, and the 
number of dementia cases has been estimated to increase to 74.7 million by 2030.7 Due to the global 
effect of dementia on patients, family members, care-givers, health systems and the economy, 
dementia has been declared a public health priority by the World Health Organisation.1 As a result, 
research on dementia and AD has also been prioritised. 
In order to develop potential drug therapies for AD – which can either prevent the onset of AD, delay 
the progression of the disease or act as curative treatment – the possible causes of AD have been 
explored, based on the associated molecular mechanisms and neuropathological hallmarks of the 
disease. 
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1.2 The main neuropathological hallmarks of the disease 
The characteristic neuropathological hallmarks of AD have been well defined by histopathological 
examinations of the AD brain, at autopsy. On an anatomical level, cerebral atrophy as a result of 
neuronal loss, as well as the loss of synapses and dendritic spines (responsible for signal transduction), 
have been observed.5 At the microscopic level, the main neuropathological hallmarks of AD are the 
deposits of intracellular neurofibrillary tangles (NFTs) and extracellular β-amyloid (Aβ) plaques.4 It is 
the accumulation of these deposits which damages neurons, leads to synaptic dysfunctions, and in the 
case of Aβ plaques, also promotes local microglial- and astrocyte-mediated inflammation which can 
result in the further degeneration of neurons.8,9 
1.2.1 Extracellular β-amyloid plaques 
The extracellular β-amyloid plaques consist of aggregated Aβ peptides (38 – 43 amino acids), which 
are formed by the proteolytic cleavage of β-amyloid precursor protein (APP).10 APP is a type-1 
transmembrane glycoprotein expressed in many peripheral organs. In the brain, APP and its cleaved 
products have shown to contribute to neurogenesis, plasticity, synaptic function, lipid homeostasis 
and cellular stress response.11 
 
Figure 1.1: Aβ peptides are generated when APP is cleaved by β-secretases and ƴ-secretases in the 
amyloidogenic pathway. Aβ peptides aggregate to form β amyloid plaques. In the non-
amyloidogenic pathway, α-secretases cleave the Aβ sequence (figure obtained from Chow et al.10). 
PM: plasma membrane; ex: extracellular; cyt: cytosol; LTP: Long-term potentiation; 
CTF 83/p3/AICD50/CTF 99/CTF 89: C-terminal fragments; sAPPα/sAPPβ: N-terminal fragments. 
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APP processing can follow either the amyloidogenic or non-amyloidogenic pathway (Figure 1.1). The 
canonical amyloidogenic pathway (that is, β-amyloid plaque producing) leads to Aβ peptide formation 
and in this pathway, β-secretases and ƴ-secretases are responsible for proteolytic cleavage.11 The 
nonamyloidogenic (non-Aβ-producing) pathway involves cleavage of APP by the α-secretase enzyme. 
The cleavage site of this enzyme is located within the Aβ sequence of the APP protein, and as a result 
cleavage by α-secretase will prevent the formation of Aβ peptides.10 
β-site APP-cleaving enzyme 1 (BACE 1) is the prime enzyme responsible for β-secretase activity in the 
amyloidogenic pathway.12 BACE 1 reaches the plasma membrane (where the transmembrane protein, 
APP, is located) by trafficking in endocytic pathways, but is recycled rapidly, thereby limiting BACE 1 
activity with APP at the plasma membrane.10 Of additional interest is that the activity of the BACE 1 
enzyme is promoted by the low pH in endosomes and intracellular compartments.12  
Thus, the amyloidogenic pathway commences primarily with the internalisation of the APP protein 
into an endosome. In early endosomes, APP is cleaved by β-secretases to release a soluble amino-
terminal fragment, sAPPβ, and a C-terminal fragment (CTFβ), either CTF99 or CTF89, depending on 
the cleavage site.10 sAPPβ can be reinserted into the plasma membrane by endosome recycling, 
whereas CTFβ is internalised further to late endosomes, lysosomes, the trans-Golgi network, 
endoplasmic reticulum (ER) and multivesicular bodies (MVBs). ƴ-Secretases are active in these 
compartments, with high activity in especially the trans-Golgi network and the mitochondria-
associated endoplasmic reticulum membrane.11 CTFβ is cleaved by ƴ-secretases via endoproteolytic 
ε-cuts, to form Aβ49 and Aβ48 peptides. These peptides are then sequentially trimmed by 
ƴ-secretases to generate Aβ peptides ranging from 38 to 43 residues in length (Figure 1.2).13 
Thereafter, the Aβ peptides are transported into the extracellular space by exocytosis, where 
accumulated Aβ peptides may aggregate to form Aβ oligomers and amyloid plaques.11 
 
Figure 1.2: ƴ-Secretases initially cleave CTFβ at the ε-sites to form the Aβ49 and Aβ48 species. 
Sequential trimming by ƴ-secretase produces shorter Aβ peptides, such as Aβ40, Aβ38, and Aβ42 
(figure obtained from Andrew et al.14). 
Unfortunately, the understanding of APP processing pathways in neurodegeneration and β-amyloid 
plaque formation is complicated by the subcellular localization of enzyme processes, the activities of 
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APP metabolites and the alternative substrates of APP-cleaving enzymes.10 Furthermore, Aβ peptides 
are subjected to post-translational modifications, which can change the toxicity, fibril-forming and 
oligomerisation properties of the Aβ peptide.11 Also, the complexity of the accepted model of APP 
proteolytic cleavage has increased due to the discovery of novel noncanonical APP enzymes, 
δ-secretase, η-secretase, meprin-β and cathepsin B, which can also partake in proteolytic cleavage of 
APP to produce potentially toxic metabolites in the brain.14 
1.2.1.1 The link between Aβ peptides and neurotoxic effects 
The normal amyloidogenic APP pathway produces predominantly Aβ40 peptides (~ 90%), together 
with Aβ42 (~ 5 – 10%) and other minor Aβ species.15 The Aβ40 peptides have been proposed to be 
less amyloidogenic than Aβ42, Aβ43, and longer Aβ peptides, which are more hydrophobic and highly 
self-aggregating.13 Indeed, increased extracellular concentrations of Aβ42 have been shown to 
promote amyloid deposition, whereas high levels of Aβ40 have demonstrated to inhibit Aβ 
deposition.15,16 Thus, increased ratios of Aβ42 and highly self-aggregating Aβ peptides relative to Aβ40, 
result in amyloid plaque formation and neurotoxicity.13 
Several types of Aβ peptide assemblies have been identified in the human brain, referred to as amyloid 
plaques (aggregates of amyloid fibrils) and Aβ oligomers (e.g. dimers, trimers, dodecamers).11 In the 
literature, Aβ oligomers have been described to be more neurotoxic than amyloid plaques.17 Soluble 
Aβ oligomers that are not confined to amyloid plaque surfaces, are able to disperse into brain tissue, 
where it can exhibit high levels of neurotoxicity by impairment of synaptic functions and synaptic 
structures.13,17 
In general, many studies have provided evidence that increased production of neurotoxic Aβ peptides 
or failure in Aβ peptide clearance mechanisms, can lead to oligomerisation and amyloid plaque 
formation.13 
1.2.2 Intracellular neurofibrillary tangles 
The presence of intracellular neurofibrillary tangles (NFTs) is the other major neuropathological 
hallmark associated with AD. NFTs are formed when tau proteins are hyperphosphorylated. Tau 
proteins are microtubule-associated proteins (MAP) and associate via certain sequence motifs to 
tubulin in order to stabilise cytoskeletal microtubules in central nervous system (CNS) nerve cells. 
When tau proteins are hyperphosphorylated, tau-microtubule associations are disrupted, which result 
in the detachment of tau proteins and microtubule degeneration. The tau proteins then pair up with 
other threads of tau protein to form paired helical filaments (PHFs) and straight filaments (SFs), which 
accumulate to form insoluble tangles inside the affected cell.18,19 
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Tau proteins are generally axonal proteins, i.e. proteins that stabilise microtubules in the axon of the 
neuron. However, the hyperphosphorylation of tau proteins results in the movement of detached tau 
proteins from the axon to the somatodendritic compartment of the neuron, where the tangles 
accumulate and deposit as insoluble aggregates (Figure 1.3).11 These abnormal deposits in the 
somatodendritic compartment disrupt neuronal communication and vital physiological functions, by 
sequestering stabilising proteins and obstructing other proteins, such as kinesins and dynamins, which 
are responsible for neuronal transport.11 General cytoskeletal dysfunction takes place, due to 
microtubule degeneration and microtubule transport inhibition, which impedes the transport of 
organelles and endocytic vesicles.20 
 
Figure 1.3: The hyperphosphorylation of tau proteins results in NFT assembly. A: CNS neuron, B: 
Tau proteins stabilise axonal microtubules, C: Hyperphosphorylation of tau protein by a protein 
kinase, e.g. GSK-3β., D: Hyperphosphorylated tau detaches from the microtubule, causing 
microtubule degeneration, E: Tau proteins pair-up, tangle together and aggregate, F: The insoluble 
NFTs accumulate in the somatodendritic compartment of the neuron (Figure is reproduced from 
Dubey et al.21). 
In vivo studies have also suggested that soluble tau oligomers, which precede NFTs, are neurotoxic, 
and that they contribute to synaptic and mitochondrial dysfunction, as well as memory loss, before 
they aggregate into fibrils to form NFTs.22 Fibril formation is characterised by an increase in β-sheet 
structure, in contrast to tau proteins which are soluble, natively unfolded proteins with limited 
secondary structure.23 
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Although tau is principally known to become dysfunctional by hyperphosphorylation, abnormal post-
translational modifications such as acetylation, carboxy-terminal truncation by caspase 3, and 
N-glycosylation have also been reported to result in tau aggregation.19,20 These post-translational 
events were identified by the comparison of tau proteins from the brains of AD patients and 
cognitively-healthy elderly persons.20 
Tau phosphorylation is one of the earliest modifications that occur in the AD brain.19,24 Braak and Braak 
performed a study in which the six well-defined stages of NFT and neuropil thread deposition were 
observed.25 The deposits resulted in an increase in cortical destruction, which was mirrored by a 
worsening in clinical AD symptoms.6 Stages I – II corresponded to pathological changes in the 
transentorhinal region of the brain, and these stages developed preferentially in the absence of Aβ 
deposits.24 Stages III – IV entailed the distribution of the tangles into both the entorhinal and 
transentorhinal regions, whereas stages V – VI were characterised by isocortical destruction.6 In 
contrast, a corresponding study on the stages of β-amyloid plaque deposition depicted an inconsistent 
relationship between the number of amyloid deposits and clinical severity.6 
 
Figure 1.4: Tangle distribution during different stages of continual AD progression (image obtained 
from Braak and Braak.25) 
The characteristic pattern of tau pathology and its correlation with clinical symptoms in AD, have thus 
made NFTs an important hallmark of the disease. 
1.2.3 Translating neuropathological hallmarks to the molecular mechanism of AD 
The underlying mechanisms and factors which induce the accumulation of extracellular and 
intracellular fibrillary proteins in AD are not fully understood.8 Multiple factors, including aging, 
genetic factors, chemical factors, infectious agents, vascular disturbances, pre-existing syndromes, 
immune system dysfunctions, mitochondrial dysfunctions, nerve growth factor disruptions and other 
environmental factors have been hypothesised to induce pathways leading to Aβ peptide production, 
amyloid deposits and NFT formation.8,26 
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1.3 Risk factors for AD 
The cause of AD is multifactorial and has been proposed to be influenced by a complex combination 
of several genetic, epigenetic and environmental factors. Aging is the predominant risk factor for AD, 
while numerous environmental factors have also been proposed to contribute to late-onset AD, 
including head injury, diabetes, obesity, hyperlipidemia, hypertension and low education levels.5 
Early-onset AD is found in only 1 – 5% of AD patients and refers to the clinically observable onset of 
AD disease in an adult before the age of 65.27,28 This type of AD is often found in patients with a family 
history of AD, Down’s syndrome or lymphoma, and the disease progress is relatively rapid. In contrast, 
AD with a late onset refers to the beginning of the disease after the age of 65. Usually, the disease 
only commences in the late 70s or thereafter, and deterioration usually takes place slower.3 More 
than 95% of AD cases have a late onset and therefore support aging as a major risk factor.27 
1.3.1 Genetic aspects in early-onset AD 
92 – 100% of early-onset AD cases are inherited (familial AD), but only approximately 10% of these 
early-onset AD cases (that is <1% of all early- and late-onset cases) could be directly linked to 
autosomal dominant inheritance due to mutations in the APP, presenilin-1 (PS-1) and presenilin-2 
(PS-2) genes.28,29 AD-causative mutations in the APP gene, and the location of the APP gene on 
chromosome 21, furthermore explained the high incidence of AD-like brain pathology detected in 
aged Down syndrome patients with a trisomy 21.28 The PS-1 gene located on chromosome 14 displays 
the highest mutation frequency, and more than 100 mutations have been identified in this gene.27 The 
PS-2 gene is located on chromosome 1 and mutations in this gene are more rare. PS-1 and PS-2 
mutations result in aberrant ƴ-secretase activity, which activates the amyloidogenic APP processing 
pathway, resulting in increased levels of neurotoxic Aβ42 peptides.28 The rest of the early-onset AD 
cases are genetically unexplained and could potentially be connected to epigenetic dysregulations and 
undetected genetic alterations.30 
1.3.2 Genetic and non-genetic aspects in late-onset AD 
Late-onset AD (>95% of AD cases) has a complex etiology, which has been linked to genetic and 
non-genetic factors. Late-onset AD has been found to have a highly polygenic mechanism of 
inheritance, with a heritability of approximately 70%.29 Wingo and co-workers29 also found that 
heritability decreases with age of AD onset, implying that AD onset at older ages correlates more 
strongly to non-genetic environmental causes.29 
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Risks for sporadic forms of AD (i.e. with no family history) have been connected to aging, the presence 
of apolipoprotein E4 (apoE4), vascular disturbances and environmental/lifestyle factors. 
ApoE is a polymorphic protein, with three common alleles—apoE2, apoE3 and apoE4—which can 
occupy the gene’s locus. It has been estimated that individuals with two copies of the apoE4 allele 
(homozygotes) have a ~60% risk of developing AD by the age of 85, whereas the chance is reduced to 
~30% for apoE4 heterozygotic individuals.5 ApoE4 proteins decrease Aβ clearance, thereby increasing 
amyloid deposition. Furthermore, it has been suggested that brain stress responses and injuries can 
amplify neuronal apoE production, to induce repair and remodelling. The process also involves 
proteolytic cleavage; however, apoE4 species are more susceptible to truncation than apoE3. Thus, in 
individuals with apoE4, high levels of neurotoxic apoE4 fragments are produced. These apoE4 
fragments have been connected to tau pathology and mitochondrial dysfunction.5 
A third of AD cases worldwide can be related to vascular disturbances and environmental/lifestyle 
factors.31 These factors often co-exist with genetic factors across the life-span, thereby increasing AD 
risk. Vascular disturbances and environmental/lifestyle factors are considered modifiable risk factors, 
which can be altered through lifestyle changes or pharmacological treatment.32 Major protective 
factors which may reduce AD risk, include education, physical activity, improved socioeconomic 
factors, diet and medical care. Ultimately, the interplay of risk factors and protective factors impacts 
the overall risk for late-onset AD (Figure 1.5).32 
 
Figure 1.5: Major vascular and lifestyle-related risk factors, as well as protective factors across the 
lifespan, associated with late-onset AD  (figure obtained from Sindi et al.32). 
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1.4 Therapeutic drug developments: Major strategies 
The neuropathology of the AD brain and the links between risk factors and AD pathogenesis, had led 
to several hypotheses for the origin and mechanism of AD development, which have influenced the 
choice of drug targets and the design of novel drug candidates in therapeutic drug development. No 
curative treatment has been found for the disease yet and no new drugs have been approved for AD 
treatment since 2003, making drug development for AD a priority.33 Next, the major areas for 
therapeutic development over the past years will be discussed. 
1.4.1 Cholinergic drug therapies 
From AD neuropathological findings, the cholinergic hypothesis was the first to emerge (1976) and 
was based on the early loss of cholinergic neurons in the basal forebrain of AD patients.34,35 Cholinergic 
neurons use the neurotransmitter, acetylcholine, to transmit chemical signals. Thus, the loss of 
cholinergic neurons and the deficiency in acetylcholine decrease neurotransmittance and result in 
cognitive decline and memory impairment.36 Drug development following the cholinergic hypothesis 
focused firstly on acetylcholinesterase (AChE) inhibitors, and secondly on the design of acetylcholine-
receptor agonists. AChE inhibitors can reduce the normal levels of acetylcholine cleavage by AChE in 
the synaptic space, thereby resulting in enhanced acetylcholine response. Alternatively, acetylcholine-
receptor agonists can enhance acetylcholine responses in postsynaptic neurons, thereby accounting 
for lowered levels of acetylcholine.37 
1.4.1.1 AChE inhibitors 
Four AChE inhibitors (Donepezil, Rivastigmine, Galantamine and Huperzine-A) have been successfully 
developed and clinically approved, but these cholinergic drugs are symptomatic therapeutics and 
result temporarily in slight cognitive and behavioural enhancement (Figure 1.6).34 Initially, tacrine 
(1993) was the first AChE inhibitor to be FDA approved; however, the drug was soon withdrawn from 
the market due to liver toxicity. Apart from low organ specificity, the first generation AChE inhibitors 
lacked selectivity for acetylcholine — they also inhibited butyrylcholinesterase (BuChE). Therefore, the 
second generation AChE inhibitors (incl. Donepezil, Galantamine, Huperzine-A) were focused mainly 
on improving AChE selectivity.8 Rivastigmine, notably, inhibits both AChE and BuChE, but specifically 
in brain tissue. The drug’s slowly reversible (pseudo-irreversible) binding mode inactivates the 
enzymes for a prolonged time, which allowed Rivastigmine to have a low protein-binding profile (low 
risk).38 Octohydroaminoacridine succinate is another example of an AChE inhibitor and is currently in 
phase III trials (Figure 1.6).33,39 




Figure 1.6: The structures of the discussed AChE inhibitors.8,39 Donepezil, Rivastigmine, 
Galantamine and Huperzine-A are clinically approved symptomatic treatments. 
Although the drugs following the cholinergic hypothesis are symptomatic therapeutics, drug 
development in this pipeline is still ongoing, in order to provide more effective symptomatic 
treatments to the more than 15 million people already affected by AD worldwide, especially for 
patients in the moderate to advanced stages of the disease.33 As mentioned, drug development based 
on the loss of cholinergic neurotransmission has not only been focused on AChE inhibitors, but also 
the design of acetylcholine-receptor agonists (activators) and 5-HT6/H3 receptor antagonists (which 
block or reduce response). 
1.4.1.2 Acetylcholine-receptor agonists 
The activation of muscarinic and nicotinic acetylcholine-receptors has been proposed to enhance 
levels of acetylcholine response, which may temporarily improve cognition and memory. M1 
muscarinic acetylcholine-receptor modulators in phase II and III clinical trials have displayed promising 
efficacy in cognition, but presented acute adverse effects including gastrointestinal symptoms, 
increased salivary flow, sweating and frequent urination, which generally limited the success of these 
compounds.40 Nicotinic acetylcholine-receptor agonists also resulted in cognitive enhancement, but 
of even greater interest was that in vivo studies demonstrated that nicotinic acetylcholine-receptors 
were also involved in positive Aβ detoxification mechanisms, making it a more attractive 
pharmacological target. The nicotinic receptors act as carrier proteins in the binding of extracellular 
Aβ, to facilitate autophagic degradation and to reduce Aβ neurotoxicity.41 Encenicline (EVP-6124) and 
Ispronicline (AZD-3480) are examples of nicotinic receptor agonists which had reached phase III and 
phase II trials, respectively (Figure 1.7).8,42 However, trials on Encenicline were paused due to serious 
gastrointestinal side effects.8 Ispronicline is also no longer in clinical trials, and the recent clinical 
results are not yet available. 




Figure 1.7: The structures of selected acetylcholine receptor agonists and 5-HT6/H3/NMDA 
receptor antagonists.8,42–45 
1.4.1.3 5-HT6/H3 receptor antagonists 
Serotonin (5-hydroxytryptamine, 5-HT) is involved in the regulation of multiple signalling pathways, 
with the serotonergic neuron network distributed throughout almost all the brain structures. 
Imbalanced serotonergic signalling has been related to AD, and the 5-HT6 receptor subtype is 
specifically involved in memory and cognition.8 Furthermore, blockage of the 5-HT6 receptors 
enhances cholinergic transmission and several 5-HT6 receptor antagonists have been included in 
clinical trials.37 In 2017, Idalopirdine (Lu AE58054) and Intepirdine (RVT-101) failed in phase III trials 
due to primary efficacy endpoints that were not met, despite the promising efficacy and safety results 
in phase II (Figure 1.7).33,37,43,44 SUVN-502 is another potent, selective and orally active antagonist 
currently in phase II clinical trials.8,33,45 
Histamine H3 receptors are expressed mainly in the CNS, and the blockage of these receptors 
enhances presynaptic release of histamine and other neurotransmitters such as acetylcholine.37 
Needless to say, H3 receptor antagonists were developed and included into clinical trials. 
1.4.2 Glutamatergic neurotransmission 
Aberrant stimulation of N-methyl-D-aspartate (NMDA) glutamate receptors, which are a major class 
of receptors in the mammalian brain, results in increased concentrations of intracellular Ca2+ which 
can be excitotoxic to neurons. The degeneration of glutamatergic pathways early in AD was confirmed 
by neuropathological and neurochemical studies, and follow a pattern that corresponds to the 
deposition of β-amyloid plaques and NFTs.46 Memantine is the only NMDA antagonist on the market 
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and is the most recently (2003) FDA approved AD drug (Figure 1.7). Memantine provides temporary 
improvements in cognition, behaviour and functional state in AD patients with moderate to severe 
AD.8,34 
1.4.3 Moving from symptomatic treatments to disease-modifying therapeutics 
The palliative nature of drugs developed alongside the cholinergic hypothesis and glutamatergic 
neurotransmission theory necessitated a re-assessment of the hypothesis of AD pathogenesis. The 
development of disease-modifying therapeutics (DMTs) which can intervene in primary molecular 
mechanisms of AD is necessary to prevent or delay the onset/progression of the disease. In order to 
target primary molecular mechanisms, alternative AD hypotheses and drug development strategies 
were focused on the major neuropathological hallmarks of the disease, i.e. β-amyloid plaques and NFT 
formation. 
1.4.4 Anti-amyloid drug therapies 
The amyloid cascade hypothesis has dominated research in the AD therapeutic development pipeline 
and the choice of pharmacological targets since its proposal in 1991, by Hardy and Allsop.47 The 
hypothesis was grounded on one of its major neuropathological hallmarks—extracellular β-amyloid 
plaque deposits—in the AD-affected brain, as well as the amyloidogenic pathway associated with the 
formation of Aβ peptides and β-amyloid plaques. The amyloid cascade hypothesis proposed that Aβ 
peptide overproduction occurs very early in the disease pathology and that it further drives β-amyloid 
plaque formation, tau hyperphosphorylation, NFT formation, inflammatory responses and 
neurotoxicity, leading to progressive neuronal death.40  
Aβ peptides are produced mainly through the canonical amyloidogenic pathway, through sequential 
cleavage of APP by β- and ƴ-secretases (as explained in Section 1.2.1, Figure 1.1). The amyloid cascade 
hypothesis has further been connected to an imbalance in Aβ42 peptide ratio relative to other Aβ 
species, which is proposed to induce Aβ accumulation and oligomerisation in AD pathology. 
Progression in Aβ accumulation was proposed to translate directly to increased clinical symptoms.13 
Therapeutic strategies have focused mainly on the inhibition of Aβ peptide production or the removal 
of Aβ peptides, with the major strategies pertaining to β-secretase inhibitors, ƴ-secretase inhibitors, 
α-secretase activators and anti-aggregants. Active and passive immune-mediated mechanisms have 
been explored to inhibit Aβ generation or to promote Aβ peptide clearance, which included the use 
of Aβ-binding antibodies or the phagocytosis of opsonised Aβ peptides.34 In January 2018, clinical trial 
activities, based on the annual review by Cummings et al.,33 comprised 14 (54%) anti-amyloid agents 
in phase III, 18 anti-amyloid agents in phase II, and 5 in phase I. These anti-amyloid agents included 
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mainly immunotherapies, BACE inhibitors (β-secretase 1 inhibitors) and anti-aggregation drug 
candidates. 
1.4.4.1 β-secretase (BACE) inhibitors 
β-secretase inhibitors have been developed to interfere in the Aβ producing amyloid cascade, in which 
APP is cleaved by β-secretase. β-site APP-cleaving enzyme 1 (BACE 1) is the prime enzyme responsible 
for β-secretase activity in the amyloidogenic pathway. The development of these inhibitors has proved 
to be challenging since the enzyme has several cellular substrates apart from APP, due to its role in 
other physiological processes required to maintain cognitive function.48 Furthermore, BACE inhibitors 
must be able to penetrate the blood-brain barrier to modulate the enzyme’s activity.34 The first-
generation BACE inhibitor, BI 1181181 (structure not yet disclosed), was orally administered, but was 
suspended in the third round of phase I trials due to side-effects (skin reaction).49 The second-
generation BACE inhibitors failed due to liver toxicity, whereas several third-generation BACE 
inhibitors (e.g. E2609, AZD3293, CNP520, JNJ-54861911) have now reached phase III clinical trials 
(Figure 1.8).33,37,50,51 Verubecestat (MK-8931) is an orally active small-molecule BACE inhibitor which 
successfully reduced Aβ levels in the cerebrospinal fluid of AD patients in early clinical trials. However, 
Verubecestat resulted in much disappointment when the drug failed in phase III, due to overall futility 
(lack in the reduction of cognitive and functional decline 50 months after onset) and adverse side-
effects.52 
 
Figure 1.8: The structures of some third-generation BACE-inhibitors in clinical trials8,50,51,53 
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1.4.4.2 ƴ-Secretase inhibitors 
After cleavage by BACE, ƴ-secretase participates in the final cleavage steps to generate Aβ from APP. 
However, ƴ-secretases also facilitate the intramembranous cleavage of the Notch protein and several 
other substrates, including ErbB4, p75NTR, neurotrophin receptor, N-cadherin and the β4 sodium 
channel subunit, which complicates ƴ-secretase inhibitor development.34 Unselective ƴ-secretase 
inhibitors have been associated with hematological toxicity, gastrointestinal side-effects, hair-colour 
changes and skin reactions, mainly due to the concomitant inhibition of the Notch signalling pathways 
which further affects cell differentiation.34 Several ƴ-secretase inhibitors with increased selectivity, 
have reached clinical trials and have successfully reduced Aβ levels in the plasma or cerebrospinal fluid 
of patients, but unfortunately, serious adverse events accompanied these studies. Semagacestat 
(Figure 1.9) is the only agent to have reached phase III trials thus far and was withdrawn in 2010 due 
to futility, dose-related worsening of functional ability and serious side-effects (e.g. skin cancer, weight 
loss, infections).54,55 More concerning is that the amyloid-level reductions induced by Semagacestat 
did not result in any significant effects/changes in brain-imaging studies. 
 
Figure 1.9: The structures of ƴ-secretase inhibitor, Semagacestat, protein kinase C activator, 
Bryostatin-1, and anti-aggregant ALZT-OP1 (Cromolyn sodium + Ibuprofen).8,55,56 
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1.4.4.3 α-Secretase activators 
α-Secretase partakes in the non-amyloidogenic pathway of APP processing and cleaves APP within the 
Aβ sequence, as described in Section 1.2.1. Therefore, the upregulation of α-secretase activity is 
proposed to reduce the levels of Aβ peptide production. For example, Bryostatin-1 (Figure 1.9) 
activates protein kinase C and sAPPα excretion, which further stimulates α-secretase activity. This 
agent recently completed phase IIa clinical trials and was well tolerated in AD patients.8,34,57 
1.4.4.4 Anti-aggregants 
Anti-aggregants are focused on the development of drugs that will prevent Aβ peptide aggregation 
and plaque formation. The neurotoxicity of Aβ oligomers in synaptic function is well known, therefore 
anti-aggregants are also aimed at destabilising Aβ oligomeric species.17,34 This strategy is mainly 
focused on the design of small-molecules or peptides that can bind and stabilise Aβ monomers, to 
prevent oligomerisation and rather accommodate natural Aβ clearance mechanisms. Other strategies 
are aimed at the neutralisation of toxic Aβ assemblies, by binding to them and promoting clearance 
mechanisms.58 Challenges encountered in the design and clinical trials of anti-aggregants include 
limited knowledge on the molecular structure of the target, uncertain modes of action, selectivity 
challenges, modest potencies and brain-blood barrier permeability challenges.58 ALZT-OP1 is currently 
in phase III clinical trials and is a combination drug therapy comprised of Cromolyn sodium and 
Ibuprofen (Figure 1.9). Cromolyn sodium, a small-molecule known for its anti-inflammatory effect in 
asthma treatment, was found to inhibit Aβ monomer aggregation in vitro and to reduce soluble Aβ 
levels in the brain in vivo.56 Another promising candidate is the oligosaccharide drug, sodium oligo-
mannurarate (GV-971), which recently completed phase III clinical trials. This orally active drug 
successfully reached its efficacy end points in phase III trials and works through a multi-targeting 
mechanism to inhibit Aβ fibril formation and decrease neuroinflammation.59 
1.4.4.5 Immunotherapy 
Immune-mediated mechanisms investigated in AD drug development include the use of antibodies to 
solubilise Aβ peptides through binding, the use of plasma antibodies to extract Aβ peptides from the 
brain, or to opsonise Aβ peptides to facilitate phagocytosis.34 Solanezumab—a monoclonal antibody 
designed to bind soluble Aβ peptide and facilitate its removal—was a very promising passive 
immunotherapy developed by Eli Lilly and Company, but failed in three large phase III trials when no 
significant improvement in cognitive decline and function was observed.60 The study further 
highlighted the improbability that the removal of free Aβ peptides from plasma will lead to increased 
Aβ clearance in the brain (peripheral sink hypothesis).60 Plenty of research has been devoted to the 
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development of immunotherapies, with six anti-amyloid immunotherapies in phase III, six in phase II 
and five in phase I, as determined by Cummings et al. in January 2018.33 These agents include 
monoclonal antibodies, polyclonal antibodies, amyloid vaccines and other active immunotherapies. 
CAD-106 (phase III) is an example of an amyloid vaccine. CAD-106 consists of a short Aβ1-6 peptide (a 
specific B-cell epitope) connected to a virus-like QB particle, which elicits the production of Aβ-specific 
antibodies without uncontrolled T-cell responses (longer Aβ fragments induce uncontrolled immune 
responses). The Aβ-specific antibodies are proposed to further bind and clear Aβ peptides.34,37 
1.4.4.6 Conclusion on anti-amyloid drug development 
Several drug candidates following the amyloid hypothesis and targeting mild to moderate AD, have 
failed thus far or have shown controversial results.19 As in the cases of Tramiprosate (first-generation 
anti-aggregant), Rosiglitazone (β-secretase inhibitor), Verubecestat (β-secretase inhibitor), 
Semagacestat (ƴ-secretase inhibitor), Bapineuzumab (monoclonal antibody) and Solanezumab 
(monoclonal antibody), the compounds have shown positive results in preclinical, phase I and phase 
II trials, but have failed in phase III, showing no efficacy or a worsening in cognition.8,34 These failures 
have given rise to the reconsideration of the role of β-amyloid deposits in the pathogenesis of AD. As 
a result, interest has also grown in the tau-based hypothesis, which will be described next. 
1.4.5 Tau-centric drug therapies 
The tau hypothesis is more recent and focuses on intracellular NFTs as the major contributor to the 
pathogenesis of AD. The pathology of NFT formation was discussed in Section 1.2.2. The major protein 
kinases associated with the hyperphosphorylation of tau (>95% of in vivo phosphorylation) are 
glycogen synthase kinase 3 (GSK-3) and cyclin-dependent kinase 5 (CDK-5).61 
Tau-based drug development has lagged behind Aβ-targeted drugs and the target is relatively 
unexploited.19 Therapeutic approaches in this class focus on anti-aggregants, the inhibition of tau-
phosphorylating kinases, tau clearance, increased microtubule stabilisation and immunotherapies. 
Few drug trials have involved tau-centric drugs and only two tau-directed drug candidates, Valproate 
(GSK-3 inhibitor) and TRx-0237 (aggregation inhibitor) have yet reached phase III clinical trials.33,34 
1.4.5.1 Anti-aggregants 
Based on tauopathies, hyperphosphorylated tau proteins assemble to form paired helical filaments 
(PHFs) which accumulate into insoluble tangles to form NFTs. Tau protein aggregation inhibitors aim 
to prevent the aggregation of tau that has been hyperphosphorylated or subjected to abnormal post-
translational modifications.37 Methylene blue (also known as Rember) is a first-generation tau anti-
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aggregant which interferes in tau-tau binding, and further displays antioxidant activity and 
mitochondrial function enhancement (Figure 1.10).19 In phase II trials, the drug displayed promise in 
slowing disease progression in patients with moderate AD within 24 weeks; however, bioavailability 
was low and side-effects included diarrhea, dizziness, painful urination and accidental falls.37,62 The 
leuco-form of methylene blue, TRx-0237, replaced methylene blue in clinical trials, since the reduced 
form is better absorbed in the stomach (Figure 1.10). Although phase III clinical trials are still ongoing, 
TRx-0237 has completed three phase III clinical studies in which efficacy endpoints were unfortunately 
not met.63 
 
Figure 1.10: The structures of selected tau-centric drug therapies8,55,64 
1.4.5.2 Kinase inhibitors 
Tau-phosphorylating kinases, especially CDK-5 and GSK-3, are often over-expressed/over-activated in 
the brains of AD patients, resulting in the hyperphosphorylation of tau.61 Tau-phosphorylating kinase 
inhibitors are proposed to counteract hyperphosphorylation and NFT formation. Recent years in tau-
phosphorylating kinase inhibitor development were thus focused mainly on preclinical efforts to 
address issues involving toxicity and specificity. The most clinical advances have been made in the 
development of GSK-3 inhibitors.65 
Valproate and lithium salts are well-known therapeutics for psychiatric disorders, and additionally, 
these drugs are also GSK-3 inhibitors known to reduce tau phosphorylation. Valproate reached phase 
III clinical trials on mild to moderate AD patients. However, results were disappointing with no 
significant improvements in cognition and function.34 Preclinical studies with lithium chloride in mice, 
have shown decreased β-amyloid production due to the inhibition of GSK-3. An in vivo reduction of 
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tau phosphorylation was observed in different animal models. However, the results from AD clinical 
trials with lithium chloride were controversial due to clinical trial design flaws.61 
The non-ATP competitive, irreversible GSK-3 inhibitor, Tideglusib (NP-12, Figure 1.10), has shown 
positive results in animal models, with reductions in tau phosphorylation, Aβ load, neuronal death, 
and astrogliosis.20 In phase IIa studies orally administered doses were found to improve the cognitive 
levels of mild to moderate AD patients; however, efficacy endpoints were unfortunately not met in 
the phase IIb trials. Ultimately, the drug was well tolerated (safe), but did not result in any clinical 
benefits.66 
Tau proteins are also subjected to other post-translational modifications, which can result in tau 
dysfunction. Therefore, other kinase inhibitors that can target for example tau acetylation, tau 
deglycosylation and tau truncation, have been explored as possible AD therapeutics.20 
1.4.5.3 Microtubule stabilisers 
Hyperphosphorylated tau proteins detach from microtubules, resulting in microtubule destabilisation. 
In 2007, Bahr and co-workers67 conducted a study with a hippocampal slice model in which they firstly 
proved that a loss in microtubule integrity can contribute to synaptic decline in AD, and secondly that 
microtubule-stabilising drugs can counteract the synaptic deterioration. As a result, the therapeutic 
potential of microtubule stabilisers is under investigation. TPI-287, a taxane derivative, is an example 
of a microtubule protein modulator in phase I clinical trials (Figure 1.10).33 
1.4.5.4 Immunotherapy 
Similar to anti-amyloid strategies, anti-tau immunotherapy holds much potential in AD therapeutic 
development. Antibodies against phosphorylated, mutant, oligomeric or misfolded tau can reduce 
pathological tau levels.20 AADvac-1 was the first tau-vaccine to enter phase I clinical trials (2013) and 
is currently in phase II.33,68 The vaccine, AADvac-1, contains synthetic tau294-305 peptides based on a 
regulatory sequence which is essential for oligomerisation in natural tau.68 The peptides are 
conjugated to keyhole limpet hemocyanin (KLH) carriers and combined with aluminium hydroxide as 
an adjuvant. In animal studies, AADvac-1 produced antibodies capable of targeting brain tau, and 
reduced tau pathology and behavioural improvements were observed.20 
The vaccine, ACI-35, follows an alternative approach wherein a tau epitope is selectively targeted. 
Phosphorylation at the Ser396 and Ser404 sites of tau was reported to be an early event in AD 
pathology.69 ACI-35, therefore, contains synthetic tau393-408 peptides which are phosphorylated at 
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Ser396 and Ser404, and as a result, antibodies targeting the phosphorylated epitope are produced. 
The vaccine is currently in phase 1b clinical trials.37,65 
Developments in passive immunisation, pertaining to humanised antibodies, have yielded multiple 
new clinical candidates, including RG-7345, BMS-986168, ABBV-8E12, RO 7105705, LY3303560.20 
1.4.6 Other therapeutic approaches 
The etiology of AD remains complex and the adaptation of hypotheses to explain the etiology and 
pathogenesis of the disease, results in the frequent exploration of new therapeutic targets and 
therapeutic approaches. Herewith the main areas in alternative therapeutic strategies: 
1.4.6.1 Drugs to target oxidative stress and mitochondrial dysfunction 
Oxidative stress, due to an imbalanced system of oxidants and anti-oxidants, has been well-
documented in the brains of AD patients and AD transgenic mice.70 The oxidants, such as reactive 
oxygen species (ROS) and reactive nitrogen species (RNS), are capable of reacting with lipids, proteins, 
carbohydrates, DNA, RNA and other biomolecules in the brain. Oxidative modification damages the 
biomolecules and results in dysfunction.71 The oxidative stress hypothesis suggests that the AD brain 
is under increased oxidative stress and that free radical species may influence neuronal degeneration 
and the pathogenesis of AD directly.70 As a result, drugs with strong antioxidant activities (mostly 
multitargeted drugs), have been included in clinical trials to achieve neuroprotection.8 
Several factors, including amyloid plaques, neurotoxic trace elements, mitochondrial dysfunction, 
tissue injury and aging have been associated with free radical production.70 Mitochondrial disfunction 
occurs early in AD disease progression and has been connected to increased mitochondrial DNA 
mutations due to cytochrome oxidase dysfunction.72 Latrepirdine is an example of a drug that was in 
clinical trials and was proposed to exert protective effects on mitochondrial structure and function 
(Figure 1.11).34 
 
Figure 1.11: The structure of Latrepirdine44 
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1.4.6.2 Neurotrophic drugs 
Neurogenesis (generation of new neurons) occurs continually in distinct regions of the adult brain. 
Nerve growth factor (NGF) is important for the survival and outgrowth of cholinergic neurons in the 
basal forebrain, and an imbalance in NGF has been linked to the activation of the amyloidogenic 
pathway and neuronal death. As a result, the increased delivery of NGF to the cholinergic neurons has 
been explored as a drug strategy to prevent neuron degeneration and to protect synapses.34,73 
1.4.6.3 Drugs to target neuroinflammation 
AD is associated with chronic inflammation in the AD brain, which further results in neuron 
degeneration. It was discovered that Aβ plaques promote local microglial- and astrocyte-mediated 
inflammation. Immune responses produce superoxide, complement components, complement 
receptors and cytokines, which can be neurotoxic to cells and contribute to AD progression in the 
cases of hyperactivation.9 Microglia are the prime immune cells responsible for active immune 
response in the CNS.9 As a result, some therapeutic strategies have entailed the design of microglial 
activation inhibitors, in order to inhibit neuroinflammation. The cognitive benefit of anti-inflammatory 
drugs is also being explored.37 
1.4.6.4 Multitargeted approaches 
The multifactorial nature of AD pathogenesis has been recognised and has influenced drug design to 
include multitargeted drug strategies. Multitargeted drugs in the context of AD were defined by 
Bachurin et al. to have “an integrated action on a number of biological targets involved in the 
pathogenesis of the disease”.8 The integrated action of a potential drug on multiple neurobiological 
targets—including the major neuropathological hallmarks, Aβ peptides and hyperphosphorylated 
tau— holds interesting potential. 
1.5 The GSK-3 hypothesis 
Glycogen synthase kinase 3, GSK-3, is a serine/threonine protein kinase that regulates signal 
transduction in several physiological pathways, including glycogen metabolism, gene transcription, 
apoptosis and microtubule stability.4 GSK-3 overexpression contributes to the hyperphosphorylation 
of tau proteins, which results in NFT formation in AD. GSK-3 inhibitors were discussed in Section 
1.4.5.2 as a kinase inhibitor strategy in tau-centric drug development for AD. The design of this project 
was based on the recently formulated GSK-3 hypothesis, in which GSK-3 is proposed to play a central 
role in the etiology and multifactorial pathogenesis of AD, an integrated role which stretches beyond 
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tau hyperphosphorylation.4 The central role of GSK-3 in AD neuropathology is depicted in Figure 
1.12.74 
 
Figure 1.12: The central role of GSK-3 in the neuropathology of AD (figure reproduced from Jope 
and Johnson).74 PHFs: paired helical filaments; GVD: Granulovacuolar degeneration. 
Substantial evidence supports the GSK-3 hypothesis and has confirmed the role of GSK-3 
dysregulation—most likely due to aberrant upstream wingless-type MMTV integration site family 
(Wnt) signalling or insulin signalling—in the pathogenesis of sporadic and familial forms of AD.4 The 
GSK-3 hypothesis regards GSK-3 to be a critical link between tau hyperphosphorylation and β-amyloid 
plaques.75  
As discussed in previous sections, the overexpression of GSK-3 results in the hyperphosphorylation of 
tau proteins, which destabilises tau-microtubule associations, give rise to the misfolding of tau 
proteins and results in insoluble tangles (NFTs) inside the affected neuron. However, GSK-3 
overexpression also results in the elevated production of Aβ peptides from APP through GSK-3 activity 
on α-secretase. Three α-disintegrin and metalloproteases (ADAM), ADAM-10, ADAM-17, and ADAM-
9, constitute the α-secretase complex. GSK-3 is suggested to down-regulate α-secretase activity 
through ADAM inhibition.75 The down-regulation of α-secretase favours the amyloidogenic (β-amyloid 
producing) pathway. Furthermore, GSK-3 may also modify the function of PS-1, a protein which forms 
part of the APP processing enzyme, ƴ-secretase.75 The effect of GSK-3 on BACE1 (β-secretase which 
facilitates the amyloidogenic pathway) was observed through a GSK-3 inhibition study. GSK-3 
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inhibition was found to reduce BACE1 gene expression, reduce the activity of BACE1 on APP, and to 
reduce Aβ peptide production in AD model mice.75,76 It should be further noted that Aβ peptides can 
increase GSK-3 activity, whereas studies have shown that GSK-3 inhibition can reduce Aβ-induced 
neurotoxic effects.77 
Throughout numerous studies on the effects of GSK-3 on AD pathogenesis, it became clear that GSK-3 
is not only involved in tau hyperphosphorylation and Aβ plaque production, but also in inflammatory 
responses, neurotoxicity, reduced acetylcholine synthesis, adult neurogenesis impairment, 
endoplasmic reticulum (ER) stress and apoptosis.4,75  
GSK-3 levels are known to be up-regulated in the brains of AD patients and due to the multifactorial 
role of GSK-3 in AD pathogenesis, it has become a popular CNS target in the development of disease-
modifying AD therapeutics.36 It has also been postulated that GSK-3 inhibitors might exert therapeutic 
effects at several main stages of the disease. 
1.6 Chapter conclusion 
As the predominant form of dementia, AD is a progressive neurodegenerative disease associated with 
clinical symptoms of memory loss and cognitive decline, and major neuropathological hallmarks of 
intracellular NFTs, extracellular Aβ plaques and neuroinflammation in the brain. AD has a global effect 
on patients, family members, caregivers, health systems and the economy, therefore the 
development of potential drug therapies for AD is necessary. 
AD drug discovery is challenging since the risk factors and molecular mechanisms of AD development 
are multifactorial and not fully understood. In the last decade, more than 50 potential AD therapeutics 
have reached phase II clinical trials, but none has successfully completed phase III.8 In this chapter, the 
major trends in AD drug discovery were highlighted and included strategies pertaining to cholinergic, 
glutamatergic, anti-amyloid, tau-centric, antioxidant, neurotrophic and anti-inflammatory drug 
therapies. GSK-3 is also a promising CNS drug target, since dysregulated GSK-3 activity plays a central 
role in AD development and provides a link between β-amyloid plaques, tauopathy, inflammatory 
responses and reduced cholinergic transmission. 
The next chapter will commence with a project problem statement, whereafter the formulation of our 
hypothesis will be discussed based on work previously performed in the literature. Chapter 2 will also 
highlight important aspects in the design of our proposed library of GSK-3 inhibitors. 
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Chapter 2: The Roots of our Hypothesis 
2.1 Problem statement: The need for disease-modifying therapeutics 
Therapeutic agents in the AD drug developing pipeline can be grouped according to their proposed 
mechanisms of action.1 These mechanisms can be classified further as being either symptomatic or 
disease-modifying.1 Symptomatic therapies generally target neurotransmitter mechanisms, to achieve 
cognitive enhancement or to treat neuropsychiatric symptoms.2 Symptomatic treatments aim to 
improve the behaviour and memory of AD patients. Disease-modifying therapeutics (DMTs) in AD aim 
to prevent or delay the onset or progression of AD, and target the inherent pathophysiologic 
mechanisms of the disease.2 Although AD drug development has been successful in terms of 
symptomatic treatments, attempts to develop DMTs have failed.3 
The failures in DMT research and development in the AD field have accentuated the urgent need for 
DMT candidates in the AD drug development pipeline. An assessment of the DMT candidates in 
globally registered clinical drug trials for AD in January 2018, revealed only 17 DMT candidates to be 
in phase I, 36 DMTs in phase II and 17 DMTs in phase III trials.4 This limited number of DMT candidates 
in trials is concerning, as it is restricting the advancement of AD drug development.4 
In the past years, the DMT drug pipeline has been focused mainly on the amyloid hypothesis. Given 
the repeated failures of trials with anti-amyloid candidates targeting mild to moderate AD through 
different mechanisms of action, the interest in tau-based candidates has grown.5 This is a natural step, 
since AD therapeutic approaches are influenced greatly by the disease’s two major neuropathological 
hallmarks, extracellular β-amyloid plaques and intracellular NFTs (mainly consisting of 
hyperphosphorylated tau protein) in the brain.5 It is noteworthy that when this project was initiated 
in 2017, the number of tau-related candidates in clinical trials amounted to nine,2 and in 2018 the 
number of tau-related candidates have increased to 16.4 Recent and past therapeutic approaches to 
tau-related therapies have included tau protein kinase inhibitors, active and passive 
immunotherapies, microtubule-stabilizing agents and tau aggregation inhibitors, and provide many 
more opportunities for exploration.5 
The potential for tau-based therapies is supported by studies which indicate a significant relationship 
between NFT counts and neuronal loss.6,7 Giannakopoulos et al.7 reported that approximately 84% of 
patient neuronal loss in their studied areas (CA1 field in the hippocampus, entorhinal cortex and 
Brodmann area 9) could be accounted for by NFTs. This link between NFT topography and clinical 
phenotype promoted the interest in tau-based targets.5 In contrast, amyloid deposition appears to 
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contribute to cognitive decline in AD, but only a weak correlation exists between the stages of 
deposition and the severity of clinical expression.6,8 
With the hope of contributing to the AD drug pipeline and knowing that many opportunities are 
available in tau-based therapies, we undertook the task of exploring the development of new hit 
molecules which have the potential to generate a new DMT in the field of AD.  
2.2 Our central nervous system target: GSK-3 
Target-based drug discovery is largely dependent on the success of choosing a target that is critical to 
the disease process, i.e. a validated target.4 The complex multifactorial nature of AD and the well-
established connections between β-amyloid plaques and tau hyperphosphorylation,7,9 have directed 
the interest of our group to the GSK-3 hypothesis (discussed in Chapter 1). The GSK-3 enzyme plays a 
central role in the multifactorial pathogenesis of sporadic and familial forms of AD, and GSK-3 
inhibition has been shown to decrease Aβ peptide production, as well as tau hyperphosphorylation.9,10 
Building on earlier work done by Dr A.R. Hamann on inhibitors of this enzyme in our research group,11 
our aim was to develop a new GSK-3 protein kinase inhibitor. It should be noted that very few GSK-3 
inhibitors have successfully reached clinical trials yet and that the 2018 AD drug development pipeline 
included only one GSK-3β inhibitor (phase II).4 
Mammalian GSK-3 exists in two isoforms, known as GSK-3α (51 kDa) and GSK-3β (47 kDa). GSK-3β has 
a 85% amino acid sequence homology to GSK-3α and their kinase binding sites share 98% similarity.12 
Rodent and bovine models have shown that the GSK isoforms are expressed in various mammalian 
tissues, but that both isoforms are the most abundant in the brain tissue and contribute to AD.12 The 
GSK-3β isoform exists almost primarily in the brain tissue of the adult rat, with very low concentrations 
in other tissues such as the testis, ovary, lung, heart and thymus.13 GSK-3β has been identified as the 
key kinase responsible for abnormal tau hyperphosphorylation and was co-crystallised with ATP 
analogues ADP and AMPPNP in 2003 by Kohno, Sugio and co-workers.14 Most of the research in the 
literature pertaining to this topic has been focused on the GSK-3β enzyme as therapeutic target, due 
to this enzyme’s pivotal role in many cellular signalling processes in the brain.15 
The homology of the GSK3α and GSK3β binding sites complicates the development of isoform-specific 
inhibitors. As a result, most of the GSK3 inhibitors in the literature are not isoform-specific and thus 
inhibit both isoforms with the same potency.10 
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2.3 Reversible GSK-3 inhibitors and their binding interactions 
The development of reversible GSK-3 inhibitors has prospered in recent years. The majority of GSK-3 
inhibitors explored were ATP competitive.10 Major structural classes of known ATP competitive GSK-3 
inhibitors include maleimides, indolyl-maleimides, staurosporine-related organometallic ruthenium 
complexes, indoles, indirubins, paullones, pyrazolamides, pyrimidine-/furopyrimidine derivatives, 
oxadiazoles, thiazoles, benzimidazoles, pyrazolones and pyridones.10 Many of these inhibitors 
displayed good or excellent inhibition potencies, allowing the identification of key binding interactions 
in the ATP binding pocket.10  
GSK-3 inhibitors can be tested against either the GSK-3β or the GSK-3α isoform. Due to the focus on 
GSK-3β and the availability of crystallographic structures of GSK-3β/ligand complexes, most inhibitors 
are tested specifically against GSK-3β. Table 2.1 was constructed in order to obtain an overview of 
important residues which contribute to the hinge region of the GSK-3β ATP binding pocket, for a 
number of popular inhibitor motifs. The available IC50 data are also reported. The overview is based 
on the comprehensive studies of Kramer et al.10 in which several GSK-3 inhibitors were evaluated in 
order to obtain insight into the activity and selectivity profile of the GSK-3β ATP binding site. 
The images in Table 2.1 were generated by Kramer et al.10 and represent GSK-3β/inhibitor complexes 
extracted from the Protein Data Bank (PDB IDs: 1Q4L,16 1Q3D,16 1Q41,16 1Q3W,16 3F7Z,17 2O5K18). The 
interactions of the inhibitors with GSK-3β were illustrated by Kramer et al.10 
Table 2.1: An overview to highlight hinge interactions in the GSK-3β ATP binding pocket 
The inhibitor’s binding mode to the ATP binding 
pocket of GSK-3β10 
Structural class example 
 
Maleimide derivative, named I-5 
PDB ID: 1Q4L 
 
 
IC50 (GSK-3β, GSK-3α)16: 160 nm, 76 nm 
Key interactions:16 Asp133 (carbonyl O), 
Val135 (backbone N), Arg141 & Gln185 





PDB ID: 1Q3D 
 
IC50 (GSK-3β):16 15 nm 
Key interactions:16 Val135 (backbone N), 
Asp133 (carbonyl O), water-mediated 
interaction with Gln185 (not shown). 
 
Indole derivative, indirubin-3’-monoxime 
PDB ID: 1Q41 
 
IC50 (GSK-3β):16 22 nm 
Key interactions:16 Val135 (backbone N, 
carbonyl O), Asp133 (carbonyl O), water-
mediated interaction with Gln185 (not 
shown) 
 
Paullone derivative, Alsterpaullone 
PDB ID: 1Q3W 
 
IC50 (GSK-3β):16 4 nm 
Key interactions:16 Val135 (backbone N, 
carbonyl O), water-mediated interaction 
with Asp133 and Gln185 (not shown) 





PDB ID: 3F7Z 
 
IC50 (GSK-3β):17 65 nm 
Key interactions:17 Val135 (backbone NH, 
carbonyl O), Asp133, water-mediated 




PDB ID: 2O5K 
 
IC50 (GSK-3β):18 15 nm 
Key interactions:18 Asp133 (carbonyl O), 
Val135 (carbonyl O), Arg141 & Arg220 (with 
SO2) 
 
Through an inspection of different structural classes, by Kramer et al.,10 it became apparent that all 
ATP competitive GSK-3 inhibitors bind the hinge region through one or more hydrogen bonds with 
Val135. In most cases, a hydrogen bond to the Asp133 backbone strengthened the inhibitor’s 
interaction with the hinge region. These results were in accordance with the binding interactions 
which were observed in the crystal structure of GSK-3β with the non-hydrolysable ATP-analogue, 
adenylyl imidodiphosphate (AMPPNP, PDB ID: 1PYX16). AMPPNP’s adenine ring forms hydrogen bonds 
with residues Val135 and Asp133 in the hinge binding region.16 
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Good interactions with the hinge region enhance an GSK-3 inhibitor’s affinity for the GSK-3 ATP 
binding pocket, which promotes good inhibition activity. However, good selectivity requires additional 
binding interactions which will favour GSK-3 over other kinases. Figure 2.1 depicts a schematic outline 
of the different areas in the GSK-3β ATP binding pocket that may contribute to activity and 
selectivity.10 
 
Figure 2.1: Important binding interaction regions of the GSK-3β ATP pocket and their potential to 
provide activity and selectivity10 
The selectivity of reversible ATP-competitive inhibitors for GSK-3 over other kinases was improved 
through additional hydrogen bond contacts with residues in the selectivity areas. Interactions with the 
small hydrophobic pocket (Ile62, Gly63, Phe67, Val70), water-mediated bonds with Gln185 and water-
mediated interactions with the Lys85-Glu97-Asp200 network, also contributed to improved degrees 
of selectivity.10 However, selectivity remained a challenge with reversible ATP-competitive inhibitors.  
The translation of potent small-molecule GSK-3 inhibitors into clinically approved therapeutics has 
posed difficulties over the past years, with the major obstacles pertaining to selectivity, blood-brain 
barrier penetration and chronic toxicity.19 
2.4 The selectivity challenge 
Protein kinases encoded by the human kinome are known to possess a more or less conserved binding 
site for ATP.20 Many of the previously reported GSK-3 inhibitors have not achieved the required 
selectivity over kinase panels, due to high sequence conservation in the ATP binding site. This was 
especially the case with CDK-1, CDK-2 and CDK-5. CDK-2 displays the greatest structural homology 
with GSK-3β, by sharing 33% of its amino acid sequence over the core kinase domain (residues 55 – 
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345 of GSK-3β).21,22 GSK-3’s role in many different signalling pathways necessitates selective and 
moderate inhibition, in order to prevent adverse off-target- and side-effects.10 
No time was spent in this project on the development of isoform-selective GSK-3 inhibitors, 
considering that both isoforms have been suggested to contribute to the pathogenesis of AD and since 
the catalytic domains of the GSK-3β and GSK-3α isoforms are 98% identical.21,23 The acquirement of 
selectivity towards GSK-3 over the different protein kinases of the human kinome was regarded as 
first priority.  
Non-ATP competitive GSK-3 inhibitors have been proposed as an alternative strategy towards 
selectivity and include allosteric modulators and substrate competitive inhibitors.24 In the case of 
allosteric modulators, allosteric pockets on the GSK-3 enzyme surface have been discovered and 
provide the opportunity for modulation through conformational changes.20 The uniqueness of the 
allosteric pocket promotes kinase selectivity and the inhibitor no longer competes with ATP.24 In the 
case of substrate competitive inhibitors, the substrate site may offer enhanced selectivity, but the 
inhibitor will have to compete with the substrate.24 The substrate is usually a pre-phosphorylated 
substrate to which GSK-3 introduces another phosphate group. 
Irreversible protein kinase inhibitors provide another alternative towards selectivity by targeting a 
unique reactive residue in the ATP binding site of GSK-3 through covalent modification. Irreversible 
inhibitors have gained interest in cancer research, where they have been utilised to avoid resistance 
in protein kinase therapy.20,25 
2.5 The covalent target residue: Cys199 
Martínez and co-workers26 were the first to describe irreversible GSK-3β inhibitors. They utilised the 
halomethylketone (HMK) moiety as electrophile and developed a library of thienylhalomethylketones, 
obtaining an IC50 of 0.5 µM after optimisation. The HMK moiety proved to be the key structural feature 
towards activity and their enzyme mapping, reversibility and kinetic studies further supported 
inhibition through the covalent modification of cysteine 199 in the ATP binding pocket of GSK-3β. 
Covalent bond formation between the Cys199 thiol and the HMK moiety would entail the formation 
of a new thioether carbon-sulfur bond (Figure 2.2). The HMK halide atom is situated close to a 
protonated Lys85 residue in the ATP pocket, which might stabilise the halide anion upon elimination.26 
The location of Cys199 in the GSK-3β ATP binding pocket can be seen in Figure 2.1. 
This covalent strategy is very attractive in terms of selectivity, since the ATP binding pocket of GSK-3 
uniquely contains this Cys199 residue, which is not conserved in structurally related kinases such as 
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CDK-1, CDK-2 and CDK-5.26,27 Of importance is that this unique cysteine residue is present in the ATP 
binding site of GSK3α and GSK3β.26 
 
Figure 2.2: HMK GSK-3β inhibitors are postulated to target and covalently modify the Cys199 
residue. The Lys85 residue is presented in dark blue.26 
Martínez and co-workers27 managed to successfully switch reversible maleimide-based inhibitors into 
potent irreversible GSK-3β inhibitors by incorporating an HMK moiety onto the scaffold in a position 
that would be suitable for Cys199 modification (Scheme 2.1). A time-dependent study of inhibition 
percentage versus preincubation time confirmed the irreversible binding mode of the new 
compounds. Of note is that for reversible inhibitors, the inhibition percentage remains constant for 
different preincubation times, while irreversible inhibitors show an increase in inhibitory activity when 
the enzyme and the ligand are preincubated for a longer time before measuring inhibition 
percentage.27 
 
Scheme 2.1: Martínez and co-workers switched reversible inhibitors into potent irreversible HMK 
inhibitors of GSK-327 
Inspired by the success of this approach, herein we aim to design and synthesise covalent inhibitors 
of GSK-3 through a reaction with Cys199. Using molecular modelling to allow for further key 
interactions in the active site, we hope to increase selectivity through this approach. 
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2.6 Targeted covalent inhibitors: Considerations 
A covalent inhibitor is designed to contain a mildly electrophilic moiety, which has an affinity for a 
molecular nucleophilic target.28 Irreversible covalent modification will suppress a kinase’s biological 
function through a covalent binding interaction which is irreversible on the biological timescale. The 
irreversible covalent approach potentially affords the advantages of high selectivity and potency, 
prolonged duration of action and low dosages.28 
Historically, the pharmaceutical industry has been reluctant to follow covalent inhibition strategies, 
due to hepatotoxic risks exerted by these drugs.28 Toxicological effects were related to protein 
haptenization, where the haptens were electrophilic metabolites generated by P-450 cytochrome 
catalysed oxidation reactions. These haptens covalently bind cellular proteins in an indiscriminate 
fashion, causing functional damage.28,29 
Targeted covalent drug strategies have gained significant interest in the past decade, after several 
chemotherapeutic targeted covalent inhibitors were demonstrated to be safe and effective.29 The 
approval of these drugs onto the market has created reassurance that targeted covalent inhibitors do 
not necessarily create hepatotoxicity. It was also discovered, retrospectively, that some well-known 
marketed drugs, such as aspirin, penicillins and cephalosporins, rely on covalent modification to exert 
their function. It was concluded that reactive metabolites from hepatotoxic drugs are highly 
electrophilic and react indiscriminately, in contrast to the ideal covalent inhibitor which should contain 
a weakly electrophilic warhead and selectively modify a unique protein target.28 
Irreversible drug development strategies adopt several approaches in an attempt to reduce the risks 
of toxicity. Firstly, a high degree of target selectivity is essential. In the design of an inhibitor, good 
bioinformatics and proteomic tools are advantageous. A high-affinity reversible inhibitor is considered 
to be a good starting point in the design of a scaffold because the molecule must first associate 
reversibly in the ATP-binding pocket, before a covalent bond can form. In order to react irreversibly, 
an electrophilic moiety of suitable reactivity must be incorporated onto the scaffold at a position 
correctly orientated for interaction with the nucleophilic protein moiety. The nucleophilic residue in 
the protein pocket should be accessible and uncommon in other kinases.28 
Secondly, low drug doses and less frequent administration decrease the risks of off-target effects and 
high burdens of reactive metabolites. Therefore, the drug molecule should have high potency and 
good oral bioavailability. Few drugs with dosages of less than 10 mg/day have been associated with 
liver injury.28 
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Lastly, candidate covalent inhibitors should be screened for their susceptibility towards metabolic 
activation at an early stage. Metabolic activation of the electrophilic warhead or another group on the 
molecule can increase the electrophilic nature of the inhibitor and result in off-target effects.28 
In order to minimize toxicity risks, it is important to keep these various aspects of irreversible inhibitor 
design in mind when pursuing covalent inhibitor strategies. 
2.7 The design of our scaffold: Incorporating aims of high selectivity and 
non-toxicity 
In an attempt to obtain a high degree of selectivity, this project aims to design and synthesise covalent 
GSK-3 inhibitors which target Cys199 in the ATP-binding pocket. In accordance with Perez et al.,27 we 
intend switching a known reversible inhibitor into an irreversible inhibitor, by connecting a reactive 
electrophilic warhead onto the scaffold. To reduce toxicity risks, as discussed in Section 2.6, we will 
utilise a highly selective, high affinity reversible GSK-3 inhibitor as a scaffold for the design of our 
targeted covalent inhibitor. 
In 2003, AstraZeneca21 reported the potent activity and high selectivity of the novel small-molecule 
GSK-3 inhibitor, AR-A014418 (3, Figure 2.3). This thiazole is a reversible ATP-competitor and inhibited 
GSK-3 (equal mix of α and β) with an IC50 value of 104 nm. It was shown to bind the hinge region of 
the GSK-3β ATP pocket through three hydrogen bond interactions (PDB ID: 1Q5K). In addition, the 
nitro group forms water-mediated polar interactions with Lys85-Glu97-Asp200 and the phenyl ring 
forms a stacking interaction with Arg141.21 
 
Figure 2.3: The binding site interactions of AR-A014418 with GSK-3β (The figure was prepared by 
Kramer et al.10 from the enzyme/inhibitor complex structure with PDB ID: 1Q5K) 
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AR-A014418 was shown to be highly selective for GSK-3 and did not significantly inhibit CDK-2, CDK-5 
or the rest of the 26 protein kinases which were assayed.21 However, AR-A014418 was unfortunately 
found to be toxic.30  
With the use of a zebrafish embryo phenotype assay, Lo Monte et al.30 showed that when the thiazole 
ring of AR-A014418 was replaced with a pyridine or benzothiazole ring structure, the toxicity of the 
compound diminished. This benzothiazole derivative (4, Figure 2.4) had a GSK-3 inhibition potency 
comparative to AR-A014418 and was also suggested to have a kinase selectivity profile and docking 
mode similar to AR-A014418, based on brief biological activity and docking studies.30 The calculated 
logP of benzothiazolyl urea 4 was 3.34, which is favourable according to Lipinski’s general rule of 5 
which predicts that: “poor absorption or permeation is more likely when there are more than 5 H-bond 
donors, 10 H-bond acceptors, the molecular weight is greater than 500 and the calculated Log P is 
greater than 5.”30,31 
 
Figure 2.4: The potent and less toxic benzothiazole derivative of AR-A014418 
In our study, we intend combining several desirable structural characteristics to establish our 
structural scaffold. Benzothiazolylurea GSK-3β inhibitor 4 (Figure 2.4) will be utilised as a scaffold in 
the design of our Cys199-targeted covalent inhibitors. Bearing in mind the proposed docking mode of 
4, we hypothesise that the electrophilic warhead should be incorporated onto the benzothiazole ring 
in order to position it in close proximity of the Cys199 target residue. This approach was also followed 
by Perez et al.27 when they designed the Cys199-targeted benzimidazole-derived HMK GSK-3 inhibitor 
5 (Figure 2.5, IC50 = 580 nM). 
 
Figure 2.5: The irreversible benzimidazole-derived HMK GSK-3 inhibitor synthesised by Perez et 
al.27 
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We will attempt to introduce different reactive electrophilic warheads onto the structural scaffold. 
We will also explore the benzimidazole derivatives of the proposed compounds. In conclusion, the 
general benzazole urea scaffold of our proposed irreversible GSK-3 inhibitors is depicted in Figure 2.6. 
 
Figure 2.6: The 1-aryl-3-(4-methoxybenzyl)urea scaffold of our proposed irreversible GSK-3 
inhibitors 
2.8 Project aims 
The aim of this project is to design, synthesise and biologically evaluate a small library of structurally-
related, irreversible GSK-3 inhibitors as potential Alzheimer’s disease drug candidates. Our library will 
include two sets of 1-aryl-3-(4-methoxybenzyl)ureas, wherein the incorporated aryl group will be a 
benzothiazole or benzimidazole scaffold, respectively. The benzothiazole scaffold has displayed 
potential in previous GSK-3 inhibitor design studies,30 whereas the benzimidazole scaffold will be 
investigated as an alternative core structure to evaluate its possible effect on activity. Each molecule 
will contain an electrophilic warhead, with the potential to form a covalent (irreversible) bond with 
nucleophilic Cys199 in the GSK-3 ATP binding pocket. Typical electrophilic warheads capable of 
reacting with reactive cysteine residues will be explored, based on electrophilic moieties that have 
been widely utilised in reported irreversible inhibitors of the protein kinase cysteinome.29 
Molecular modelling studies will be used to confirm the viability of our proposed covalent inhibitors 
and to design the final library for synthesis. Next, synthetic procedures will be developed to prepare 
the compound library. Several characterisation techniques will be employed to confirm the structures 
of the synthesised compounds. 
Finally, we aim to send the library of synthesised compounds away for biological testing, to test their 
inhibitory activity against the GSK-3β enzyme. The biological activity scores will be compared to the 
molecular modelling results, in a structure-activity study. This structure-activity study will evaluate our 
understanding of the interactions of our proposed inhibitors with the active site of GSK-3β. 
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Chapter 3: Molecular modelling studies 
3.1 The structure of GSK-3β: Brief overview 
The first binary complex structure of GSK-3β was solved from the X-ray crystallographic structures of 
GSK-3β with the ATP analogues, ADP (PDB ID: 1J1C) and AMPPNP (PDB ID: 1J1B).1 Since then, several 
ATP-competitive inhibitors have been co-crystallised with GSK-3β and studied by X-ray diffraction (see 
for example PDB files: 1Q5K,2 1Q4L,3 1Q3D,3 1Q41,3 1Q3W,3 3F7Z,4 and 2O5K5). GSK-3β forms a dimeric 
complex in its asymmetric unit, which consists out of two molecules of GSK-3β (protein chain A and 
B). Each GSK-3β protein chain has an independent ATP-binding site as shown in Figure 3.1.1 
 
Figure 3.1: The dimeric complex of GSK-3β with AMPPNP (PDB ID: 1J1B).1 The green and cyan 
surfaces each represent a GSK-3β protein chain. The AMPPNP ligands are represented by yellow 
spheres in the two independent ATP-binding pockets. (Figure prepared with Maestro v11.1 
Schrödinger Drug Discovery Suite6) 
A surface representation of the GSK-3β protein is depicted in Figure 3.2.7 The GSK-3β protein chain 
has two major domains, known as the N-terminal and the C-terminal domains. The N-terminal domain 
comprises antiparallel β-strands and a short helix denoted as ‘helix αC’. The C-terminal domain of the 
GSK-3β protein chain is α-helical. The inhibitor or ATP analogue binds in a deep cleft which is situated 
between the C- and N-terminal lobes. The hinge region, which is crucial for effective ATP binding site 
interactions, forms a loop which connects the C- and N- terminal domains.1 
 
 




Figure 3.2: A surface representation of the GSK-3β protein monomer in complex with an inhibitor 
(PDB ID: 1UV5).8 The inhibitor atoms are depicted by spheres. (Figure reproduced from Li et al.7) 
3.2 Molecular Modelling 
The molecular modelling docking studies were performed using the Maestro v11.1 Schrödinger Drug 
Discovery Suite.6 Maestro v11.1 is the graphical user interface, from which Glide v7.49–11 was run to 
perform high accuracy docking studies. Glide (Grid-based ligand docking with energetics) is a docking 
methodology that uses hierarchical filters to search the positional, orientational and conformational 
space around a docked ligand, in order to optimise its interactions with the receptor active-site.9 The 
receptor’s shape and properties are defined in a receptor grid. In the final steps of the hierarchy, the 
best docking poses are energy minimised and scored.12 
Energy minimisation in the Maestro v11.1 suite was performed with the molecular mechanics force 
field, OPLS3.13 The basic characteristics of the OPLS potential energy function include that it is based 
on a fixed charge electrostatic model. Non-bonded interactions are described by Coulomb and van der 
Waals terms. At the heart of the OPLS model is the non-bonded parameter set which was produced 
when the parameters were optimised to simulate liquid state thermodynamics. Bonding interactions 
include bond-stretching and angle-bending interactions which are described by harmonic terms. 
Torsion is described by a condensed Fourier transform term. The parameters required in bonded 
terms were fitted to quantum chemical data in the design of the OPLS3 force field model.13 
The X-ray crystallographic structure of the reference compound, AR-A014418 (3),2 in complex with 
GSK-3β was utilised to perform our docking studies (PDB ID: 1Q5K). Docking studies performed by 
Lo Monte et al.14 suggested that their reversible benzothiazole urea inhibitors had a similar docking 
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mode to AR-A014418. Therefore, we were operating from the reasonable presumption that the 
proposed benzothiazole- and benzimidazole ureas would display a docking mode similar to AR-
A014418. Considering that an irreversible inhibitor first binds the ATP-binding pocket in a reversible 
fashion, whereafter the covalent bonding step takes place, the modelling studies were commenced 
with reversible docking studies. The best reversible ligand poses would then be subjected to covalent 
modelling studies. 
3.2.1 Protein preparation 
The typical protein structure obtained from the Protein Data Bank requires preparation before it can 
be utilised for molecular modelling purposes. These protein files consist solely out of heavy atoms 
(hydrogen atoms are omitted) and may contain water molecules, co-crystallised ligands, co-factors 
and metal ions. Connectivity information, such as bond orders and formal charges are generally 
omitted. Several other issues, such as ionisation- and tautomeric state assignments and side chain 
orientations were thus addressed during protein preparation in order to obtain a chemically correct 
structure.12 
To this end, the GSK-3β/AR-A014418 co-crystallised structure (resolution: 1.94 Å) was imported into 
Maestro from the Protein Data Bank (PDB ID: 1Q5K).2 The multimeric protein was next reduced to a 
single ligand-receptor unit by deleting protein chain B, in order to reduce computational cost. All Glide 
computations were thus performed on protein chain A. 
The GSK-3β protein was prepared with the ‘Protein Preparation Wizard’.6 The structure was pre-
processed to assign bond orders, add missing hydrogen atoms, fill in missing side chains and loops, 
delete water molecules beyond 5 Å of the ligand and to return the most favourable protonation state 
for the ligand at pH 7 ± 2. The protein structure was further refined by optimising the hydrogen bond 
network at pH 7, which included the sampling of asparagine, glutamine and histidine residue 
orientations.12 After hydrogen bond optimisation, water molecules with fewer than 3 hydrogen bond 
interactions to non-water molecules were removed. In the final step, the refined structure was energy 
minimised, using the OPLS3 force field and an RMSD tolerance of 0.30 Å to restrain heavy-atom 
displacement. 
3.2.2 Receptor grid generation 
Before a ligand can be docked to a receptor molecule, the receptor molecule’s physical properties, 
and more specifically the active site, must be defined and represented on a receptor grid. The receptor 
grid is rigid and only allows for side-chain hydroxylated carbon rotations. However, Glide incorporates 
a degree of protein flexibility by decreasing the van der Waals radii of non-polar atoms in the active 
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site, with a constant factor. Smaller penalties for close contacts allow for more flexible docking since 
proteins can adjust their active-site slightly to accommodate ligands.10 
The receptor grid of the GSK-3β protein was generated using the ‘Receptor Grid Generation’ panel. 
The co-crystallised ligand in the active site was used to define the size of the receptor grid box, 
whereafter the ligand was excluded from the receptor grid. The centre of the active site grid box was 
set to the following coordinates: x = 24.91 Å, y = 22.48 Å, z = 9.30 Å, based on the centroid of the 
co-crystallised ligand. 
3.2.3 Our selection of electrophilic warheads and subsequent ligand preparation 
Several electrophilic moieties capable of targeting nucleophilic residues, such as cysteine, have been 
identified and employed in the development of irreversible covalent inhibitors. These warheads 
include electrophilic moieties such as α-halomethylketones, acrylamides, alkynes, vinyl sulfonates 
sulfonyl fluorides and epoxides.15,16 These electrophilic warheads achieve irreversible bond formation 
most commonly through Michael addition, nucleophilic substitution or nucleophilic addition 
mechanisms.16 
The α-halomethylketone-, acryloyl-, propioloyl- and acrylamide warheads were explored in this 
project. In the case where our hypothesis and small library of irreversible inhibitors yield positive 
results, additional electrophilic warheads could be investigated in the future. Since our work is based 
on the irreversible halomethylketone inhibitors developed by Perez et al.17 (see Chapter 2), we began 
with exploration of the α-halomethylketone moiety. As a matter of intellectual and scientific curiosity, 
the C-Br bond of the α-halomethylketone group was also replaced with a double or triple bond to form 
the acryloyl- and propioloyl moieties, which are proposed to react through a Michael addition 
reaction. Furthermore, the acrylamide moiety was explored, due to its predominant employment in 
covalent inhibitor development.15 Acrylamide warheads are favoured, since they display weak 
electrophilic properties and require close proximity to their targets, in order to interact.15 This 
variation in electrophilic warhead could prove useful as we develop knowledge and capability in the 
broader field of developing new irreversible inhibitors for kinases involved in a variety of disease 
processes. In the context of this project we hoped it would give variation in the biological efficacy of 
the inhibitors, which could be useful. 
The modelling studies were focused mainly on the set of ligands depicted in Scheme 3.1. The proposed 
set is based on the chosen scaffold, 1-(6-cyanobenzo[d]thiazol-2-yl)-3-(4-methoxybenzyl)urea (4), as 
discussed in Chapter 2. Therefore the cyano-substituted ureas were also included in the modelling and 
synthetic studies. It should be noted that nitrile warheads have been proposed to act as reversible 
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targeted covalent inhibitors in their reactions with cysteine.18,19 A reversible targeted covalent 
inhibitor binds the target residue through a covalent interaction, to form a covalent protein-inhibitor 
complex, but its reversible mechanism of bond formation enables the inhibitor to dissociate from the 
protein on the biological timescale.15 
 
Scheme 3.1: The main set of ligands that was used in the molecular docking studies 
It is worth mentioning that an additional brief modelling study was performed, where ligands with a 
one carbon atom linker between the electrophilic warhead and the benzothiazole/benzimidazole ring 
were docked (Figure 3.3). The linker-type ligands delivered poor results for the benzothiazole series 
during the reversible docking stage – it pushed the ligands slightly towards the outside of the pocket 
– therefore the linker-type ligands were not further explored. 
 
Figure 3.3: Ligands with a one carbon atom linker 
Reference ligand, AR-A014418 (3), and the ligands in Scheme 3.1 required ligand preparation before 
they could be utilised in the docking studies. The ‘LigPrep’ function was used to convert the 2D ligand 
structures into chemically correct 3D structures. The correct protonation state of the ligands at 
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pH 7 ± 2, as well as tautomeric structures, were generated. The final step of ‘LigPrep’ entailed 
geometry optimisation to generate low-energy structures. 
Theoretically, the benzimidazole ligands have three tautomeric state structures (Scheme 3.2). The 
tautomeric states of the benzimidazole ring undergo rapid exchange, thereby rendering substitution 
positions 5 and 6 equivalent in an unsubstituted aromatic ring.20 After ligand preparation, we chose 
to dock both the tautomeric structures a and b for all benzimidazole ligands. 
  
Scheme 3.2: The tautomeric states of the benzimidazole urea 
Throughout this thesis, all benzimidazole ureas were drawn in the tautomeric form a, as defined in 
Scheme 3.2. We hypothesised that tautomer a might be more favoured, due to the intramolecular 
hydrogen bond that is able to form between N1 and the urea carbonyl oxygen, to form an 
intramolecular 6-membered ring. Tautomeric form a was also supported by crystal structure analysis, 
which will be discussed further in Chapter 5, Section 5.3.1.1. 
3.2.4 Reversible docking of our proposed GSK-3β inhibitors 
The Glide ligand docking calculations were next performed using the extra-precision (XP) sampling 
mode. This is a more extensive sampling and scoring method that applies strict penalties to docking 
poses that do not comply with established physical chemistry concepts. The improved scoring function 
includes concepts such as adequate solvation, hydrophobic pocket occupancy and the differentiation 
of hydrogen bond types, with the aim of removing false positives.11 
Ligands were docked flexibly, by the sampling of ligand conformations in the receptor site. Following 
the default settings, ligand conformations were restricted to the sampling of pyramidal nitrogen 
inversion and ring conformations. We chose to restrict amide bonds to trans conformations within an 
angle range of 20°. No additional constraints were applied during the docking stage and final post-
dock minimisation was performed using the OPLS3 force field. 
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Overall, the described method resulted in good reversible docking 
results. In the initial stages, the docking model was validated by 
docking the co-crystallised ligand of the parent PDB file (3, 
AR-A014418, also known as the reference ligand), into the modelled 
protein structure (Figure 3.4). The pose of docked ligand 3 was used to calculate an RMSD (root-mean-
square deviation) value relative to its core position in the crystal structure. The RMSD value was 
0.800 Å and this low deviation value confirmed the accuracy of the docking model. AR-A014418 (3) 
had an XP docking score of -7.005 kcal/mol and this value was used as a reference in the comparative 
docking studies of the proposed inhibitors. 
 
Figure 3.4: An overlay of reference ligand AR-A014418 (3) in its co-crystallised conformation (PDB 
ID: 1Q5K; coloured by element) and docked conformation (green); RMSD = 0.800 Å. The position of 
the Cys199 residue relative to the ligand is highlighted. Binding interactions are displayed in 
dotted lines: yellow – hydrogen bonds; blue – aromatic hydrogen bonds; green – pi-pi stacking 
interaction. 
3.2.4.1 Evaluating the position of the electrophilic warhead relative to Cys199 in the reversible 
docking pose 
We also docked Perez et al.’s17 irreversible halomethylketone inhibitor 
5 (IC50 = 580 nM) in the modelled protein to investigate the position of 
its electrophilic warhead relative to Cys199, in the reversible docking 
stage (Figure 3.5). There is no X-ray crystallographic structure available 
in the literature for this compound, so the modelled docking pose could 
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not be compared to the binding mode of a co-crystallised ligand. In this docking model, the distance 
from the Cα atom of the HMK moiety to the sulfur of Cys199 was 4.82 Å. 
We had to decide on a suitable distance criteria which would guide the selection of non-covalently 
docked ligands for subsequent covalent docking studies. Herein, the distance refers to the distance 
between the sulfur atom of Cys199 and the reactive atom of the electrophilic moiety. For 5, the 
modelled distance was 4.82 Å. In essence, if this distance was too large, the electrophilic warhead 
would not be in close enough proximity of Cys199 during the reversible docking stage to allow for 
covalent modification. A maximum distance – which would be used in the visual inspection of 
reversible docking poses – had to be defined, in order to select favourable ligands for further covalent 
docking studies. 
 
Figure 3.5: Our docking model of Perez et al.'s17 irreversible HMK GSK-3β inhibitor. The measured 
distance between the sulfur atom of Cys199 and the Cα carbon of the halomethylketone moiety is 
highlighted (4.82 Å). 
In the covalent docking protocol of Maestro Schrödinger, the Cys199 side chain conformation is 
sampled with respect to different conformations of the ligand’s electrophilic moiety. Poses must 
satisfy a distance of ≤ 5 Å between the two atoms which will constitute the new covalent bond. This 
distance is unrealistic for a covalent bond, but is tolerated due to optimisation steps that follow 
downstream in the modelling process.21 In our case, we investigated the covalent feasibility of our 
non-covalently docked ligands, before subjecting them to the covalent docking protocol (which have 
high computational cost). At this stage, the configuration of the electrophilic moiety had not yet been 
optimised with respect to the Cys199 side chain conformations, therefore we would generally accept 
a distance close to 5 Å (or less). 
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3.2.4.2 Reversible docking results 
The proposed set of GSK-3 inhibitors displayed good reversible docking results and similar binding 
modes to reference ligand, AR-A014418 (3). The docking results of the proposed halomethylketone 
inhibitors (7, 8a, 8b) will be used to demonstrate the general docking modes observed for the 
benzothiazole and benzimidazole series, respectively.  
Figure 3.6 represents the surface binding site of the receptor and the orientation of benzothiazole 
urea 7 in the pocket. Both the benzothiazole and the benzimidazole series fit inside the pocket in this 
manner. The electrophilic warhead is positioned in the deepest end of the pocket, the urea 
functionality acquires hydrogen bonds to the hinge binding region and the 4-methoxybenzyl group is 
situated towards the outside of the pocket. The L-shape of the binding pocket is noteworthy. The 
pocket is elongated along the hinge region, which facilitates the planarity of the core regions of our 
inhibitors. The benzylic carbon of the 4-methoxybenzyl group, allows out-of-plane bending to facilitate 
the entrance region of the pocket. 
Figure 3.7 depicts the binding interactions of HMK benzothiazole urea 7. In this modelling outcome, 
both NH protons of the urea functionality formed hydrogen bonds with hinge residue Val135. A 
weaker aromatic hydrogen bond was visible between one of the benzothiazole aromatic hydrogens 
and the backbone carbonyl oxygen of hinge residue Asp133. In addition, the HMK carbonyl oxygen 
formed a hydrogen bond with Asp200. The distance between the Cα carbon of the HMK group and the 
sulfur atom of Cys199 was 4.45 Å, which is a promising target distance (based on our parameters) for 
further covalent studies. The rest of the benzothiazole series (4, 9, 11, 13) displayed the same binding 
modes. The binding interactions of the acrylamide benzothiazole urea 13 differed slightly. The larger 
electrophilic moiety pushed the molecule slightly towards the outside of the pocket. Instead of 
forming two hydrogen bonds with Val135, the two NH protons formed bonds with Pro136 and Val135 
respectively. 
The binding modes and binding interactions of HMK benzimidazole urea 8a and its tautomer, 8b, are 
represented in Figure 3.8 and Figure 3.9. Both benzimidazole urea tautomers have similar docking 
modes, therefore tautomerism was not expected to hinder successful docking. The benzimidazole 
series accommodated the formation of one additional hydrogen bond in the hinge region. Hydrogen 
bond interactions are established with hinge residues Val135 and Pro136, and an aromatic hydrogen 
bond with Asp133 is present in most cases. The imidazole moiety allows rotation of the benzimidazole 
ring while maintaining the additional hydrogen bond in the hinge region, thereby allowing the 
electrophilic moiety to manoeuvre itself into the most favourable docking position.  





Figure 3.6: The positioning of proposed HMK inhibitor 7 in the GSK-3β binding pocket 
 
Figure 3.7: Ligand-receptor interactions of HMK ligand 7 with the binding site residues. Dotted 
lines: yellow – hydrogen bonds; blue – aromatic hydrogen bonds. The measured distance between 
the sulfur atom (Cys199) and the Cα atom (HMK) is highlighted (4.45 Å). 




Figure 3.8: Ligand-receptor interactions of HMK ligand 8a with the GSK-3β binding site residues. 
Dotted lines: yellow – hydrogen bonds; blue – aromatic hydrogen bond. The measured distance 
between the sulfur atom (Cys199) and the Cα atom (HMK) is highlighted (4.73 Å). 
 
Figure 3.9: Tautomer 8b of the HMK ligand and its ligand-receptor interactions with the GSK-3β 
binding site residues. The measured distance between the sulfur atom (Cys199) and the Cα atom 
(HMK) is highlighted (3.38 Å). 
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The benzimidazole scaffold’s ability to form one additional hydrogen bond can be ascribed to the 
donating ability of the lone pair on the unprotonated nitrogen in the imidazole ring. The lone pair 
nitrogen of unsubstituted benzimidazole is a weak base in nature, due to the strong acidic properties 
of its conjugate acid (pKa [BH+] = 5.59).22 If the benzimidazole ring is rotated towards the hinge region, 
the weak base can form a hydrogen bond interaction with the backbone amide hydrogen of Val135. 
However, the lone pair nitrogen of unsubstituted benzothiazole is a much weaker base (the conjugate 
acid is much stronger, pKa [BH+] = 1.2)23 and does not seem to facilitate this hydrogen bond. 
The reversible docking results are summarised in Table 3.1. All of the proposed inhibitors displayed 
more favourable (lower energy) docking scores than reference ligand 3 (AR-A014418)’s docking score 
of -7.005 kcal/mol. The benzimidazole series yielded the best docking scores, with scores ranging from 
-9.338 kcal/mol to -8.469 kcal/mol. This is most likely due to the benzimidazole urea’s ability to 
accommodate an additional hydrogen bond to the hinge region of the ATP binding site. The 
benzothiazole series also yielded good docking scores in the range of -7.651 kcal/mol to -7.206 
kcal/mol. 
Tautomeric structures of the benzimidazole-derived ureas were originally docked to ensure that 
tautomerism does not cause major shifts in the docking poses of ligands. Generally, the tautomeric 
structures docked similarly in the binding site. The different tautomers resulted in changes in the 
distances of the electrophilic warheads from the Cys199 target residue and may also provide improved 
stereoelectronic effects, i.e. in the orientation of the electrophilic warhead. No favourable docking 
poses were obtained for ligands 10b and 12b, although good docking scores were obtained for their 
tautomers 10a and 12a, respectively. In these two cases, the existence of a tautomeric equilibrium 
might result in lower activity scores. 
When the proposed ligands were compared, the propioloyl-substituted ureas (11, 12) displayed the 
least favourable docking scores and gave relatively long target distances in the non-covalent docking 
stage. The linearity of the propioloyl group, together with the planarity of the core structure, are 
proposed to disadvantage this type of ligand. 
Overall, the distances measured between electrophilic warhead reactive atoms and the sulfur of 
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Table 3.1: A summary of the reversible docking results (Glide v7.4, Schrödinger Drug Discovery 
Suite). 
Reversible and irreversible reference ligands 
  

















   
3 -7.005  5 -5.939 4.82    
Proposed ligands 













































-7.278 4.45  
8a 





-7.305 5.53  
10a 
-9.338 3.84  
10b 
No result – 
 
11 
-7.206 5.16  
12a 
-8.596 5.15  
12b 
No result – 
 
13 
-7.562 5.08  
14a 
-9.180 5.20  
14b 
-8.963 4.86 
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3.2.5 Covalent docking studies of the proposed GSK-3β inhibitors 
The reversible docking poses associated with the results in Table 3.1, were used as the input ligands 
for the covalent studies. The covalent docking study was performed using the Glide ‘Covalent Docking’ 
function.21 This function commences with a reversible docking step wherein non-covalent ligand poses 
of the input ligand are sampled in order to obtain poses which are stabilised by non-covalent 
interactions and in which the reactive warhead is in close proximity of the target residue. Then the 
receptor side chain conformation is sampled relative to these poses. Subsequently, the receptor and 
ligand are linked by a covalent bond and the protein-ligand complex is optimised by OPLS3 and 
VSGB2.0.24 VSGB2.0 is an energy model used in protein structure modelling. 
Due to the formation of a covalent protein-ligand complexes, a different scoring method is used to 
score covalent ligand poses. A binding affinity score is used to compare the ligands. The affinity score 
combines the non-covalent Glide docking score with a Glide docking score obtained from a ‘non-
covalent’ version of the final covalent docking pose.21  
The covalent binding modes and binding interactions of HMK ligands 7 and 8 are stacked on their non-
covalent binding modes in Figure 3.10 and Figure 3.11, respectively. These covalent binding modes 
are also representative of the covalent poses observed for the rest of the benzothiazole- and 
benzimidazole urea series. From the docking results, it appeared that covalent bond formation was 
tolerated well inside the binding site, with only minor shifts in ligand orientation being observed. The 
covalent bond tended to shift the ligand slightly towards the outside of the pocket. Therefore it was 
observed that instead of forming two hydrogen bonds with Val135 in the hinge region, the ligands 
tended to form one hydrogen bond with Val135 and one hydrogen bond with either Pro136 or Tyr134. 
The rest of the ligand-receptor interactions (hydrogen bonds and aromatic hydrogen bonds) were 
maintained throughout covalent docking.  
The tautomeric structures of the benzimidazole-based ligands docked similarly during the non-
covalent studies, therefore the best covalent affinity score that was obtained for a ligand regardless 
of its tautomeric state, was reported (Table 3.2). An affinity score of -7.359 kcal/mol was calculated 
for covalent reference ligand 5. The nitrile ligands, 4 and 6, displayed good covalent affinity scores of 
-7.670 kcal/mol and -8.447 kcal/mol, respectively. It should be noted that the nitrile ligands are aimed 
to provide selectivity through a covalent attack on Cys199, but may also provide decreased toxicity 
risks due to the potential reversible nature of the bond. The rest of the proposed set of ligands 
obtained positive covalent docking results, with affinity scores ranging between -9.457 kcal/mol 
and -7.548 kcal/mol. These promising covalent results supported our aim of designing and 
synthesising targeted covalent inhibitors for the GSK-3 enzyme. 




Figure 3.10: An overlay of HMK ligand 7 (benzothiazole-derived) in its covalent docking pose 
(coloured by element) and in its non-covalent docking pose (green); Dotted lines: yellow – 
hydrogen bonds; blue – aromatic hydrogen bonds. The covalent bond with Cys199 is highlighted. 
 
Figure 3.11: An overlay of HMK ligand 8 (benzimidazole-derived) in its covalent docking pose 
(coloured by element) and in its non-covalent docking pose (green); Dotted lines: yellow – 
hydrogen bonds; blue – aromatic hydrogen bonds. The covalent bond with Cys199 is highlighted. 
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Table 3.2: A summary of the irreversible docking results (Covalent Docking, Schrödinger Drug 
Discovery Suite) 
Irreversible reference ligand 
 
  
 Affinity score (kcal/mol)   
5 -7.359   
Proposed ligands 
 * 
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3.3 Concluding remarks 
The modelled binding modes, target distances and docking scores in both the non-covalent and 
covalent stages were very promising for the proposed 1-benzazole-3-(4-methoxybenzyl)urea series. 
Therefore, it was decided that the whole series, as was depicted in Scheme 3.1, would be synthesised. 
If the variations in ligand binding modes correlate to variations in biological efficacy, it could provide 
good evidence that this molecular modelling approach can be used to develop and refine potential 
lead molecules. The synthesis of the proposed compound library will be discussed next. 
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Chapter 4: The synthesis of functionalised benzothiazole- and 
benzimidazole urea scaffolds 
4.1 Key retrosynthetic steps 
The retrosynthetic analysis in Scheme 4.1 highlights the major steps that we envisioned would 
constitute the synthetic route to the 1-benzazole-3-(4-methoxybenzyl)urea series. The urea 
functionality of the proposed inhibitors would be constructed from a nucleophilic 2-aminobenzazole 
ring and an electrophilic equivalent of 4-methoxybenzylamine (15). To this end, the synthesis of 
appropriately functionalised, bicyclic benzothiazole/benzimidazole ring scaffolds was commenced. 
Due to the electrophilicity of the reactive warheads, we aimed to incorporate the warheads after urea 
formation, through modification of the substituent R- group. 
 
Scheme 4.1: Important retrosynthetic steps that would form part of the synthetic approach 
The first priority was to synthesise the benzothiazole and benzimidazole heterocycles that would serve 
as scaffolds in the proposed inhibitors. 
4.2 Privileged structures: Benzothiazoles and benzimidazoles 
Privileged structures are extremely useful in drug discovery strategies, especially in the rational design 
and/or optimisation of new lead compounds.1 IUPAC (International Union of Pure and Applied 
Chemistry) defined a ‘privileged structure’ as a “substructural feature which confers desirable (often 
drug-like) properties on compounds containing that feature. [A privileged structure] often consists of 
a semi-rigid scaffold which is able to present multiple hydrophobic residues without undergoing 
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hydrophobic collapse.”2 A privileged structure provides a core structure with highly favourable 
characteristics to a drug design process and this core structure can then be functionalised to improve 
potency and selectivity.1 
Benzothiazoles are privileged bicyclic compounds which are present in marine and terrestrial natural 
products of medicinal use. Benzothiazole-derived therapeutics have shown a broad range of biological 
activities including antitubercular, antimicrobial, antimalarial, anticonvulsant, anthelmintic, analgesic, 
anti-inflammatory, antidiabetic and anticancer properties.3 The benzothiazole heterocycle is stabilised 
by its aromatic structure and contains reactive sites which permit functionalisation.4,5 
The benzimidazole heterocyclic structure attracted attention in the 1950s when it was found to form 
a characteristic part of the structure of Vitamin B12 (Figure 4.1).6 Benzimidazole derivatives are also 
bioisosteres of the purine nucleotides, which promote their interactions with biomolecules in living 
organisms.7 Benzimidazole-derived therapeutics have been associated with a broad range of biological 
activities including anthelmintic, antitubercular, antimicrobial, antimalarial, anticonvulsant, analgesic, 
anti-inflammatory, antidiabetic, anticancer, antifungal, antiviral and antioxidant properties.7 
 
Figure 4.1: The structure of vitamin B12 and the purine nucleotides, adenine and guanine. (Image 
of Vitamin B12 reproduced from Pan et al.8) 
4.3 The synthesis of the 6-substituted 2-aminobenzothiazoles 
There are several reported methods for 2-aminobenzothiazole synthesis. After a literature survey on 
2-aminobenzothiazole synthesis,3,9 it could be concluded that substituted anilines and arylthioureas 
are the most commonly used starting materials. Synthetic methods toward N-substituted 
2-aminobenzothiazoles were also present in the literature and could provide an alternative synthetic 
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route to our target compounds in the case of synthetic complications. Typical examples of the 
reported methods for the synthesis of 2-aminobenzothiazoles are described below and displayed in 
Scheme 4.2. These include: 
1. Anilines and substituted anilines in glacial acetic acid have been reacted with alkali 
thiocyanates in the presence of an oxidising agent such as bromine, at low temperatures, to 
yield the 2-aminobenzothiazole ring.9,10 
2. In the Hugerschoff reaction, arylthioureas are treated with bromine in chloroform to promote 
cyclisation.11,12 
3. The condensation reaction of 2-aminothiophenols with substituted aldehydes, carboxylic 
acids, alcohols, amines, nitriles and isocyanates are widely utilised in the synthesis of 
2-substituted benzothiazoles.3,13 
4. Various transition metals, including palladium, copper and iron, have been involved in the 
catalytic synthesis of N-substituted 2-aminobenzothiazoles, through the promotion of C-S 
bond formation/C-H functionalisation.3,14 
 
Scheme 4.2: Examples of synthetic procedures towards 2-aminobenzothiazoles 
The first-mentioned procedure was followed, given that the substituted anilines were available as 
starting material and since the success of the method had been well-documented. This type of system, 
where a thiocyanation agent (KSCN, NaSCN or NH4SCN) is combined with an oxidant, is regarded as 
the general procedure for the thiocyanation of aromatic amines.15 Several different oxidants have 
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been used successfully in thiocyanation reactions in the literature, including Br2, Cl2, I2, dichlorourea, 
FeCl3, HIO3, I2O5 and NBS.15  
Thiocyanation refers to the substitution of a hydrogen atom with a thiocyano group and is mediated 
by thiocyanogen (SCN)2.16 Thiocyanogen acts as the electrophile in an electrophilic aromatic 
substitution reaction (eq. 4.1). It is therefore expected to favour substitution at the para and the ortho 
positions when it is reacted with an aromatic compound, containing an electron-donating group.16 
ArH + (SCN)2 → ArSCN + HSCN (eq. 4.1) 
Thiocyanogen is unstable in solution, with a tendency to polymerise and hydrolyse. Therefore 
thiocyanogen is commonly generated in situ when it is employed in reactions.16 The oxidant is 
responsible for the liberation of thiocyanogen from the alkali thiocyanate salts (eq. 4.2).17 
2KSCN + Br2 → (SCN)2 + 2KBr (eq. 4.2) 
After the ortho thiocyanation of our para substituted anilines (starting materials 16 – 19), cyclisation 
was required to form the 2-aminobenzothiazoles (20 – 23). The ease of cyclisation was influenced by 
the substituents located on the thiocyanated ring, and could occur either spontaneously or require 
heating under acidic conditions.16 
 
Scheme 4.3: The initial strategy towards 2-aminobenzothiazole synthesis 
The R-groups (R= CN, COMe, CO2Me, NO2) in Scheme 4.3 were selected in accordance with the 
proposed strategy to modify these precursor groups into electrophilic warheads after urea synthesis. 
4.3.1 The synthesis of 2-aminobenzo[d]thiazole-6-carbonitrile (20) 
As a first attempt to synthesise 2-aminobenzo[d]thiazole-6-carbonitirile (20), a two-step literature 
procedure described by Sawhney and Boykin was followed (Scheme 4.4).18 To this end, 
4-aminobenzonitrile (16) and KSCN were dissolved in glacial acetic acid and treated dropwise with a 
solution of Br2 in glacial acetic acid, at 5 °C. From Sawhney and Boykin’s procedure, it was deduced 
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that the thiocyanated intermediate (24) can be isolated, whereafter a 2 h reflux in HCl would promote 
cyclisation to afford 20. The reaction was carried out following their KSCN/Br2 procedure and the 
intermediate (24) was isolated, but in only a low yield of 36%. 
 
Scheme 4.4: A two-step procedure to synthesise 2-aminobenzo[d]thiazole-6-carbonitrile (20) 
Several by-products were visible on TLC during the synthesis of the thiocyanated intermediate (24), 
which explained the low yield. Firstly, the molecular bromine (Br2) present in the solution is highly 
reactive and difficulties in controlling the stoichiometric amount of Br2 could result in brominated side 
products.19 Secondly, the nascent thiocyanogen generated in the reaction solution is unstable and 
could participate in side reactions.17 Optimisation studies were performed to increase the yield of the 
thiocyanation reaction. The results of the optimisation studies are concluded in Table 4.1, which will 
follow after the discussion of the results. The following optimisation strategies were thus explored: 
4.3.1.1 Avoiding bromination side-products 
Jordan and co-workers prepared a series of 2-aminobenzothiazoles using the Hugerschoff reaction 
and managed to improve the stoichiometric control over their bromine source by substituting Br2 with 
the organic ammonium tribromide, benzyltrimethylammonium tribromide (PhCH2NMe3Br3).19 The 
high molecular weight and crystallinity of the organic ammonium tribromide allowed for better 
control over stoichiometry. Jordan and co-workers19 extended their studies to explore the use of 
PhCH2NMe3Br3 in the synthesis of 2-aminobenzothiazoles from substituted anilines. They successfully 
combined PhCH2NMe3Br3 with NH4SCN in acetonitrile to synthesise their 
2-alkylaminobenzothiazoles.19 Based on their studies, Br2 in the thiocyanation reaction (16 to 24, 
Scheme 4.4) was replaced with an organic ammonium tribromide. Phenyltrimethylammonium 
tribromide (PhNMe3Br3/ PTAB) was available, and increased the yield of the thiocyanation step to 62%. 
Phenyltrimethylammonium tribromide served as a bromine source (eq. 4.3). 
PhNMe3Br3 ⇄ Br2 + PhNMe3Br (eq. 4.3) 
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4.3.1.2 Considering a neutral solvent 
DCM was explored as a neutral reaction solvent in the thiocyanation reaction with PTAB and KSCN, to 
determine whether solvent acidity affects the thiocyanation substitution reaction. The described 
conditions led to a much lower yield of 16%, therefore no other neutral solvents were explored. 
4.3.1.3 Avoiding side-reactions due to nascent thiocyanogen 
Side-reactions in the thiocyanation step due to freshly generated, reactive thiocyanogen, can be 
limited through the optimisation of various variables, including reagent equivalents, addition times, 
temperature and water content.17 An optimisation study performed by Pilyugin et al.,17 on the efficient 
preparation of 2-nitro-4-thiocyanoaniline in acetic acid with bromine and a thiocyanate salt, provided 
insight into the influence of these variables on thiocyanation. Based on their findings, the 
thiocyanogen equivalents generated in situ were optimised, which resulted in an increased yield of 
75% for compound 24. PTAB (the oxidant) was added in slight excess (1.4 equiv) to ensure that an 
excess of thiocyanogen was generated, in order to thiocyanate all of the starting material (16, 
1.0 equiv). However, to limit the formation of bromination by-products, potassium thiocyanate was 
used in excess (3.2 equiv) relative to PTAB. The results of the discussed optimisation strategies are 
summarised in Table 4.1. 
 
Scheme 4.5: The thiocyanation of 4-aminobenzonitrile (16) 
Table 4.1: Summary of attempted thiocyanation reactions, step a (Scheme 4.5) 
Step a 
Entry Reagents and reaction conditions % yield 
1 
1) KSCN (2 equiv), glacial AcOH 
2) Br2 (1 equiv), glacial AcOH, 5 °C to r.t., 2 h 
36 
2 
1) KSCN (2 equiv), glacial AcOH 
2) PTAB (1 equiv), 10 °C to r.t., 5.5 h 
62 
3 
1) KSCN (2 equiv), DCM 
2) PTAB (1.1 equiv), r.t., 20 h 
16 
4 
1) KSCN (3.2 equiv), glacial AcOH 
2) PTAB (1.4 equiv), 5 °C to r.t., 5 h 
75 
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In the literature,18 the thiocyanation reaction is quenched with water, whereafter the yellow 
precipitate is filtered and then recrystallised from EtOH. This procedure was followed for entries 1 and 
2 in Table 4.1. However the dense yellow precipitate was difficult to work with, therefore a work-up 
step was incorporated into entries 3 and 4 which involved the extraction of the yellow precipitate with 
EtOAc and then purifying with silica column chromatography. 
The presence of the thiocyanate group was confirmed by IR spectroscopy (Figure 4.2), 
to ensure that it is the thiocyanated product (24) and not the cyclised product (20). The 
C≡N stretch of the nitrile group was visible at 2220 cm-1. A strong peak at 2158 cm-1 
represented the stretch of the thiocyanate group. It should be noted that the isomeric 
isothiocyanates (R-NCS) usually display a broad, strong characteristic peak in the region 
2105 – 2060 cm-1.20 The absence of such a peak confirmed the successful attachment of a thiocyanate 
group to the ring and not a rearranged isothiocyanate group. 
 
Figure 4.2: The IR spectrum of 4-amino-3-thiocyanatobenzonitrile (24) 
In the 1H NMR spectrum of 24, the doublet of ArH2 resonated at 7.95 ppm with a meta J-coupling 
constant of 2.0 Hz, ArH6 resonated at 7.57 ppm as a doublet of doublets with J-coupling constants of 
8.6 Hz and 2.0 Hz, and ArH5 resonated as a doublet at 6.87 ppm with an ortho J-coupling constant of 
8.6 Hz. The amine protons were represented by a broadened singlet at 6.93 ppm integrating for 2H. 
In the 13C NMR spectrum, the expected number of eight carbon resonances were clearly visible. The 
1H NMR spectrum of 24 correlated well with the literature,21 whereas the 13C NMR spectrum has not 
yet been recorded in the literature. 
Next, the cyclisation of 4-amino-3-thiocyanatobenzonitrile 24 (step b, Scheme 4.6) was approached. 
Following a literature procedure,18 intermediate 24 was heated under reflux in 3.5 M HCl/H2O for 2 h, 
which unfortunately did not afford the desired product. With the use of 3.5 M anhydrous HCl in 
1,4-dioxane, water was excluded from the reagents and the product was obtained in a yield of 58% 
(entry 2, Table 4.2). The best yield (85%) was afforded when 24 was cyclised under anhydrous basic 
conditions, when heated under reflux with sodium hydride in THF (entry 4, Table 4.2). 




Scheme 4.6: The cyclisation of 4-amino-3-thiocyanatobenzonitrile (24) 
Table 4.2: Ring-closing reactions for Step b 
Step b 
Entry Reagents and reaction conditions % yield 
1 3.5 M HCl in H2O, reflux, 2h – 
2 3.5 M HCl in 1,4-dioxane, reflux, 1.5 h 58 
3 2 M HCl in 1,4-dioxane, reflux, 4.6 h 31 
4 NaH (1.4 equiv), THF, reflux, 2 h  85 
 
The success of the cyclisation reaction was confirmed by IR and NMR 
spectroscopy, as well as HRMS. Compound 20 displayed the C≡N stretch of the 
nitrile group at 2215 cm-1 in the IR spectrum. The thiocyanate stretch, previously 
observed at 2158 cm-1, was absent and indicated the possible formation of the 
benzothiazole heterocycle. Ring formation was confirmed by the characteristic signal of the C2 carbon 
at 170 ppm in the 13C NMR spectrum of 20 (Figure 4.3). Sawhney and Boykin18 have performed a 
13C NMR spectroscopic study on 2-aminobenzothiazoles, in which the signal of the C2 carbon was 
consistently the furthest downfield, in a range of 162 – 172 ppm, and could be identified easily. The 
13C NMR spectroscopic resonance signals of 20 corresponded very well with the literature.18 Sawhney 
and Boykin’s study allowed the assignment of all the carbon chemical shifts. The 1H NMR spectrum 
accounted for the amine as a broad singlet at 8.03 ppm, integrating for 2H. The signal of the ArH7 
aromatic proton appeared as a doublet (J = 1.7 Hz) at 8.17 ppm, the ArH4 doublet (J = 8.4 Hz) resonated 
at 7.41 ppm and ArH5 resonated as a doublet of doublets (J = 8.4, 1.7 Hz) at 7.60 ppm, again confirming 
the presence of a 1,2,4-trisubstituted aromatic ring. 




Figure 4.3: The 13C NMR spectrum (DMSO-d6) of 2-aminobenzo[d]thiazole-6-carbonitrile (20) 
4.3.2 Completing the synthesis of the 2-aminobenzothiazole compound set 
The syntheses of the rest of the 2-aminobenzothiazoles were approached with the hope of utilising 
the same synthetic strategy as was developed for 2-aminobenzo[d]thiazole-6-carbonitrile (20). The 
method would once again entail thiocyanation in the ortho position relative to the amine, isolation of 
the intermediate and subsequent reflux in a NaH/THF mixture to promote cyclisation. In the first 
thiocyanation step the 4-substituted anilines (17, 18,† 19, Scheme 4.7) and KSCN were dissolved in 
glacial acetic acid, treated with PTAB and stirred at room temperature for 5 h. When these reaction 
mixtures were analysed by TLC after 5 h, two major products were visible. With the help of NMR 
spectroscopy of the isolated major products in the reaction with 17, it could be reasonably concluded 
that spontaneous ring-closing was taking place alongside thiocyanation. These reactions did not reach 
completion overnight, leaving a mixture of uncyclised and cyclised products. Luckily, when the 
reaction mixtures were heated under reflux for 10 minutes after the 5 h thiocyanation period, 
cyclisation was pushed towards completion to yield 2-aminobenzothiazoles 21, 22 and 23 in one-pot 
reactions in good to acceptable yields. 
 
Scheme 4.7: The synthesis of 1-(2-aminobenzo[d]thiazol-6-yl)ethanone (21), methyl 
2-aminobenzo[d]thiazole-6-carboxylate (22) and 6-nitrobenzo[d]thiazole-2-amine (23) 
                                                          
† The preparation of 18 is described on p. 68 
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It is noteworthy that when 4-aminobenzonitrile (16, Scheme 4.5) was thiocyanated, many more 
by-products were observed on TLC than with the thiocyanation of 17, 18 and 19. These by-products 
resulted in the failure of utilising a one-pot reaction for the synthesis of 2-aminobenzo[d]thiazole-6-
carbonitrile (20). Therefore, isolation of intermediate 24 was necessary before cyclisation. 
1-(2-Aminobenzo[d]thiazol-6-yl)ethanone (21) was afforded in an 81% yield and 
6-nitrobenzo[d]thiazole-2-amine (23) was synthesised and isolated with a yield of 54%. The yield of 23 
was lowered as a result of multiple purification attempts, in order to remove a smaller impurity of 
similar polarity. Compounds 21 and 23 displayed NMR spectroscopic data in accordance with the 
literature.18,22,23 In both cases, cyclisation was confirmed by the signal of the C2 carbon in the 13C NMR 
spectra. The C2 carbon resonance was visible at 169.8 ppm for 21, and at 171.8 ppm for 23. 
Methyl 2-aminobenzo[d]thiazole-6-carboxylate (22) was afforded in a yield 
of 74%. The spectroscopic data of 22 was inaccessible in our literature 
sources, and therefore the spectrum of compound 22 will be discussed. The 
amine protons were visible in the 1H NMR spectrum at 7.90 ppm as a broad 
singlet integrating for 2H. The characteristic resonance pattern of the aromatic ring protons, entailing 
a doublet (J = 1.8 Hz), doublet of doublets (J = 8.4, 1.8 Hz) and a doublet (J = 8.4 Hz) each integrating 
for one proton, were clearly visible in the aromatic region. The methoxy hydrogens were accounted 
for by a singlet at 3.82 ppm, integrating for 3H. The important carbonyl signal of the methyl ester was 
present at 166.1 ppm in the 13C NMR spectrum and the C2 signal displayed at 169.8 ppm. The chemical 
shifts in the 13C NMR spectrum of 22 were assigned by analogy, through a comparison with ethyl 
2-aminobenzo[d]thiazole-6-carboxylate.18 The shifts correlated very well and the ethyl carbon signals 
(14.2, 60.9 ppm) were substituted with a methyl carbon signal at 51.8 ppm. In the IR spectrum of 22, 
the carbonyl stretching vibration was present at 1691 cm-1. The structure was lastly confirmed by the 
presence of the [M+H]+ ion peak in the HRMS spectrum at 209.0386 (m/z calculated: 209.0385). 
4.3.3 The synthesis of methyl 4-aminobenzoate (18) 
In Scheme 4.7, methyl 4-aminobenzoate (18) was used as starting material to synthesise methyl 
2-aminobenzo[d]thiazole-6-carboxylate (22). Compound 18 was prepared from 4-aminobenzoic acid 
(25) according to a conventional procedure (Scheme 4.8).24,25 To this end, a solution of 4-aminobenzoic 
acid (25) in an excess of methanol was cooled to 0 °C, whereafter thionyl chloride was added dropwise. 
The solution was heated under reflux overnight, followed by neutralisation, extraction and purification 
of the product (18) resulting in it being obtained in an excellent yield of 97%. In this procedure, thionyl 
chloride reacted with methanol to form anhydrous HCl, which catalysed the Fischer esterification of 
the carboxylic acid with methanol.26 




Scheme 4.8: The esterification of 4-aminobenzoic acid (25) 
4.4 The synthesis of the 6-substituted 2-aminobenzimidazoles 
Different methods have been developed in the literature to synthesise 2-aminobenzimidazoles.27 Our 
literature search focused on ring-formation and more specifically the preparation of 
2-aminobenzimidazoles which are unsubstituted at position 1 and contain a primary amine in position 
2. It should be noted that ortho-phenylenediamines are the most common starting materials utilized 
in benzimidazole heterocyclisation.7,27 Typical examples of the reported methods are described below 
and displayed in Scheme 4.9: 
1. The condensation of o-phenylenediamines with cyanogen bromide, cyanogen chloride, in situ 
generated cyanogen bromide or cyanamide afford high yields of 2-aminobenzimidazoles.27 
2. ortho-Substituted nitrobenzenes have been utilised in reductive cyclisation approaches, in 
which the compound cyclises when the nitro group is hydrogenated. Schulze and co-workers28 
heated a mixture of N-(2,4-dinitrophenyl)cyanamide, elemental iron and glacial acetic acid 
under reflux, which resulted in a partial reduction and subsequent benzimidazole formation. 
3. N-(o-aminophenyl)thioureas have been cyclised in ethanol with the help of oxidants, such as 
mercury(II) oxide and mercury(II) chloride to afford the desired 2-aminobenzimidazoles.27 
 
 
Scheme 4.9: Examples of synthetic procedures towards 2-aminobenzimidazoles 
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In this project, the first procedure utilising cyanogen bromide was followed, since the reaction method 
has been well described in the literature29 and the o-phenylenediamine starting materials could be 
synthesised from the same substituted anilines (16 – 18) that were used as starting materials for the 
benzothiazole synthesis. A proposed synthetic plan towards the set of required 6-substituted 
2-aminobenzimidazole rings is displayed in Scheme 4.10. 
 
Scheme 4.10: A proposed synthetic route towards 2-aminobenzimidazoles 39 – 42 
The synthetic plan was deduced from the available literature on the synthesis of 2-amino-1H-
benzo[d]imidazole-6-carbonitrile (39) from 4-aminobenzonitrile (16).29–31 This synthetic route would 
also be followed in the preparation of the rest of the 6-substituted 2-aminobenzimidazoles 40 – 42, 
with the hope of utilising the same or similar reaction conditions. Selectivity issues were anticipated 
in the reduction step (SnCl2·2H2O) in the synthesis of 6-nitro-1H-benzo[d]imidazol-2-amine (42) from 
4-nitroaniline (R = NO2). Therefore 4-nitrobenzene-1,2-diamine (38) was purchased, which was 
expected to be readily cyclised to form 42. 
The first three steps entailed a protection-nitration-deprotection procedure that is commonly seen in 
the literature when generating ortho-nitro anilines in strong acids. This is as a result of nitration studies 
on aniline in concentrated sulfuric acid, which resulted in mixtures of meta- and para-substituted 
products, with traces of ortho-substituted products.32 The strongly acidic media is able to protonate 
the free amine to form the anilinium ion which is meta-directing. The equilibrium between aniline 
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(para-/ortho-directing) and the anilinium ion results in mixtures of mainly the ortho and meta 
products.32 This mixture of products can be avoided by acylation of the amine. The resultant 
acetanilide is much less basic and acts as a para-/ortho-director. Acylation also decreases the reactivity 
of the aniline by delocalisation of the lone pair into the carbonyl group, which reduces the risk of over-
nitration. To this end, the substituted anilines 16 – 18 would be acylated before nitration. 
After the three-step sequence, the new nitro group would be reduced to form the 
o-phenylenediamine, which could subsequently be cyclised with cyanogen bromide to form the 
6-substituted 2-aminobenzimidazoles. 
4.4.1 The acetylation reactions 
The acetylation of compounds 16, 17 and 18 (Scheme 4.10) was readily accomplished with an excess 
of acetic anhydride, resulting in yields of 83%, 97% and 94% respectively. 4-Aminobenzonitrile (16) 
was acetylated according to the literature procedure of Fairley et al.,31 in which acetic anhydride 
served as reagent and solvent. To this end, 4-aminobenzonitrile (16) was added portion-wise to an 
excess of acetic anhydride over 1 hour. Iced water was then added to the white suspension, 
whereafter the precipitated product was collected, washed and dried. The acetylation reactions of 17 
and 18 were carried out in mixtures of acetic anhydride and DCM to allow for efficient stirring. The 
NMR spectra of synthesised compounds 26, 27 and 28 compared well to the literature.33–36 
4.4.2 Nitration of the acetamides 
The nitration of N-(4-cyanophenyl)acetamide (26) was conducted in accordance with the 
nitration procedure described by Fairley et al.31 Following their procedure, the acetamide 
(26) was added portion-wise to a cooled solution of potassium nitrate in concentrated 
sulfuric acid. In this procedure, concentrated nitric acid was generated in situ from the 
mixture of potassium nitrate and concentrated sulfuric acid. Nitric acid reacted further with 
concentrated sulfuric acid to yield nitronium ions (NO2+).37 This mechanism is displayed in 
Figure 4.4.38 It is well-known that the nitronium ion is the active nitrating agent that participates as 
the electrophile in the electrophilic substitution reaction on the aromatic ring.37 




Figure 4.4: The formation of the nitronium (NO2+) ion and its electrophilic role in the nitration of 
acetamide 26.38 
In our hands it was found that the nitration reaction was very sensitive to temperature. Fairly et al.31 
reported a yield of 88% (29) when they maintained the reaction temperature below 0 °C. In order to 
minimise overnitration, it was found necessary to conduct the reaction at −15 °C, to quench the 
reaction after 3.5 h and to utilise less than 2 equivalents of potassium nitrate. The optimisation studies 
for this reaction are summarised in Table 4.3, with the best reaction combination highlighted. 
Table 4.3: Optimisation of the nitration of N-(4-cyanophenyl)acetamide (26) 
Entry 
Reagents and reaction conditions 
% yield 
Reagents Temperature (°C) Time (h) 
1 KNO3 (2 equiv), 96 % H2SO4 0 to 5 3 20 
2 KNO3 (1.5 equiv), conc. H2SO4 −15 to −10 3.5 69 
3 KNO3 (1.5 equiv), conc. H2SO4 −15 to −10 5.5 43 
4 KNO3 (2.1 equiv), conc. H2SO4 −15 to −10 3.5 67 
5 KNO3 (3 equiv), conc. H2SO4 −15 to −10 2.5 51 
 
From the optimisation experiment, N-(4-cyano-2-nitrophenyl)acetamide (29) was 
isolated in a yield of 69%. In terms of spectroscopic characterisation, the amide NH 
proton appeared as a broad singlet at 10.54 ppm in the 1H NMR spectrum and the acetyl 
methyl protons integrated for 3H at 2.34 ppm. The aromatic protons appeared as a 
doublet (J = 8.9 Hz, ArH6) integrating for 1H at 9.02 ppm, a doublet (J = 2.0 Hz, ArH3) 
integrating for 1H at 8.55 ppm and a doublet of doublets (J = 2.0, 8.9 Hz, ArH5) 
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integrating for 1H at 7.87 ppm. This aromatic substitution pattern confirmed the presence of the 
mononitrated product. In the IR spectrum, the nitrile stretching vibration was visible at 2231 cm-1 and 
according to the bands of nitro compounds in the literature,39 it is suggested that the bands at 
1499 cm-1 and 1345 cm-1 represent the N=O asymmetric and symmetric stretches of the nitro group. 
All in all, the NMR spectroscopic results compared well to the literature.40 
Succeeding in the development of a nitration strategy, the optimised KNO3/conc. H2SO4 nitration 
procedure (entry 2, Table 4.3) was applied to N-(4-acetylphenyl)acetamide (27). Surprisingly, a very 
low yield of 10% was obtained and TLC analysis represented a mixture of starting material, 
mononitrated product and dinitrated product. Lowering of the reaction temperature to −25 °C did not 
improve the results. It was postulated that a milder nitrating agent would be required to nitrate 27. 
The KNO3/conc. H2SO4 system is known to be very reactive, since the in situ generated nitric acid is 
ionised completely into nitronium ions, resulting in a high concentration of nitronium ions, which can 
cause overnitration.37 
A mixture of aqueous nitric acid and concentrated sulfuric acid (mixed acid) proved to be an effective 
and well-known alternative for nitration. The presence of water lowers the concentration of nitronium 
ions, resulting in milder nitrating action.37 From Figure 4.4 it can be deduced that the equilibrium 
leading to nitronium ion formation is pushed backwards by the addition of water, whereas an increase 
in sulfuric acid concentration pushes the nitration reaction forward. 
A very convenient nitration procedure was developed to nitrate acetamides 27 and 28 (Scheme 4.11). 
The N-(4-substituted phenyl)acetamide (27/28) and 65% nitric acid were combined and cooled to 0 °C. 
An equal volume of concentrated sulfuric acid (1:1 v/v; 65% HNO3/conc. H2SO4) was then added 
dropwise, whereafter the mixture was left to stir for 1 hour at 0 °C. The reaction was quenched with 
water, basified to pH = 8 with conc. NH4OH, extracted with EtOAc and then purified further by silica 
column chromatography. Very good selectivity for the mononitrated product was obtained using this 
procedure. 
 
Scheme 4.11: The nitration of acetamides 27 and 28 with mixed acid 
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Using this approach, N-(4-acetyl-2-nitrophenyl)acetamide (30) was obtained in a yield of 69% and in 
terms of characterisation the NMR spectroscopic results of 30 compared well to the literature.41 
Methyl 4-acetamido-3-nitrobenzoate (31) was also obtained in an excellent yield of 90%. The 1H NMR 
spectroscopic data of 31 displayed the amide NH proton signal at 10.55 ppm, the methoxy protons at 
3.88 ppm and the amide methyl protons at 2.12 ppm, both integrating for 3H. The three aromatic 
proton signals observed, each integrating for 1H, confirmed mononitration. 
4.4.3 The deacetylation and hydrogenation procedures 
The next deacetylation step proceeded without any difficulty. Compounds 29, 30 and 31 were 
individually heated under reflux in 1 M H2SO4 for 2 hours to afford compounds 32, 33 and 34 in 
excellent yields of 95%, 96% and 82% respectively (Scheme 4.12).30 The nitrile group of compound 29 
and the methyl ester group of compound 31 were stable against hydrolysis under these conditions. 
Again, the NMR spectroscopic results of all the compounds corresponded well to that available in the 
literature.30,40,42–44 
 
Scheme 4.12: The deacetylation and subsequent hydrogenation of compounds 29 – 31 
The reduction of 4-amino-3-nitrobenzonitrile (32) was first attempted under reflux with tin(II) chloride 
dihydrate, concentrated HCl and methanol.29 This reaction produced the desired product, but 
subsequent failure to separate the product from a by-product of similar polarity necessitated an 
alternative method. The diamines 35, 36 and 37 were therefore obtained by hydrogenation with a 
H2-balloon over 10% Pd/C at room temperature, in very clean reactions following the procedure of 
Tawar et al.45 The solvent ratio was adjusted from 4:1 (EtOAc: MeOH) to 2:1 (EtOAc: MeOH) in the 
hydrogenations of 33 and 34 to allow for dissolution of the starting material. The hydrogenation 
reactions could be monitored through reaction colour and were found to be complete when the 
reaction mixtures had changed colour from bright yellow to a transparent orange or red.  
Diamines 35, 36 and 37 were obtained in excellent yields of 99%, 90% and 91% respectively. In terms 
of spectroscopic analysis, the two amine signals were observed in the 1H NMR spectrum of each 
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compound. The amine signals appeared at 3.81 ppm and 3.39 ppm for 35, at 5.36 ppm and 4.63 ppm 
for 36 and at 5.27 ppm and 4.65 ppm for 37. 
In the hydrogenation of 32 the mild reaction conditions provided chemoselectivity to reduce the nitro 
group, which is highly reactive towards catalytic hydrogenation, in the presence of a nitrile 
functionality. 
4.4.4 Cyclisation to form the 6-substituted 2-aminobenzimidazoles 
Diamines 35 – 38 were cyclised according to the method of Starcevic et al.,29 in which the diamines 
were treated with 1.3 equivalents of cyanogen bromide in a mixture of methanol, water and 
acetonitrile (Scheme 4.13). The reaction was stirred at room temperature overnight and then basified 
with ammonium hydroxide. No precipitate formed, as suggested in the literature, and therefore a 
work-up procedure followed by silica column chromatography was required to isolate products 
39 – 42 in excellent yields. 
 
Scheme 4.13: The cyclisation of diamines 35 – 38 to form 6-substituted 2-aminobenzimidazoles 
The ring cyclisation step afforded 2-amino-1H-benzo[d]imidazole-6-
carbonitrile (39) in a yield of 89%. The 1H NMR spectroscopic data correlated 
with the literature data,29 however small differences in the chemical shift 
values were seen since the literature values were internally referenced to 
tetramethylsilane. Our values were referenced to the residual solvent signal in DMSO-d6 (δ 2.50 ppm 
in 1H NMR). In terms of key structural features, the primary amine integrated for 2H at 6.65 ppm and 
the imidazole NH1 was present as a single broad signal at 11.14 ppm. The aromatic protons were visible 
as a doublet at 7.46 ppm (J = 1.6 Hz, 1H) representing ArH7, a doublet of doublets at 7.26 ppm (J = 
1.6 Hz, 8.1 Hz, 1H) representing ArH5 and a doublet at 7.20 ppm (J = 8.1 Hz, 1H) representing ArH4. The 
nitrile band was visible at 2213 cm-1 in the IR spectrum of 39. The structure was lastly confirmed by 
the [M+H]+ ion in the HRMS spectrum (m/z calculated 159.0671, found 159.0666). 
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To our knowledge, the 13C NMR spectrum of 39 has not been reported in the literature before. The 
13C NMR spectrum of 39 displayed eight carbon signals, as expected, but four of these carbon signals 
appeared very weak and broad (Figure 4.5, broadened signals: δ = 144.0, 138.0, 114.4 and 112.4 ppm). 
In general, the acquisition of the 13C NMR spectra of the benzimidazoles was challenging. Even after 
running the sample overnight and increasing the concentration of the sample in the NMR 
spectroscopy tube, several of the signals were not visible or appeared as very weak, broad signals. 
Increasing the relaxation delay of the 13C NMR spectroscopic pulse sequence from 1s to 3s also did not 
improve the signal shapes. These problems were not observed in the equivalent 
2-aminobenzothiazole set, since 1,3-tautomerism in the benzothiazole ring was not possible. In 
previous studies on 2-substituted benzimidazoles, the tautomerism in the benzimidazole ring has been 
reported to result in the broadening of the C3a/C7a, C4/C7 and C5/C6 signal sets in the 13C NMR spectra.46 
Therefore the tautomeric effect is also suggested to result in the broadening of carbon signals in the 
13C NMR spectrum of 39. From the data of an NMR spectroscopic study by Lopyrev et al.47 on 2-
substituted 5(6)-nitrobenzimidazoles, it is suggested that the four broadened signals of 39 correspond 
to C3a, C7a, C4 and C7, which further supports the involvement of tautomeric effects. 
 
Figure 4.5: Tautomerism in the benzimidazole ring resulted in the broadening of signals in the 
13C NMR spectrum (DMSO-d6) of 39.46 
To assist in resolving the 13C NMR spectra of the 6-substituted 2-aminobenzimidazoles synthesised in 
this project, two-dimensional NMR spectroscopic studies were performed on methyl 2-amino-1H-
benzo[d]imidazole-6-carboxylate (41). No 13C NMR spectroscopic data has been reported in the 
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literature for compound 41. The 13C NMR spectrum of 41 displayed eight carbon shift signals instead 
of the expected number of nine signals (Figure 4.6). In an attempt to explain the 13C NMR spectrum of 
41, the gHSQC and gHMBC spectra were acquired and thus allowed for the assignment of the 13C NMR 
signals. As seen in the spectra of both compounds 39 and 41 (Figure 4.5 and Figure 4.6), the ArC3a and 
ArC7a carbons are associated with very weak, broad signals. The missing carbon signal in the 13C NMR 
spectrum of 41 was accounted for by the equivalent chemical shifts of the ArC4 and ArC7 signals at 
111.7 ppm. 
 
Figure 4.6: The 13C NMR spectrum (DMSO-d6) of methyl 2-amino-1H-benzo[d]imidazole-6-
carboxylate (41). Signals were assigned with the help of two-dimensional NMR spectroscopy 
(gHSQC, gHMBC). *: An asterix represents a tentative assignment. 
The 2D NMR spectroscopic data, correlations and assignments are available in tabular form in the 
experimental chapter (Chapter 9). The key correlations in the 2D NMR spectroscopic data, which 
allowed for the assignment of carbon signals, will be discussed next. The signals at 167.2 ppm and 
51.5 ppm in the 13C NMR spectrum of 41 represented the methyl ester’s carbonyl carbon and methoxy 
carbon respectively. The position of the 167.2 ppm shift of the ester carbonyl carbon was confirmed 
by 3-bond couplings to H5, H7 and OCH3 in the gHMBC spectrum (summarised in Figure 4.7). In the 
gHSQC spectrum of 41, two benzimidazole aromatic ring protons, H4 and H7, correlated to the signal 
at 111.7 ppm, representing the 1H4 – 13C4 and 1H7 – 13C7 one-bond connectivities. The signal at 
121.6 ppm arose from the carbon’s one-bond connectivity with H5. 




Figure 4.7: Long range 1H – 13C correlations in the gHMBC spectrum of compound 41 
The gHMBC spectrum of 41 assisted in the assignment of the remaining carbon signals of ArC2, ArC3a, 
ArC6 and ArC7a. The carbon signal at 157.4 ppm had no correlations in the gHSQC and gHMBC spectra 
and was assigned as ArC2. H5 and H7 correlated with ArC3a through 3-bond couplings, therefore the 
signal at 144.9 ppm was assigned ArC3a. The carbon atoms resonating at 119.8 ppm and 137.2 ppm 
each coupled to only H4 in the gHMBC spectrum, which was best explained by the 3-bond couplings of 
ArC6 and ArC7a with H4. Unfortunately, ArC6 and ArC7a could not be assigned unambiguously. The 
signals were thus tentatively assigned based on previously reported data on benzimidazoles,47 and the 
assumption that the quaternary carbons, ArC7a and ArC3a, would have similar chemical environments 
and signal intensities. Therefore 137.2 ppm was assigned ArC7a and 119.8 ppm was assigned ArC6. 
The 1H NMR spectroscopic data collected for compound 41 corresponded well to the literature (no 
13C NMR spectroscopic data was available).48 The imidazole NH1 proton was not visible in the 1H NMR 
spectrum due to tautomerism. Finally, the structure of methyl 2-amino-1H-benzo[d]imidazole-6-
carboxylate (41) was confirmed by the [M+H]+ ion in the HRMS spectrum (m/z calculated 192.0773, 
found 192.0779). 
1-(2-Amino-1H-benzo[d]imidazol-6-yl)ethanone (40) was afforded in a yield 
of 87%. The compound’s structure was confirmed with the help of 1H NMR, 
13C NMR, FT-IR and HRMS. Again, the imidazole NH1 proton was not visible in 
the 1H NMR spectrum due to tautomerism. Again, the resonances of the ArC3a 
and ArC7a signals appeared as broadened signals at 145.1 and 137.1 ppm in the 13C NMR spectrum of 
40. 
6-Nitro-1H-benzo[d]imidazol-2-amine (42) was synthesised in a quantitative 
yield. Of significance was that the rate of the reaction was slower and required 
an additional day of stirring. The 1H NMR spectroscopy data collected for this 
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compound fitted the literature.49 In the 13C NMR spectrum, the carbon signals of ArC3a, ArC4, ArC5, 
ArC6, ArC7 and ArC7a were broadened. 
Upon the investigation of the 13C NMR spectra of the synthesised 6-substituted 2-aminobenzimidazole 
set, it was concluded that the signals of carbons affected by tautomerisation often appeared weak 
and broad, which complicated interpretation. The largest extent of signal broadening was observed 
for the ArC3a and ArC7a carbons, but the tautomeric effects often influenced more carbons in the 
benzimidazole ring. 
The required 6-substituted 2-aminobenzothiazoles and the 6-substituted 2-aminobenzimidazoles 
were thus successfully prepared. The developed procedures have the potential to be extended to the 
synthesis of a broader range of 6-substituted- 2-aminobenzothiazoles and 2-aminobenzimidazoles. 
Proceeding from these successes, the prepared set of 2-aminobenzazoles was utilised as nucleophiles 
in the upcoming urea formation step. 
4.5 The formation of the ureas 
The objective for the urea formation step was to establish a synthetic procedure which could be 
applied to both the benzothiazole and the benzimidazole scaffolds. From the retrosynthetic analysis 
in Scheme 4.14, we envisaged transforming 4-methoxybenzylamine (15) into an equivalent 
electrophilic carbamoylating reagent (R1R2NC=O). This reagent could then be reacted with the 
nucleophilic 2-aminobenzazoles (20 – 23, 39 – 42) to produce the corresponding ureas. Effectively, the 
aim was to couple two primary amines, resulting in the formation of the urea functionality. 
4.5.1 Carbamoyl transfer agents 
Four electrophilic carbamoyl cation equivalents (43 – 46) were proposed in Scheme 4.14. Carbamoyl 
transfer reagents can be monosubstituted (R1HNC=O) or disubstituted (R1R2NC=O). The carbamoyl 
derivative of the primary amine, 4-methoxybenzylamine (15), would be monosubstituted, therefore 
the synthesis of N-monosubstituted carbamoylating reagents was explored. 
Compound 43 represents the isocyanate carbamoylating equivalent and it is known that isocyanates 
are able to transfer monosubstituted carbamoyl groups (R1HNC=O) onto nucleophiles.50 
Unfortunately, the most common preparations of isocyanates from primary amines require the use of 
toxic phosgene.51 The reaction with phosgene yields the carbamoyl chloride equivalent from which 
hydrogen chloride can be eliminated, either thermally or with a tertiary base, to form the isocyanate 
equivalent.52 Since N-monosubstituted carbamoyl chlorides can be unstable, the isocyanate 
equivalents are preferred.53 But still,  the general characteristics of isocyanates include toxicity, high 
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reactivity and instability.54,55 In addition, in the presence of moisture, many isocyanates will 
decompose rapidly.54 These characteristics are associated with handling difficulties when isocyanates 
are utilised in reactions, as well as storage difficulties.55 
The high reactivity and instability of isocyanates can result in lowered yields during urea synthesis. In 
the synthesis of several 1-aryl-3-benzylureas by Lo Monte et al.,56 isocyanate carbamoyl equivalents 
were generated in situ from benzylamines and triphosgene. These isocyanates were then reacted with 
unactivated or n-BuLi-preactivated aryl amines. The overall yields of the reactions ranged between 
11% and 75%, with only a third of the yields reading above 50%.56  
 
Scheme 4.14: A retrosynthetic analysis towards urea formation 
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Research has been aimed at the development of more stable, safe and storable carbamoylating 
reagents which can be obtained from greener, non-toxic synthetic procedures.50,57 These procedures 
utilise non-toxic phosgene substitutes, such as S,S’-dimethyl dithiocarbonate (DMDTC), 
N,N’-disuccinimidyl carbonate (DSC) and N,N’-carbonyldiimidazole (CDI) (Figure 4.8), to synthesise 
alternative carbamoyl transfer agents.  
 
Figure 4.8: The structures of S,S’-dimethyl dithiocarbonate (DMDTC), N,N’- disuccinimidyl 
carbonate (DSC) and N,N’-carbonyldiimidazole (CDI) and a general carbamate ester 
Possible carbamoyl cation derivatives which can be synthesised with use of DMDTC, DSC and CDI were 
displayed in Scheme 4.14, 44 – 46. Compound 44 represents a proposed S-methyl 
N-alkylcarbamothioate carbamoylating equivalent. Fochi and co-workers57 have published research 
on the synthesis of the S-methyl N-alkylcarbamothioates utilising the non-toxic reagent, DMDTC. In 
their work, the methylthiocarbonylating step with DMDTC required an excess of primary amine. 
Thereafter, the S-methyl N-alkylcarbamothioate equivalents were reacted with primary aliphatic 
amines to afford the ureas in high yields (>94%). The efficiency of urea formation with aromatic amines 
was not discussed.57 
The carbamate esters (Figure 4.8) of primary and secondary amines have been widely used to 
accommodate urea formation. Several carbamate protecting groups, e.g. t-butyl, Bn, Cl3CCH2 (Troc), 
have produced ureas in high yields.58 The N-hydroxysuccinimide (NHS) esters are popular carbamate 
esters in urea syntheses since the succinimidyl group withdraws electrons from the ester carbonyl 
carbon which promotes nucleophilic attack on the carbonyl group.54,59 Compound 45 in Scheme 4.14 
represents a proposed N-hydroxysuccinimide (NHS) ester equivalent of the carbamoyl cation synthon. 
Ogura and co-workers59 have developed a method in which NHS esters were prepared from primary 
or secondary amines with DSC (Figure 4.8), in acetonitrile and triethylamine at room temperature, to 
afford the NHS esters in yields of 50% – 90%. Unfortunately, the subsequent reactions of the NHS 
esters with primary amines yielded low to moderate quantities of urea 59 
Batey and co-workers have performed a substantial amount of research (from 1998 – 2012)50,60–64 on 
the use of CDI to prepare N,N-disubstituted carbamoyl cation synthon equivalents which can be 
applied to the synthesis of ureas, thioureas, carbamates, thiocarbamates and amides.50 Their results 
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on these  N,N-disubstituted carbamoylating reagents were outlined in a ‘full study’ in 200550 and were 
successfully concluded in 200864 with the establishment of common reaction- and purification 
conditions. 
CDI is commercially available, crystalline and readily handled.50 In the work of Batey and co-workers 
(Scheme 4.15), secondary amines were reacted with CDI in THF under reflux for 16 h, to form stable 
carbamoylimidazoles (47) in high yields.50 These N,N-disubstituted carbamoylimidazoles (47) 
displayed low reactivity towards nucleophilic attack and where therefore activated by N-alkylation 
with methyl iodide to form the resonance-stabilised carbamoylimidazolium salts (48).60 The 
carbamoylimidazolium salts (48) were more susceptible to nucleophilic attack.  
 
Scheme 4.15: The preparation of carbamoylimidazolium salts (48) from secondary amines in a two-
step procedure utilising CDI and iodomethane. The reaction of the salts (48) with primary and 
secondary amines yield tri- and tetrasubstituted ureas (49).50 
In most cases, these salts (48) were readily synthesised in high to quantitative yields, stable and 
storable for long periods of time.50 The carbamoylimidazolium salts (48) act as N,N-disubstituted 
carbamoylating reagents and form unsymmetrical tri- or tetrasubstituted ureas (49) in high to 
quantitative yields upon reaction with primary or secondary amines.50,64 
The use of CDI in urea synthesis attracted our attention due to the advantages that are offered with 
regard to reaction yields, non-toxicity and the stability of the carbamoylimidazoles. In order to use CDI 
in our synthetic procedures, we would have to synthesise N-monosubstituted carbamoylimidazole 
equivalents. Although most of Batey and co-workers’ research were focused on N,N-disubstituted 
carbamoylating reagents, they expanded their work to monosubstituted N-alkyl carbamoylimidazoles 
in 2012.65  
4.5.2 CDI coupling with primary amines: The synthesis of monosubstituted N-alkyl 
carbamoylimidazoles 
Batey and co-workers65 attempted to synthesise the monosubstituted N-alkyl carbamoylimidazole, N-
methyl carbamoylimidazole 50, by reacting methylamine (MeNH2) with CDI (Scheme 4.16). As 
previously discussed, when secondary amines were reacted with CDI, stable N,N-disubstituted 
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carbamoylimidazoles formed, which required alkylation to react further. However, when this primary 
amine, MeNH2, was reacted with CDI, a mixture of carbamoylimidazole 50 and the symmetrical urea 
product 51 formed. This implied that the N-monosubstituted carbamoylimidazole 50 was sufficiently 
reactive to react with a second MeNH2 molecule to form the symmetrical urea product. Additionally, 
the reactivity of the unhindered amine, MeNH2, could also promote the symmetrical urea formation. 
 
Scheme 4.16: The reaction of methyl amine with CDI by Batey and co-workers65 
Batey and co-workers65 solved this problem of symmetrical urea formation, by using the protonated 
methyl amine salt, methylammonium chloride (MeNH3Cl) as starting material and reacting it with CDI 
in the absence of a base. A proposed mechanism of the reaction is displayed in Figure 4.9 below.65 It 
is proposed that a MeNH3Cl molecule in close proximity to CDI in solution will activate the CDI by 
protonation. This protonation step will also provide a local concentration of MeNH2 molecules which 
can attack at the CDI electrophilic centre. The nucleophilic substitution reaction releases imidazole 
and a subsequent deprotonation step affords the carbamoylimidazole 50.65 This method thus afforded 
50 in a quantitative yield.  
 
Figure 4.9: The proposed mechanism of N-Alkyl carbamoylimidazole formation from the 
ammonium hydrochloride salt, MeNH3Cl. 
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N-methyl carbamoylimidazole (50) proved reactive enough to serve as a carbamoylating agent – the 
synthesis of the carbamoylimidazolium salt was not necessary – and was successfully reacted with 
primary and secondary amines in the presence of base (EtN3 or NaH) to form ureas in high yields.65 
Batey and co-workers65 briefly expanded their studies to the synthesis of alternative N-alkyl 
carbamoylimidazoles. A high yielding procedure to synthesise GSK-3 inhibitor, AR-A014418 (3), was 
developed and is displayed in Scheme 4.17. The ammonium hydrochloride salt of 
4-methoxybenzylamine (15) was generated in situ using 4 M HCl in dioxane in DCM, whereafter CDI 
and DMF were added to the mixture to form the carbamoylimidazole 46 in 98% yield. 
Carbamoylimidazole 46 was utilised as carbamoylating agent with 2-amino-5-nitrothiazole (52) to 
construct urea 3 in 97% yield. We envisaged utilising this procedure in the synthesis of our 
1-benzazole-3-(4-methoxybenzyl)ureas. 
 
Scheme 4.17: The synthesis of AR-A014418 (3) by Batey and co-workers65 
To explain the mechanistic aspects of urea formation with N-monosubstituted carbamoylimidazoles, 
the dissociation properties of the N-monosubstituted carbamoylimidazoles had to be considered. In 
contrast to the well-known stability of N,N-disubstituted carbamoylimidazoles, Staab66 reported that 
N-monosubstituted carbamoylimidazoles (53) tend to dissociate into isocyanates (55) and imidazole 
when in solution (Scheme 4.18). Therefore in the urea formation mechanism, it has been proposed 
that the carbamoylimidazole (53) dissociates into its isocyanate first, whereupon the isocyanate (55) 
reacts with an amine nucleophile to form the urea (54).67 This was established for aryl 
N-monosubstituted carbamoylimidazoles, wherein the aryl substituent can resonance-stabilise the 
zwitterionic intermediate which forms during dissociation.67 In contrast, N-benzyl carbamoylimidazole 
and N-methyl carbamoylimidazole did not dissociate in solution, supposedly due to their inability to 
provide resonance stabilisation.65,67 These results suggested that alkyl N-monosubstituted 
carbamoylimidazoles are attacked directly by nucleophiles to form ureas. 
 




Scheme 4.18: Aryl N-monosubstituted carbamoylimidazoles dissociate in solution to form 
isocyanate equivalents that participate in urea formation67 
Based on these results, we hypothesised that N-(4-methoxybenzyl) carbamoylimidazole (46) would 
not dissociate in solution, since the zwitterionic intermediate cannot be resonance-stabilised. 
Following the hypothesis, we proposed a mechanism in Scheme 4.19 for urea formation with 
N-(4-methoxybenzyl) carbamoylimidazole (46). In this mechanism, the deprotonated nucleophile 
reacts with carbamoylimidazole in a nucleophilic substitution reaction. 
 
Scheme 4.19: A possible reaction mechanism for urea formation with N-(4-methoxybenzyl) 
carbamoylimidazole (46) 
4.5.3 Our synthetic strategy towards urea formation 
Having studied the literature, our synthetic strategy would entail the installation of the urea moiety 
by CDI-mediated coupling. CDI would be reacted with the ammonium hydrochloride salt of 
4-methoxybenzylamine (15) to form the N-(4-methoxybenzyl) carbamoylimidazole (46), as displayed 
in Scheme 4.20. Carbamoylimidazole 46 would be reacted with the 6-substituted 2-aminobenzazoles 
to afford the 1-benzazolyl-3-(4-methoxybenzyl)ureas. The reagents were chosen to react with CDI in 
this order, as this would allow the bulk synthesis of N-(4-methoxybenzyl) carbamoylimidazole (46) for 
subsequent reactions with various 2-aminobenzazole scaffolds. 




Scheme 4.20: Our synthetic strategy to afford a series of 1-benzazolyl-3-(4-methoxybenzyl)ureas 
4.5.4 The synthesis of N-(4-methoxybenzyl) carbamoylimidazole (46) 
A mixture of 4-methoxybenzylamine (15) in DCM was treated with 4 M HCl in 1,4-dioxane while stirring 
at room temperature. The mixture changed colour from colourless to white, indicating the in situ 
formation of the ammonium hydrochloride salt. After 10 minutes of stirring, DMF and CDI were added 
to the mixture at 0 °C. The reaction reached completion within 7 minutes of stirring, as indicated by 
the solution’s end-point colour change from white to colourless. This short reaction time was found 
to be crucial to the success of the reaction and was in contrast with the 2 h reaction time reported in 
the literature.65 When the reaction mixture was left to stir for longer, additional by-product formation 
took place. 
A work-up procedure was carried out after the 7 minute reaction, in which the colourless solution was 
immediately concentrated in vacuo at 30 °C, diluted with EtOAc and washed four times with a 
saturated aqueous solution of NH4Cl to achieve DMF removal. The product was further purified by 
column chromatography to afford N-(4-methoxybenzyl) carbamoylimidazole (46) as a crystalline white 
solid in quantitative yield. 
The reaction method was readily scaled up from 0.14 g to 1.1 g (80% yield). The crystalline nature and 
stability of N-(4-methoxybenzyl) carbamoylimidazole (46) overcame the handling difficulties often 
associated with carbamoylating agents such as isocyanate. In addition, carbamoylimidazole 46 was 
storable in a sealed vial at room temperature for several months. 
In the proposed reaction mechanism (Scheme 4.21), 4-methoxybenzylamine hydrochloride increases 
the electrophilicity of CDI by protonation. This step also releases a local concentration of free 
4-methoxybenzylamine molecules which can participate in nucleophilic attack. A tetrahedral 
intermediate forms, from which imidazole (pKa [BH+] = 6.94 in DMSO, 25 °C)68 is expelled, due to its 
better leaving group ability in comparison to 4-methoxybenzylamine (pKa [BH+] = 10.32 in DMSO, 
25 °C).69 




Scheme 4.21: The reaction mechanism of the synthesis of N-(4-methoxybenzyl) carbamoylimidazole 
The 1H NMR spectrum of N-(4-methoxybenzyl) carbamoylimidazole 46 is depicted in Figure 4.10. The 
three imidazole ring protons were accounted for at 8.06 ppm, 7.41 ppm and 6.89 ppm, respectively. 
The para-methoxybenzyl protons resonated as doublets at 7.23 ppm and 6.85 ppm. 
 
Figure 4.10: The 1H NMR spectrum (CDCl3) of N-(4-methoxybenzyl) carbamoylimidazole (46) 
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It should be noted that the amide proton (NH) and the benzylic CH2 protons couple with one another. 
Therefore the amide proton was observed as a broad triplet at 7.57 ppm (J = 5.3 Hz) and the methylene 
protons were observed as a doublet integrating for 2H at 4.47 ppm (J = 5.6 Hz). The J-coupling values 
measured for these multiplets were not constant and this phenomenon was best accounted for by the 
broadness of the triplet signal. The broadened signal decreased the precision with which J-coupling 
values could be measured from the 1H NMR spectrum. Therefore the J-coupling value of the sharper 
methylene proton signal was reported in the experimental data of compounds displaying this 
phenomenon. The 1H NMR spectroscopic values of 46 deviated slightly from the values of Batey and 
co-workers,65 but the 13C NMR spectroscopic values corresponded very well. In addition, the structure 
was validated by the [M+H]+ ion in the HRMS spectrum (m/z calculated 232.1086, found 232.1092). 
The absence of additional sets of proton resonances67 in the 1H NMR spectrum — due to dissociated 
imidazole and isocyanate molecules — reinforced the hypothesis that N-(4-methoxybenzyl) 
carbamoylimidazole (46) do not dissociate spontaneously into its isocyanate equivalent in solution. 
The corresponding isocyanate [M+H]+ ion was also not present in the HRMS spectrum of 46. 
N-(4-methoxybenzyl) carbamoylimidazole (46) was successfully synthesised in a quantitative yield and 
allowed for subsequent urea formation reactions with the prepared 2-aminobenzazole heterocycles. 
4.5.5 Urea synthesis: Utilising the prepared 6-substituted-2-aminobenzothiazoles 
The N-(4-methoxybenzyl)-N’-(6-substituted benzothiazolyl)ureas (4, 56 – 58) were prepared in high 
yields, in a procedure that commenced with the dissolution of 2-aminobenzothiazole (20 – 23) and 
N-(4-methoxybenzyl) carbamoylimidazole (46) in DMF (Scheme 4.22). The mixture was treated 
portion-wise with 60% NaH in mineral oil and was left to stir at room temperature for 22 h. A work-up 
procedure involving multiple washes with a saturated aqueous solution of NH4Cl was conducted to 
accomplish DMF removal. 
 
Scheme 4.22: The synthesis of N-(4-methoxybenzyl)-N’-(6-substituted benzothiazolyl)ureas 
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These urea formation reactions proceeded fairly cleanly; however small quantities of excess 
N-(4-methoxybenzyl) carbamoylimidazole (46) had to be removed by column chromatography. This 
purification step was not simple, since the polarity of carboxamide 46 was close to the polarity of the 
urea products. Purification was achieved when a mixed mobile phase, which consisted of MeOH, 
EtOAc and DCM, was used during silica column chromatography. 
1-(6-Cyanobenzo[d]thiazol-2-yl)-3-(4-methoxybenzyl)urea (4) 
was synthesised in 99% yield. This proposed inhibitor has been 
synthesised before by Lo Monte et al.56 in 70% yield, with the 
use of an isocyanate equivalent. It was concluded that we 
significantly improved the yield of 4, with the use of N-(4-methoxybenzyl) carbamoylimidazole (46) as 
carbamoylating agent. The 1H NMR and 13C NMR spectroscopic results of 4 compared well to the 
literature.56 Again, the resonance signal of the NH3’’ proton was split by the methylene protons of 
benzylic carbon (C7’) to form a broad triplet at 7.20 ppm. The other urea proton, NH1’’, was visible as a 
broad singlet at 11.11 ppm. 
The following general trends were seen in the 1H NMR spectra of compounds 4, 56 – 58. The methoxy 
protons resonated at 3.73 ppm, the singlet integrating for 3H. The three benzothiazole proton signals 
(ArH4,5,7) coupled with one another and integrated for 1H each. The NH3’’ proton was generally 
observed as a broad triplet, whereas NH1’’ was observed in the range 11.02 – 11.25 ppm. The CH2 
proton resonance was split with a J-coupling constant of 5.8 Hz. Two doublets, each integrating for 
2H, appeared in the aromatic region due to the benzylic ring protons. In the 13C NMR spectra of 
compounds 4, 56 – 58, all expected carbon resonances were visible. 
56 and 57 are newly synthesised compounds and the structures were confirmed by 1H NMR, 13C NMR 
and FT-IR spectroscopy, as well as HRMS. Compound 58 is known and the spectroscopic data 
compared well to the literature data.56 Our synthetic procedure afforded 58 in a quantitative yield and 
improved greatly on the 26% yield reported by Lo Monte et al.56 
4.5.6 Urea synthesis: Reference ligand, AR-A014418 
Following the high yielding (97%) synthetic procedure of Batey and co-workers,65 3 was synthesised 
from the reaction of 2-amino-5-nitrothiazole (52) with N-(4-methoxybenzyl) carbamoylimidazole 46 
in the presence of sodium hydride (Scheme 4.23). Several by-products were visible on TLC when the 
reaction was monitored and after a work-up procedure and column chromatography, the product was 
still impure. Trituration with DCM successfully afforded the pure product in >95% purity by LCMS, but 
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unfortunately in a low yield of 26%. The spectroscopic data of 1-(4-methoxybenzyl)-3-(5-nitrothiazol-
2-yl)urea (3) compared very well to the literature.65 
The reason for our low yield might be explained by the fact that the 2-amino-5-nitrothiazole (52) 
starting material was old and might have decomposed slightly over several years (the powder was 
brown instead of yellow). The nature of the by-products present in the reaction mixture and the crude 
product thus necessitated purification by trituration. 
 
Scheme 4.23: The urea synthesis of AR-A014418 (3) 
4.5.7 Urea synthesis: Utilising the prepared 6-substituted-2-aminobenzimidazoles 
It was envisaged that the N-(4-methoxybenzyl)-N’-(6-substituted benzimidazolyl)ureas would be 
constructed from the 6-substituted-2-aminobenzimidazoles (39 – 42) via the same urea formation 
procedure. 
In the initial reaction, 2-amino-1H-benzo[d]imidazole-6-carbonitrile (39) was treated with 
carbamoylimidazole 46 and NaH in DMF (Scheme 4.24). However this experimental procedure proved 
to be more challenging than expected. Firstly, a substantial amount of starting material (39) was left 
unreacted in solution. Secondly, any carbamoylimidazole 46 that remained in solution could not be 
separated from the product by column chromatography, due to the small polarity difference. This 
problem was solved with the use of an excess amount of base (NaH), to ensure that all 
carbamoylimidazole 46 reacted. Thirdly, the product was slightly unstable in solution. The 
decomposed by-product displayed similar polarity and was successfully removed by column 
chromatography with a mobile phase mixture of MeOH, EtOAc and DCM. To limit the quantity of 
decomposed product, the urea product had to be purified immediately after reaction completion. 
It should be noted that no starting material remained in solution after the reaction was completed, 
when a 2-aminobenzothiazoles heterocycle (e.g. 20) was used as nucleophile. However, with the 
2-aminobenzimidazole heterocycles (e.g. 39) as nucleophiles, starting material always remained in 
solution (see the yield comparison in Scheme 4.24). It is suggested that this might be due to 
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2-aminobenzimidazole’s weaker nucleophilic nature. A lone pair or negative charge on the primary 
amine’s nitrogen atom experiences greater delocalisation into the benzimidazole ring since the 
electrons can delocalise over three nitrogen atoms. 
 
Scheme 4.24: A comparison of urea formation with 2-aminobenzothiazoles and 
2-aminobenzimidazoles 
Heating the reaction mixture to 80 °C did not push the reaction forward. It was then noted that 
although a substantial amount of 2-amino-1H-benzo[d]imidazole-6-carbonitrile (39) remained in 
solution, nearly none of the carbamoylimidazole 46 was left. Due to 39 not being a good nucleophile, 
46 was consumed in more favourable side reactions. 
To increase the nucleophilicity of the starting material, the reaction was attempted in THF with a 
stronger base, n-BuLi; however, more by-products formed. The by-products were later explained by 
the observation that the starting material (39) did not dissolve well in less polar solvents, THF and 
DCM, thereby hindering the reaction and promoting by-product formation. Therefore, the initial 
reaction conditions employing NaH and the polar solvent, DMF, were retained. Remaining starting 
material (39) could be removed readily as water-soluble salt in the work-up procedure, by washing 
with 1 M HCl. 
In future optimisation studies, an increase in the electrophilicity of the carbamoylimidazole could be 
explored as an alternative to push the reaction forward. Methylation of the distal nitrogen in the 
imidazole ring of carbamoylimidazole 46 will form the resonance-stabilised carbamoylimidazolium salt 
and may activate 46 to make it more susceptible to nucleophilic attack by 39. 
1-(6-Cyano-1H-benzo[d]imidazol-2-yl)-3-(4-methoxybenzyl)urea (6) was obtained in a yield of 49% and 
the developed procedure was applied to afford the rest of the N-(4-methoxybenzyl)-N’-(6-substituted 
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benzimidazolyl)ureas in moderate yields (Scheme 4.25). To the best of our knowledge, ureas 6 and  
59 – 61 have not been reported before in the literature. The structures of these compounds were thus 
confirmed by 1H NMR, 13C NMR and FT-IR spectroscopy and HRMS. 
 
Scheme 4.25: The synthesis of N-(4-methoxybenzyl)-N’-(6-substituted benzimidazolyl)ureas 
The three amine protons of 1-(6-cyano-1H-benzo[d]imidazol-
2-yl)-3-(4-methoxybenzyl)urea (6) were distinguishable in its 
1H NMR spectrum and resonated at 12.09 ppm, 10.21 ppm and 
7.48 ppm, respectively. The amine signal at 7.48 ppm was 
broadened and resembled the broad triplet expected for NH3’’. 
The benzimidazole ring protons resonated at 7.76 ppm as a singlet integrating for 1H (ArH7) and at 
7.44–7.41 ppm as a multiplet integrating for 2H (ArH4, ArH5). The CH2 proton signal appeared as a 
doublet (J = 5.8 Hz) at 4.32 ppm integrating for 2H and the OCH3 proton signal appeared at 3.73 ppm 
integrating for 3H. Two doublets, each integrating for 2H and with a J-coupling constant of 8.7 Hz 
represented the benzyl ring protons ArH2’, ArH3’, ArH5’ and ArH6’.  
Similar trends were seen in the 1H NMR spectra of compounds 59 – 61. However, the benzimidazole 
ring proton signals observed for ArH4, ArH5 and ArH7 appeared broadened in especially the 1H NMR 
spectra of ester-derivative 60 and nitro-derivative 61. The broadened signals are highlighted in the 
1H NMR spectrum of 60 (Figure 4.11). Signal broadening can be explained by the tautomerism in the 
benzimidazole ring. As experienced with the 6-substituted 2-aminobenzimidazoles (39 – 42) in Section 
4.4.4, it was also challenging to obtain the 13C NMR spectra of the benzimidazole ureas 6, 59 – 61, due 
to tautomeric effects. In general, the 13C NMR spectra of ureas 6, 59 – 61 were relatively inconclusive, 
due to missing carbon signals and the presence of weak, broadened signals. Only the signals in the far 
downfield and far upfield regions could be assigned; nonetheless, these signals corresponded well to 
the proposed structures. The structures were confirmed further with HRMS. 




Figure 4.11: The 1H NMR spectrum (DMSO-d6) of methyl 2-[3-(4-methoxybenzyl)ureido]-1H-
benzo[d]imidazole-6-carboxylate (60). The broadened signals of ArH4, ArH5 and ArH7 are 
highlighted in red. 
4.6 Chapter conclusion 
This chapter commenced with the synthesis of appropriately functionalised benzothiazole and 
benzimidazole heterocycles which would constitute the scaffolds of our proposed 1-benzazole-3-(4-
methoxybenzyl)urea GSK-3β inhibitors. Synthetic procedures towards these heterocycles were 
successfully developed and afforded the 6-substituted 2-aminobenzothiazoles and 6-substituted 
2-aminobenzimidazoles in good yields. The final section of this chapter addressed urea synthesis, 
which required the development of an electrophilic carbamoylating reagent which would facilitate the 
coupling of two primary amines to form unsymmetrical disubstituted ureas. The N-(4-methoxybenzyl)-
N’-(6-substituted benzothiazolyl)ureas were developed in excellent yields, whereas the synthesis of 
N-(4-methoxybenzyl)-N’-(6-substituted benzimidazolyl)ureas proved more challenging and afforded 
moderate yields. The nitrile-derivatised ureas (4 and 6) and the reference ligand AR-A014418 (3) were 
obtained from these syntheses and were sent for biological testing. The rest of the prepared ureas 
were precursors to proposed GSK-3β inhibitor molecules and their further modification will be 
discussed in the next chapter. 
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Chapter 5: Incorporating the electrophilic warheads of the proposed 
irreversible targeted covalent inhibitors 
This chapter addresses the incorporation of electrophilic warheads onto the prepared 1-benzazole-3-
(4-methoxybenzyl)ureas to complete the synthesis of the Cys199-targeted covalent inhibitors which 
were designed to react with GSK-3 through an irreversible mechanism. To this end, the 
N-(6-substituted benzothiazolyl)-N’-(4-methoxybenzyl)ureas (56 – 58) and the N-(6-substituted 
benzimidazolyl)-N’-(4-methoxybenzyl)ureas (59 – 61) were synthesised with substituents in the sixth 
position, which can be modified to afford the desirable electrophilic warheads onto the scaffold. The 
modification objectives can be grouped into three sections as depicted in Scheme 5.1. The first 
modifications will focus on the alpha-bromination of acetyl derivatives 56 and 59 in order to obtain 
the halomethylketone derivatives. The second section of modifications is aimed at the synthesis of 
the acryloyl- and propioloyl-substituted products 9 – 12 from the ester-functionalised precursors, and 
the last modifications will pertain to the synthesis of the acrylamide inhibitors, 13 and 14. 
 
Scheme 5.1: The introduction of electrophilic warheads onto the synthesised 1-benzazole-3-(4-
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5.1 Alpha-monobromination to yield the halomethylketones 
As discussed in the review of Vekariya and Patel,1 a plethora of α-monobromination methods has been 
developed in the literature to address the bromination of aryl substituted ketones and other carbonyl 
compounds.1 Several synthetic challenges, including over-bromination, low regioselectivity, the use of 
toxic reagents and long reaction times have motivated the development of a variety of procedures.1 
Different bromine sources have been utilised together with various catalysts, additives, solvents and 
temperatures in α-monobromination procedures.1 Examples of bromine sources include reactions 
with N-bromosuccinimide (NBS),2–6 molecular bromine,7–9 hydrobromic acid,10,11 copper(II) bromide,12 
bromo ionic liquids,13 bromotrimethylsilane,14 ammonium bromide15,16 and organic ammonium 
tribromides, such as tetrabutylammonium tribromide17 and phenyltrimethylammonium tribromide.18 
Aryl substituted ketones often have more than one electron-rich donor site, which necessitates 
regioselective control to promote ketone halogenation over electrophilic aromatic substitution. 
Furthermore, α-bromination is often complicated by over-bromination in which more than one 
α-hydrogen are substituted to form the α,α-dibromoketone or even the α,α,α-tribromoketone. 
Selectivity for the monosubstituted product can be optimised with the use of suitable reagents and 
reaction conditions. However, a small amount of disubstituted product almost always accompanies 
the monosubstituted product in the equimolar reaction of a ketone with a bromine source, due to the 
occurrence of a disproportionation reaction (eq. 5.1).19,20 This disproportionation reaction can 
increase the amount of dibrominated product as well as the amount of unbrominated product 
(starting material) in the reaction mixture. 
2RCOCH2Br  ⇌  RCOCH3 + RCOCHBr2 (eq. 5.1) 
5.1.1 α-Bromination of 1-(6-acetylbenzo[d]thiazol-2-yl)-3-(4-methoxybenzyl)urea (56) 
In order to minimise disubstitution on the α-carbon of the acetyl group, careful stoichiometric control 
was required in the α-bromination reaction. The crystallinity and high molecular weight of the organic 
ammonium tribromide, trimethylphenylammonium tribromide (PTAB, PhNMe3Br3), facilitated 
satisfactory control over the equivalents of bromine source that entered the reaction. The utility of 
PTAB in α-brominations was discovered by Marquet and Jacques in 1959.21 Apart from the advantages 
in stoichiometric control, PTAB is a much weaker electrophile than molecular bromine and provides 
more selectivity in reactions.18 It has been suggested that α-bromination with PTAB, commences with 
enolization of the ketone in the rate-determining step, whereafter fast-stage bromination takes 
place.17 
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In our studies, the α-bromination of 1-(6-acetylbenzo[d]thiazol-2-yl)-3-(4-methoxybenzyl)urea (56) 
was unfortunately not selective for the monobrominated product when the reaction was treated with 
PTAB in a MeOH-DCM (1:1) solvent system.22 After five hours of stirring at 20 °C, substantial amounts 
of both mono- and dibrominated products had formed, while starting material also remained in 
solution. The first option was to investigate an alternative solvent system, since the solvent is known 
to influence the degree of disproportionation (eq. 5.1), and the regioselectivity of the reaction.19 
Anhydrous THF is a very popular solvent in α-bromination reactions with PTAB. THF not only serves as 
a solvent, but also as a base to react with HBr liberated in the reaction, thereby driving the reaction 
forward and preventing side-reactions due to free HBr in the reaction mixture (eq. 5.2).18,19 
RCOCH3 + Br2 ⇌ RCOCH2Br + HBr (eq. 5.2) 
Utilising this solvent, 1-[6-(2-bromoacetyl)benzo[d]thiazol-2-yl]-3-(4-methoxybenzyl)urea (7) was 
successfully synthesised by reacting 1.1 equivalents of PTAB with aryl acetyl 56 in THF as solvent 
(Scheme 5.2). The reaction was stirred at 30 °C for 64 h whereafter the solvent was removed in vacuo 
at 30 °C. The crude reaction mixture constituted mainly of α-monobrominated product; however, 
small quantities of starting material and α,α-dibrominated product were visible on TLC. After a work-
up procedure with ethyl acetate and saturated aqueous sodium bicarbonate, the α-monobrominated 
product was isolated by column chromatography with a mobile phase mixture of EtOAc and DCM, to 
afford 7 in a yield of 35%.  
In the described procedure, it was important to maintain the reaction temperature at 30 °C, since a 
higher reaction temperature of 40 °C visibly increased the formation of α,α-dibromoketone as a 
by-product on TLC. Unfortunately, the lower reaction temperature required a longer reaction time of 
64 h. Excess PTAB also promoted α,α-dibromination, therefore the PTAB equivalents were limited to 
a range of 1.05 to 1.10 equivalents. 
 
Scheme 5.2: α-Bromination of acetyl derivative 56 to yield halomethylketone 7 
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It was extremely difficult to separate the main α-monobrominated product 7 from the starting 
material and α,α-dibrominated product using column chromatography, due to the compounds’ 
similarities in polarity. Apart from the disproportionation by-products, these purification difficulties 
contributed to the relatively low yield of the reaction (35%). Recrystallisation from EtOH was explored 
as an alternative purification technique, but the α,α-dibromoketone product was not successfully 
excluded from the crystals. It is proposed that an improved purification method will result in an 
increased isolated yield. 
Halomethylketone 7 was obtained in >95% purity 
(determined by UPLC-MS) and was sent for biological 
testing. The structure of compound 7 was established by 
1H NMR, 13C NMR and FT-IR spectroscopy, as well as HRMS. 
In the 1H NMR spectrum, the presence of the 
halomethylketone moiety was confirmed by a singlet at 
4.93 ppm integrating for 2H, which represented the CH2-Br (H9) protons. The signal of the H9 protons 
was more downfield than expected for CH2 protons, due to their connectivity to a carbon which is 
attached to an electronegative bromine atom. A broad singlet at 11.08 ppm represented the urea 
proton NH1’’. A broad signal at 7.21 ppm accounted for the urea proton NH3’’. The CH2 (H7’) proton 
signal appeared as a doublet at 4.31 ppm integrating for 2H, and was split by the proton of NH3’’ with 
a J-coupling constant of 5.8 Hz. The benzylic ring protons, ArH2’+6’ and ArH3’+5’ resonated as two 
doublets integrating for 2H each, with a J-coupling constant of 8.7 Hz. The methoxy protons were 
visible as a singlet integrating for 3H at 3.73 ppm. The three aromatic protons of the benzothiazole 
ring appeared as a doublet at 8.62 ppm (J = 1.7 Hz) representing ArH7, a doublet of doublets at 7.99 
ppm (J = 8.5, 1.7 Hz) representing ArH5 and a doublet at 7.70 (J = 8.5 Hz) representing ArH4. The 
13C NMR spectrum of compound 7 displayed a total of 16 carbon signals, as expected. The signal at 
190.5 ppm validated the carbonyl carbon of the halomethylketone group, and the CH2-Br (C9) signal 
was visible at 34.0 ppm. With the installation of the α-bromine atom, the acetyl CH3 proton- and 
carbon signals disappeared, which were previously visible at 2.60 ppm and 26.7 ppm in the 1H NMR 
and 13C NMR spectra of 56, respectively. In the HRMS spectrum of halomethylketone 7, the [M+H]+ 
molecular ion was represented by two characteristic signals, since the bromine atom has two stable 
isotopes, 79Br and 81Br, which have 50.7% and 49.3% natural abundance, respectively.23 The [M+H]+ 
molecular ion, C18H17N3O3S79Br, was found at 434.0178 (m/z calcd = 434.0174), and C18H17N3O3S81Br 
was found at 436.0162 (m/z calcd = 436.0174). 
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5.1.2 α-Bromination of 1-(6-acetyl-1H-benzo[d]imidazol-2-yl)-3-(4-methoxybenzyl)urea 
(59) 
We were hoping to apply the α-bromination procedure described in the previous section to the 
benzimidazole derivative of acetyl 56, to obtain the benzimidazole version (8) of halomethylketone 7. 
Thus, 1-(6-acetyl-1H-benzo[d]imidazol-2-yl)-3-(4-methoxybenzyl)urea (59) was treated with PTAB in 
THF, whereafter the mixture was left to stir for 64 h at 30 °C. Unfortunately, the reaction was not 
selective for the α-monobrominated product. TLC revealed the major products in the reaction mixture 
to be starting material and a new product of similar, but lower polarity. Upon staining with 
p-anisaldehyde, this new product did not display the same colour properties as were observed for the 
α-monobrominated, α,α-dibrominated and even the α,α,α-tribrominated products, despite displaying 
similar polarity properties. Unfortunately, no products could be isolated from the crude mixture, due 
to the close polarities of all the by-products in such a non-selective type of reaction. 
 
Scheme 5.3: The proposed α-bromination of acetyl derivative 59 to form halomethylketone 8 
It is, however, possible that the imidazole ring amine (N1H) activates the 6-membered ring of the 
benzimidazole core to promote electrophilic substitution in the para (or ortho) position (Figure 5.1). 
Activation increases the nucleophilicity of the benzimidazole core, making it a better nucleophile than 
the enol tautomer of the acetyl group. The reactivity of the enol is restricted by the rate of acetyl 
enolization in a neutral solvent. Compound 59 could also have been brominated on both the 
benzimidazole ring and the acetyl group. Previously, when the PTAB and THF method was performed 
on the benzothiazole derivative 56, this type of by-product was not produced, which strengthened the 
argument that the electronics of the benzimidazole core altered the regioselectivity of the reaction. 
 
Figure 5.1: Activation of the benzimidazole core is suggested to compromise regioselectivity 
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At lower reaction temperature, 0 °C, the regioselectivity for the α-monobrominated product in the 
PTAB/THF reaction did not improve, affording a mixture of at least 4 products. 
NBS is a popular and selective α-brominating agent with a milder electrophilic character than 
molecular bromine.1 Furthermore, NBS employs an ionic mechanism when the reaction is catalysed 
by acid.6 1-(6-Acetyl-1H-benzo[d]imidazol-2-yl)-3-(4-methoxybenzyl)urea (59) was treated with 1.1 
equivalents of NBS in a mixture of DCM and p-toluenesulfonic acid (0.1 equiv) at a temperature of 
0 °C, whereafter the mixture was allowed to reach room temperature. After stirring for 2 h, the 
reaction mixture constituted of substantial amounts of starting material, monobrominated product 
and dibrominated product, as concluded from TLC analysis. These reaction conditions thus lacked 
control over the bromination reaction at the α-position of the acetyl. 
At this point, a dual bromination challenge had to be addressed. Firstly, the regioselectivity of the 
reaction had to be directed towards the formation of the halomethylketone product instead of the 
benzimidazole electrophilic substitution product. Secondly, controlled bromination at the acetyl 
α-carbon was necessary to avoid over-bromination. It was envisaged that strongly acidic conditions 
would catalyse the rate of enolization at the acetyl group, thereby increasing the reactivity of the 
acetyl group. It is also well-known that α-bromination is more controlled under acid-catalysed 
conditions, in contrast to base-promoted conditions. In base-promoted conditions, bromination on 
the α-atom will continue until all hydrogen atoms have been replaced, since each additional bromine 
atom increases the acidity of the remaining α-hydrogens.24 
Utilising strongly acidic conditions, 1-(6-acetyl-1H-benzo[d]imidazol-2-yl)-3-(4-methoxybenzyl)urea 
(59) was thus dissolved in an 8:3 mixture of glacial acetic acid and 48% HBr, whereupon it was treated 
dropwise with a mixture of molecular bromine in glacial acetic acid over 3 hours at 10 °C. The mixture 
was left to stir overnight at room temperature. This procedure appeared to be very selective for the 
α-monobrominated product, by TLC analysis. The α-monobrominated product was isolated using 
column chromatography, and the product displayed as a single spot on TLC. Unfortunately, 1H NMR 
spectroscopy revealed the presence of a by-product, which displayed exactly the same Rf value on TLC 
as the product. This reaction was repeated in acetic acid and HBr, but with the less electrophilic 
bromine source, PTAB. Unfortunately, the by-product was still visible in 1H NMR the spectrum, but 
this time in a smaller quantity (approx. 1:3 ratio of by-product to product). The by-product could not 
be removed successfully from the product, despite further purification attempts. The 1H NMR spectra 
of the impure α-monobrominated products were used to investigate the nature of the by-product 
(Figure 5.2). 




Figure 5.2: The 1H NMR spectra of compound 8 (impure), isolated from the reactions with a) Br2, 
AcOH, HBr, b) PTAB, AcOH, HBr. The signals of the predominant by-product are highlighted in red. 
a) 
b) 
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In the 1H NMR spectra, it appeared that the chemical shift of the methoxy-signal (OCH3) had shifted 
from 3.73 ppm to 3.82 ppm in the by-product. After careful interpretation of integration, peak 
patterns and coupling constants in the 1H NMR spectra, it was proposed that the acidic conditions had 
also catalysed monobromination on the para-methoxybenzyl ring of 8. The large doublets of the 
benzyl aromatic hydrogens were absent in the predominant signals of the by-product. Mono-
bromination on the benzyl ring would result in a trisubstituted ring, with an aromatic substitution 
pattern appearing as two doublets and a doublet of doublets signal. This substitution pattern was 
visible (Figure 5.2) at 7.56 ppm (J = 1.6 Hz) as a doublet, 7.33 ppm (J = 1.7, 8.5 Hz) as a doublet of 
doublets and 7.09 ppm (J = 8.5 Hz) as a doublet. The J-coupling constant, 8.5 Hz, of the trisubstituted 
ring, agreed with the J-coupling constant of 8.5 Hz previously observed in the coupling pattern of the 
unsubstituted benzyl ring. Electrophilic aromatic bromination on the para-methoxybenzyl ring also 
explained the new chemical shift value of the methoxy group. No other chemical shift differences were 
visible in the spectra, which implied that aromatic bromination on the benzyl did not influence the 
chemical shift of distant hydrogens on the scaffold. 
Returning to neutral conditions to avoid the new-found regioselectivity issues, copper(II) bromide was 
utilised as last resort for α-bromination. According to the literature, copper(II) bromide has displayed 
excellent α-bromination ability when refluxing in mixtures of EtOAc and/or chloroform.12 Due to the 
low solubility of the starting material (59) in EtOAc, the reaction only commenced once ethanol was 
added to the mixture to dissolve the starting material.25 Compound 59 was reacted with copper(II) 
bromide in a 5:1.2 mixture of EtOAc and ethanol, and the reaction was heated under reflux (80 °C) for 
3 h. This reaction was also attempted at a lower reaction temperature of 55 – 65 °C. In both cases, the 
crude product mixture contained starting material, α-monobrominated product, as well as 
α,α-dibrominated product. Unfortunately, the α-bromoproduct could not be separated successfully 
from the α,α-dibromoproduct using column chromatography, as indicated by the presence of a signal 
at 5.16 ppm (CH-Br2) and a signal at 4.88 ppm (CH2-Br) in the 1H NMR spectrum. 
Table 5.1 below summarises the reagents and reaction conditions which were employed in the 
attempted α-brominations of benzimidazole urea 59. Disappointingly, the exploration of different 
brominating reagents did not provide a successful and reliable method to synthesise 
halomethylketone 8. It did not appear feasible to explore more alternative brominating agents. Due 
to the high degree of regioselectivity and halogenation control required in this bromination reaction, 
it was concluded that an alternative synthetic strategy was necessary. 
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Table 5.1: Failed attempts towards α-monobromination of benzimidazole derivative 59 (Scheme 5.3) 
Entry Reagents and reaction conditions Outcomes 
1 PTAB (1.1 equiv), THF, 30 °C, 64 h Non-selective. Major products: starting material and 
unknown product (possible electrophilic substitution 
on benzimidazole core). 
2 PTAB (1.1 equiv), THF, 0 °C, 2 h Non-selective, despite lower temperature. 
3 NBS (1.1 equiv), PTSA (0.1 equiv), DCM, 0 °C 
– r.t., 2 h 
Over-bromination at α-position. 
4 Br2 (1.0 equiv), HBr, HOAc, 10 °C, 3 h, then 
r.t., 18 h 
Selective for α-monobromination, but an inseparable 
by-product was present in low quantity (possible 
monobromination on the para-methoxybenzyl ring). 
5 PTAB (1.0 equiv), HBr, HOAc, 10 °C, 30 min, 
then r.t., 18 h 
Selective for α-monobromination, but the same 
inseparable by-product was present in low quantity. 
6 Cu(II)Br, EtOAc/EtOH, reflux (80 °C), 3 h Mixture of α-mono- and α,α-dibrominated products. 
7 Cu(II)Br, EtOAc/EtOH, reflux (55 – 65 °C), 3 d Mixture of α-mono- and α,α-dibrominated products. 
 
5.1.2.1 Synthesising halomethylketone 8 via a silyl enol ether intermediate 
In 1974, Reuss and Hassner26 described the utility of silyl enol ethers (enolate equivalents) in a 
two-step procedure to halogenate carbonyl compounds. In the first step, trimethylsilyl enol ethers 
were prepared in order to eliminate the rate-determining enolization step which often complicates 
α-bromination. In the second step, Reuss and Hassner found that silyl enol ethers react 
instantaneously with bromine (1.0 equiv) to form α-monobrominated products, under careful 
temperature control.26 
Conde-Ceide and co-workers27 successful applied this silyl enol ether-mediated procedure to an acetyl 
group situated on an imidazo[1,2-a]-pyrazine scaffold (66), as seen in Scheme 5.4. 
 
Scheme 5.4: Conde-Ceide and co-workers27 converted ketone 66 into trimethylsilyl enol ether 67 to  
synthesise the α-monobrominated product, 68, in a good yield. 
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The crude silyl enol ether intermediate (67) was isolated in a work-up procedure with cold sat. NaHCO3 
and DCM, whereafter the organic layer was dried, filtered and concentrated in vacuo. The resultant 
crude oil (67) was used in the second bromination step with NBS at −78 °C, to afford the 
α-monobromination product (68) in a 67% yield.27 
In accordance with the procedure of Conde-Ceide and co-workers,27 halomethylketone 8 was 
successfully prepared in a 48% overall yield (over two steps) as seen in Scheme 5.5. Trimethylsilyl 
trifluoromethanesulfonate (TMSOTf, 3.9 equiv) and the base, N,N-diisopropylethylamine (DIPEA, 5.2 
equiv), were initially used to generate the trimethylsilyl enol ether intermediate at 0 °C. The reaction 
mixture was left to stir overnight at room temperature, whereafter the reaction was found to be 
incomplete, as monitored by TLC. In contrast, Conde-Ceide and co-workers27 reported a yield of 97% 
for the crude silyl enol ether 67 utilising this method. Thus, an increased reaction temperature (30 °C) 
was explored, and the reagent equivalents were increased (TMSOTf, 7.8 equiv; DIPEA, 10.4 equiv), but 
the reaction remained incomplete as judged by the presence of starting material on the TLC plate. In 
future studies, it is suggested that the reaction should be repeated utilising a stronger base, to drive 
the enolization equilibrium forward. 
Nonetheless, a significant amount of silyl enol ether did form in the reaction mixture and the crude 
mixture was utilised to perform the subsequent bromination step. The crude mixture was used 
without any further purification, since silica column chromatography resulted in decomposition of the 
trimethylsilyl enol ether and regeneration of the starting material, regardless of using 0.5% Et3N as a 
buffer in the mobile phase solvent system. In the bromination step, the crude mixture was treated 
with NBS (0.76 equiv) in a mixture of THF and NaHCO3 powder (1.5 equiv) at −78 °C. After 1.5 h of 
stirring at −78 °C, the reaction was complete. The reaction was very selective for α-monobromination 
and the product was readily isolated via a work-up procedure with sat. NaHCO3 and EtOAc, followed 
by silica column chromatography, to afford the final product 8 in an overall yield of 48% and a purity 
of 98% for biological testing. The high purity achieved in this reaction was satisfying, following all the 
previous attempts which required tedious separation procedures to remove bromination by-products. 
 
Scheme 5.5: The successful synthesis of halomethylketone 8 via a silyl enol ether intermediate 
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In the 1H NMR spectrum of compound 8, the characteristic signal at 4.88 ppm integrating for 2H, 
confirmed the presence of the two BrCH2 protons. In the 13C NMR spectrum, the HMK carbonyl carbon 
signal shifted from 197.1 ppm (59) to 191.0 ppm (8). In the HRMS spectrum of 8, the [M+H]+ molecular 
ion, C18H18N4O379Br, was found at 417.0565 (m/z calcd = 417.0562), and C18H18N4O381Br was found at 
419.0545 (m/z calcd = 419.0562). 
5.2 The synthesis of the vinyl- and ethynyl ketones 
The direct functional group conversion of esters to ketones, with the use of Grignard or organolithium 
reagents, has been a challenging task in the past. In this method, the organometallic reagent would 
react with the ester to form the ketone product; however the high reactivity of the ketone product 
would result in a high propensity of over-addition of organometallic reagent to the carbonyl centre, 
to produce the tertiary alcohol.28 N-Methoxy-N-methylamides, also known as Weinreb amides,28 are 
very popularly used intermediates which facilitate the synthesis of ketones from esters, without any 
over-addition of organometallic reagent.29 When a Weinreb amide (69, Scheme 5.6) is treated with an 
organometallic reagent, a stable, metal-chelated, tetrahedral intermediate (70, 71) forms upon 
addition of one molecule of organometallic reagent to the electrophilic carbonyl centre.28 The metal-
chelated intermediate is stable under the reaction conditions and prevents collapse to a ketone, 
thereby avoiding the reaction of the ketone with a second molecule of organometallic reagent. Upon 
aqueous acidic work-up, the stable intermediate transforms to the ketone product and any remaining 
organometallic reagent is quenched concomitantly.30 
 
Scheme 5.6: The conversion of esters to ketones with Grignard reagent is well facilitated by 
Weinreb amides. Stable metal-chelated intermediates prevent the formation of over-addition 
products. 
Scheme 5.6 depicts the planned conversion of ester precursors 57 and 60 (Scheme 5.1) into their 
acryloyl- and propioloyl-derivatives, using vinylmagnesium bromide and ethynylmagnesium bromide. 
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5.2.1 The preparation of Weinreb amides 
Weinreb amides can be prepared from various compounds in the carboxylic acid oxidation state, 
including carboxylic acids, esters, lactones and acyl halides.30 Two methods pertaining to the 
preparation of Weinreb amides from esters have been utilised predominantly in the literature and will 
be discussed. These methods were developed to address the challenges associated with the 
aminolysis of esters to form amides. These challenges included high reaction temperatures and/or 
prolonged reaction times.31,32 Furthermore, strong alkali metal catalysts applied in aminolysis often 
did not accommodate sensitive functional groups.33 
The amine, N,O-dimethylhydroxylamine, required in the preparation of Weinreb amides, is 
commercially available in its hydrochloride salt form, N,O-dimethylhydroxylamine hydrochloride 
[MeO(Me)NH·HCl]. The first convenient method for the preparation of Weinreb amides was based on 
the ester to amide conversion procedures developed by Weinreb and co-workers33,34 In this method, 
a cooled solution of hydrochloride salt [MeO(Me)NH·HCl] in benzene, toluene or DCM was treated 
with trimethylaluminium (Me3Al) to form an active aluminium species, supposedly the 
methylchloroaluminum amide (eq. 5.3).34 The reaction of the active aluminium species with an ester 
produced the Weinreb amide.35  
MeO(Me)NH·HCl + Me3Al → MeO(Me)NAl(Cl)Me + 2CH4  (eq. 5.3) 
In 1997, Nakata and co-workers36 found that dimethylaluminium chloride (Me2AlCl) can also be used 
to generate active aluminium species. The active species, MeO(Me)NAlCl2, generated the amides in 
shorter reaction times and in higher yields. These species also accommodated reactions with sterically 
hindered esters and lactones, which previously delivered poor results with Me3Al.36 It should be noted 
that these aminolysis reactions with Me2AlCl and Me3Al, generally required two to five equivalents of 
the active species to form the amide, as well as strictly inert reaction conditions.29 
In 1995, Williams and co-workers37 developed a new general method for the conversion of esters to 
Weinreb amides, using the hydrochloride salt [MeO(Me)NH·HCl] and isopropylmagnesium chloride as 
a base. In this method the magnesium amide, MeO(Me)NMgCl, was generated as active species and 
was reacted with the ester. Similarly to Nakata and co-workers,36 this method was developed in an 
attempt to synthesise Weinreb amides from hindered esters.37 
The method developed by Williams and co-workers37 was optimised to ensure minimal by-product 
formation. In their initial optimisation studies, EtMgBr was used as organomagnesium reagent. 
EtMgBr and MeO(Me)NH·HCl were slurried in THF at 0 °C in the first step, whereafter the ester was 
treated immediately with the slurry in the second step. This reaction displayed low yields and Williams 
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and co-workers37 hypothesised that the generated reactive species [MeO(Me)NMgCl] was either 
decomposing or reacting with more EtMgBr, before it could react with the ester in the second step. 
Therefore Williams and co-workers37 developed a procedure in which the ester was present from the 
start of the reaction, and they achieved the formation of reactive species in the presence of the ester. 
When they created a slurry of the ester and MeO(Me)NH·HCl in THF at 0 °C and treated it with EtMgBr, 
the amide was isolated in 91% yield. The rapid reaction of the active species with the ester, 
outcompeted decomposition and the side-reactions due to EtMgBr.37 
The preparation of reactive species from organomagnesium reagents in the presence of the ester, 
most importantly required that the organomagnesium reagent does not attack the carbonyl centre of 
the newly generated ketone product in solution. This problem was not completely avoided with 
nucleophilic bases MeMgCl and EtMgBr; however, the hindered nature of the base, 
isopropylmagnesium chloride (i-PrMgCl), completely solved this problem. Williams and co-workers37 
have also demonstrated the successful use of the non-nucleophilic bases, mesityl magnesium bromide 
and lithium hexamethyldisilazide (LHMDS). Nonetheless, i-PrMgCl provided the cleanest reactions 
(and similar yields) and was selected as the organomagnesium reagent of choice. 
The efficient methods of both Nakata and co-workers36 and Williams and co-workers37 appeared 
promising for the preparation of the Weinreb amides required in this project. 
5.2.1.1 The synthesis of Weinreb amides 62 and 63 
The procedure of Williams and co-workers37 was followed in the synthesis of Weinreb amides 62 and 
63 (Scheme 5.7). However, i-PrMgCl was not available in our chemical store, therefore 
2-bromopropane was used in accordance with the Weinreb preparation methods of Suto et al.,38 to 
first prepare isopropylmagnesium bromide (i-PrMgBr) as base. The organomagnesium reagent was 
titrated and then applied to the ester and MeO(Me)NH·HCl in the Weinreb preparation reaction. 
These reactions required inert conditions and were performed under argon. 2-Bromopropane was 
distilled from calcium hydride prior to the preparation of the organomagnesium reagent. Then, at 
room temperature, a small portion of 2-bromopropane was added to a flask with dry magnesium 
turnings and THF. While stirring vigorously, the mixture was warmed by hand, until the reaction 
mixture started to dissipate heat. The rest of the 2-bromopropane was then added by slow dropwise 
addition. The end of the reaction was indicated by the cooling of the reaction mixture. 
The concentration of the prepared Grignard reagent was determined by the titration method of Lin 
and Paquette.39 In this method, i-PrMgBr in THF was added dropwise to a solution of menthol in THF, 
with 1,10-phenanthroline as an indicator. An end-point colour change from colourless to pink was 
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observed. In the preparation of Weinreb amide 62, the concentration of i-PrMgBr was 1.3 M in THF, 
and for 63, the concentration of i-PrMgBr was 1.4 M in THF. These Grignard reagents were used 
immediately after titration. 
A suspension of the ester (57/60, Scheme 5.7) and MeO(Me)NH·HCl were prepared in THF. The 
hygroscopic hydrochloride salt, MeO(Me)NH·HCl, was pre-dried overnight, under vacuum in a 40 °C 
oil bath. The suspension was then treated dropwise with i-PrMgBr at −20 °C. The reaction was allowed 
to reach −5 °C over one hour, whereafter it was quenched with sat. aq. NH4Cl. The Weinreb amide was 
isolated by a work-up procedure and column chromatography. 
 
Scheme 5.7: The preparation of Weinreb amides 62 and 63 
In the preparation of 62, the ester 57 was initially treated with 1.6 equivalents of MeO(Me)NH·HCl 
and 3.0 equivalents of i-PrMgBr, for 30 min (Table 5.2). The reaction provided a relatively clean crude 
product, which only consisted of the Weinreb product and remaining starting material. Unfortunately, 
only 10% of Weinreb product had formed, while the rest of the starting material was left unreacted. 
It was found that once the i-PrMgBr had been added, a longer reaction time or a higher reaction 
temperature (0 °C) did not affect the conversion. Instead the equivalents of i-PrMgBr played a major 
role in the degree of ester conversion to the Weinreb product. The yield of 62 was increased to 81% 
when the reaction was treated with 5.6 equivalents of i-PrMgBr (entry 3, Table 5.2). 
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Table 5.2: The optimisation of the Weinreb reaction with ester 57 




1 MeO(Me)NH·HCl (1.6 equiv), THF, i-PrMgBr (3.0 equiv) −20 to −10 0.5 10 
2 MeO(Me)NH·HCl (2.0 equiv), THF, i-PrMgBr (4.0 equiv) −20 to 0 3 38 
3 MeO(Me)NH·HCl (2.0 equiv), THF, i-PrMgBr (5.6 equiv) −20 to −5 1 81 
 
It is suggested that several factors could have contributed to this large excess of i-PrMgBr consumed 
in this reaction. The two protons of MeO(Me)NH·HCl required a minimum of 2.0 equivalents of 
i-PrMgBr to form the active magnesium amide species. However, i-PrMgBr could also have been 
consumed in the removal of acidic protons on the ester starting material (57). For instance, the urea 
functionality of ester 57 has two acidic protons. When the acidic protons of the urea are removed, the 
charges can be stabilised by delocalisation into the carbonyl group and benzothiazole ring. 
Furthermore, the hygroscopic nature of MeO(Me)NH·HCl could have required the use of excess 
i-PrMgBr. The MeO(Me)NH·HCl salt was dried before the reaction, but still the salt could have 
introduced small quantities of moisture into the reaction, which would have decomposed some of the 
Grignard reagent. 
In the reaction of the benzimidazole ester 60 (Scheme 5.7) with MeO(Me)NH·HCl and i-PrMgBr, 7.1 
equivalents of i-PrMgBr afforded the Weinreb amide 63 in 78% yield. It is suggested that more 
equivalents of i-PrMgBr were required, since ester 60 had one additional acidic proton on the 
benzimidazole ring available for deprotonation. 
In the 1H NMR spectrum of 62, the aliphatic proton chemical 
shift region clearly confirmed formation of the Weinreb amide. 
The starting material (57)’s methyl ester protons (OCH3) were 
no longer visible at 3.86 ppm. A signal at 3.56 ppm integrated 
for 3H and represented the NOCH3 protons. A new signal at 
3.27 ppm integrating for 3H, represented the NCH3 protons. The signal of the methoxybenzyl protons 
(BnOCH3) remained at 3.73 ppm. Similar changes were seen in the aliphatic proton chemical shift 
region of benzimidazole derivative 63. The structures of 62 and 63 were further confirmed with 
13C NMR and IR spectroscopy, as well as HRMS. 
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5.2.2 Grignard reactions with the Weinreb amides to produce ketones 
In four separate reactions, the Weinreb amides 62 and 63 were each treated with vinylmagnesium 
bromide in THF to form the vinyl ketones, whereas treatment with ethynylmagnesium bromide 
afforded the ethynyl ketones. Unfortunately, these reactions did not proceed well, irrespective of 
multiple attempts at optimisation. 
The syntheses were commenced with the preparation of vinyl ketone 9 (Scheme 5.8). A suspension of 
Weinreb amide 62 in THF was treated dropwise with vinylmagnesium bromide (1 M in THF) at 0 °C. 
After 2 h, the reaction was allowed to reach room temperature. The reaction was monitored by TLC— 
a few drops would be collected from the reaction mixture and then quenched with sat. aq. NH4Cl and 
extracted into EtOAc, before spotting on the TLC plate. After stirring for 20 h, the reaction was 
incomplete as starting material remained. It was found that the reaction was successfully moved to 
completion by the addition of more vinylmagnesium bromide and nearly all starting material reacted. 
Apart from driving the reaction forward, an excess of Grignard reagent was once again necessary to 
account for interaction with additional acidic protons on the Weinreb starting material. Unfortunately, 
when the reaction was quenched with sat. aq. NH4Cl, a large amount of by-product formed, which was 
not UV-active at 254 nm and was only visible on TLC upon staining with p-anisaldehyde. The ketone 
product must have been consumed in this side-reaction, since only 9% of ketone 9 was isolated from 
the reaction (entry 1, Table 5.3). 
In order to ensure that the tetrahedral intermediate was successfully quenched in the work-up 
procedure, the reaction was repeated (entry 2, Table 5.3) and quenched with a stronger aqueous acid 
mixture. The reaction mixture was therefore transferred dropwise into a stirred solution of 1 M HCl at 
0 °C, and was left to stir 30 minutes before completing the work-up procedure. Nonetheless, the side-
reaction took place and the product (9) was isolated in a 17% yield.  
 
Scheme 5.8: The synthesis of vinyl ketone 9 from Weinreb amide 62 
In the synthesis of ethynyl ketones, Pirc et al.40 found that the nucleophilic 
N,O-dimethylhydroxylamine, which is expelled from the tetrahedral intermediate in the quenching 
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step, can add to the newly synthesised ethynyl ketone by Michael addition. They managed to avoid 
this Michael reaction, by quenching with 1 M aq. NaHSO4, instead of aq. NH4Cl. To ensure that Michael 
addition was not taking place as side-reaction in our reactions, 1 M aq. NaHSO4 was thus used to 
quench the reaction. This improved the yield to 26%, but did not prevent the formation of the non-
UV active by-product (entry 3, Table 5.3). In another attempt, this reaction was repeated at a lower 
temperature of −78 °C; however no significant differences were observed using this method (entry 4, 
Table 5.3). 
Table 5.3: Attempts to synthesise vinyl ketone 9 from Weinreb amide 62 (Scheme 5.8) 
Entry Reagents Temp. (°C) Quench % yield 
1 
Vinylmagnesium bromide (1 M in THF) 
(6.4 equiv), THF 
0 °C – r.t. sat. aq. NH4Cl, −10 °C 9 
2 
Vinylmagnesium bromide (1 M in THF) 
(5.0 equiv), THF 
0 °C – r.t. 1 M HCl, 0 °C 17 
3 
Vinylmagnesium bromide (1 M in THF) 
(9.5 equiv), THF 
−20 °C – 15 °C 1 M aq. NaHSO4, 0 °C 26 
4 
Vinylmagnesium bromide (1 M in THF) 
(12.0 equiv), THF 
−78 °C – 15°C 1 M aq. NaHSO4, 0 °C 23 
 
Unfortunately, the nature of the side-reaction which hindered the formation of the product 9, was 
not successfully determined in this project. The non-UV active by-product was isolated and inspected 
by 1H NMR spectroscopy (Figure 5.3). The acquired 1H NMR spectrum could not be fully deciphered, 
but the characteristic multiplets of two vinyl groups were visible at 5.85 – 5.74 ppm, 5.13 ppm and 
4.98 ppm, and constituted a major part of the spectrum. Signals in the aromatic region of the spectrum 
were barely visible, which eliminated the common challenges associated with these reactions, such as 
diol formation (over-addition of Grignard reagent) and Michael addition to the ketone (due to 
OMe(Me)NH in solution). 
From the 1H NMR spectrum analysis was concluded that the large excess of vinylmagnesium bromide 
in solution may hinder the success of the reaction. In future studies, it is proposed that the equivalents 
of vinylmagnesium bromide are minimised, and that heating of the reaction mixture should be 
considered as an alternative to drive the reaction to completion. 
 




Figure 5.3: The 1H NMR spectrum (DMSO-d6) of the non-UV active by-product which forms upon 
quenching of the Grignard reaction with Weinreb amide 62 
Using the same reaction temperatures and work-up procedure as in the highest yielding entry of Table 
5.3 (entry 3), the synthesis of the vinyl and ethynyl ketones were completed. The results are 
summarised in Scheme 5.9. 
The required equivalents of the Grignard reagent were monitored by TLC. It is of interest to note that 
the side-reactions in the quenching step only occurred in the reactions of the Weinreb amides with 
vinylmagnesium bromide, and not in the reactions with ethynylmagnesium bromide. Therefore a 
higher yield (76%) was observed for the ethynyl ketone 11. The reaction to form ethynyl ketone 12 
required heating overnight at 40 °C. Unfortunately, all of the starting material did not react and some 
by-products formed in the overnight heating process, yielding 15% of product.  The ethynyl ketones 
were synthesised only once and their reaction- and purification procedures have not been optimised.  
Although compounds 9, 10 and 12 were obtained in very low yields, a few milligrams could be sent for 
biological testing, together with compound 11. 




Scheme 5.9: A summary of the vinyl- and ethynyl ketone formation reactions 
The structures of compounds 9 – 12 were best confirmed by 1H NMR spectroscopy and HRMS. The 
13C NMR spectra of compounds 9, 11 and 12 were also collected, whereas too small of an amount of 
compound 10 was available to acquire its 13C NMR spectrum. The 1H NMR spectrum of vinyl ketone 9, 
clearly displayed the vinylic protons (see Figure 5.4 below). Vinylic proton H9 resonated as a doublet 
of doublets at 7.50 ppm, due to the 3J-coupling (16.9 Hz) to the H10 proton trans of H9, and the 
3J-coupling (10.4 Hz) to the H10 proton cis of H9. The H10 trans proton resonated at 6.36 ppm and 
displayed a doublet of doublets splitting pattern due to the trans 3J-coupling with H9 and the 
2J-coupling with the geminal H10 proton (1.7 Hz). The doublet of doublets peak of the H10 cis proton 
appeared at 5.96 ppm, as result of the cis 3J-coupling with H9 and the geminal 2J-coupling. This vinylic 
splitting pattern was also visible in the 1H NMR spectrum of the benzimidazole derivative 10; however, 
the doublet of doublets due to H9 was disguised by overlapping with the signals of NH3’’ and one 
benzimidazole aromatic proton. 
In the 1H NMR spectrum of ethynyl ketone 11, the terminal proton of the ethynyl group resonated at 
5.06 ppm as a singlet integrating for 1H. Similarly, the ethynyl proton of ketone 12 resonated as a 
singlet at 4.95 ppm, integrating for 1H. As mentioned and discussed before in similar cases in Section 
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4.5.7, Chapter 4, the signals of the benzimidazole ring protons appeared broadened in the 1H NMR 
spectrum of 12, most likely due to tautomerism. 
 
Figure 5.4: The vinylic protons are highlighted (red) in the 1H NMR spectrum (DMSO-d6) of ketone 9 
In future work, there is ample opportunity for improvement in the Grignard reactions to form the 
vinyl- and ethynyl ketone compounds 9 – 12. In the case where these proposed compounds display 
remarkable biological efficiency, the development of an efficient synthetic pathway will be necessary. 
5.3 The synthesis of the acrylamides 
The acrylamides were synthesised from the nitro-substituted benzazole ureas 58 and 61. This 
procedure entailed two steps. In the first step the nitro-group was reduced to the amine, whereupon 
the amine was treated with acryloyl chloride to form the acrylamide moiety. 
5.3.1 Reduction of the nitrobenzazole ureas 
Nitrobenzothiazole urea 58 was utilised to develop the general reduction procedure.41,42 Due to the 
polar nature of the substrate, DMF was required to dissolve the starting material, whereafter MeOH 
and 10% palladium on carbon were added to the mixture. Heating at 60 °C was necessary to promote 
the catalytic hydrogenation reaction under a hydrogen atmosphere. The aminobenzothiazole urea 64 
was isolated in a 40% yield. The low yield was ascribed to a small quantity of unreacted starting 
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material which remained in solution, as well as minor by-products in the crude mixture which 
complicated the purification step. The product was easily detected on TLC, due to the product’s bright 
yellow colour upon staining with p-anisaldehyde. The reduction of 58 was also attempted at 60 °C with 
a Fe(0) powder, NH4Cl, dioxane, EtOH and H2O system,43 but this procedure produced two major 
products, as well as by-products. The hydrogenation procedure was thus adopted as the most efficient 
procedure. 
The catalytic hydrogenation procedure was successfully applied to nitrobenzimidazole urea 61 to 
afford the aminobenzimidazole urea 65 in 85% yield. This reaction proceeded more cleanly, which 
accounted for the higher yield. 
 
Scheme 5.10: The hydrogenation of the nitrobenzazole ureas 58 and 61 
The structures of the ureas were confirmed by 1H NMR, 13C NMR and IR spectroscopy, as well as HRMS. 
In the 1H NMR spectrum of 6-aminobenzothiazole urea 64, the new amine signal was visible at 
5.02 ppm, integrating for 2H. As for 6-aminobenzimidazole urea 65, the new amine signal resonated 
at 5.01 – 4.32 ppm as a broadened singlet. 
5.3.1.1 The crystal structure of 1-(6-amino-1H-benzo[d]imidazol-2-yl)-3-(4-methoxybenzyl)urea 
(65) 
Throughout this project, it has been challenging to obtain the 13C NMR spectra of the benzimidazole 
ureas. Often two to five signals were missing from the spectra or the appearance of the signals were 
very weak and broad. Nonetheless, the structures of the synthesised benzimidazole ureas were 
confirmed by 1H NMR, IR, HRMS and Rf values. As final validation of these benzimidazole urea 
scaffolds, the crystallographic structure of 1-(6-amino-1H-benzo[d]imidazol-2-yl)-3-(4-
methoxybenzyl)urea (65) was determined. 
The single-crystal X-ray diffraction experiment was performed 
by Ms. Monica Clements in our research group. She also 
processed the data to solve and refine the crystal structure. 
The two molecules in the asymmetric unit are connected by 
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N-H…N hydrogen bonding, between the urea group and the nitrogen atom of the benzimidazole 
moiety (Figure 5.5). Intramolecular hydrogen bonding by N-H…O bonding was facilitated by the amine 
proton of the benzimidazole moiety and the urea carbonyl oxygen. 
The primary amino group in position 6 of the benzimidazole ring is displayed without the two attached 
hydrogens in Figure 5.5. The location of these hydrogens could not be determined from the electron 
density map. The amine can rotate freely and the two hydrogens attached to the nitrogen atom can 
occupy different positions. This results in an averaged electron density around the nitrogen atom, and 
since each hydrogen atom only contributes one electron to the electron density map, the averaged 
electron density map did not allow for the placement of the hydrogens. 
 
Figure 5.5: Two molecules of 65 are linked by hydrogen bonding to form the asymmetric unit of the 
crystal lattice. (Figure generated using POV-Ray).44 
The dimers pack in columns to form the three-dimensional hydrogen-bonded network. The crystal 
packing viewed down the crystallographic a axis is displayed in Figure 5.6. 
 
Figure 5.6: The packing of the molecules (65) viewed down the crystallographic a axis. (Figure 
generated using POV-Ray).44 
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The structure of compound 65 was successfully validated by crystallography and also supports the 
data of the rest of the benzimidazole urea range. 
5.3.2 The synthesis of the acrylamides from the aminobenzazole ureas 
The acrylamides were synthesised by treating the aminobenzazole urea dropwise with 1.1 equivalents 
of acryloyl chloride at 0 °C in a solvent mixture of DMF and THF, with 1.1 equivalents of NEt3 base 
(Scheme 5.11). After work-up, 13 and 14 were obtained in yields of 54% and 40%, respectively. The 
reactions were not further optimised, but in future studies, it is suggested that lower temperatures 
are explored. 
The structures of 13 and 14 were confirmed by 1H NMR, 13C NMR, 2D NMR and IR spectroscopy, as 
well as HRMS, and the compounds were sent for biological testing. The 2D NMR spectroscopic results 
(gHSQC and gHMBC) of benzothiazole acrylamide 13 allowed for the assignment of the signals in its 
13C NMR spectrum. In general, the 13C NMR spectra of the benzothiazole urea range displayed similar 
signal patterns throughout this project, therefore the assignment of the 13C NMR spectrum of 13 was 
insightful (Table 5.3). One quaternary carbon was not visible in the 13C NMR spectrum of 13, and from 
the 2D NMR results this carbon was suggested to be C7a. The complete set of 2D NMR structural 
elucidation data is displayed in the experimental chapter (Chapter 9). 
 
Scheme 5.11: The synthesis of acrylamides 13 and 14 
Table 5.4: Assignments of the carbon signals in the 13C NMR spectrum of acrylamide 13 























A 2D NMR spectral study was also performed on the benzimidazole acrylamide 14. However, due to 
the missing signals in the 13C NMR spectrum of the benzimidazole urea (a common occurrence), 2D 
NMR spectroscopy (gHSQC and gHMBC) did not allow for complete structural elucidation. 
5.4 Chapter conclusion 
In this chapter, 1-benzazole-3-(4-methoxybenzyl)ureas with modifiable substituents in the sixth 
position of their benzazole rings, were utilised to prepare the last compounds of the proposed 
irreversible GSK-3β inhibitor set. The halomethylketones were successfully prepared from their acetyl 
precursors. The benzothiazole acetyl was α-monobrominated with a PTAB/THF system, whereas the 
benzimidazole acetyl was α-monobrominated via a silyl enol ether intermediate. These methods 
afforded 7 and 8 in low to moderate yields. The vinyl- and the ethynyl ketones (9 – 12) were prepared 
from their ester precursors by converting the esters into their corresponding Weinreb amides in good 
yields and then performing Grignard reactions. The course of the Grignard reactions was troublesome, 
yet the vinyl- and the ethynyl ketones were synthesised in generally low yields. The acrylamide 
syntheses required the reduction of the 6-nitro substituents by catalytic hydrogenation, whereafter 
acryloyl chloride was used to finish the synthesis of 13 and 14. These proposed GSK-3β inhibitors were 
sent for biological testing, which will be presented in Chapter 6. 
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Chapter 6: Biological activity and reversibility studies 
Upon completion of the synthesis of the proposed GSK-3β inhibitors (Chapters 4 and 5), the library of 
compounds was sent for biological evaluation to our collaborator, Prof. Ana Martínez at the Instituto 
de Química Medica-CSIC in Madrid, Spain. All of the synthesised compounds that were sent for 
biological testing, had a purity greater or equal to 95%, except for the benzothiazole-derived 
acrylamide 13, which was 94% pure. To determine purity, analyses were performed on a UPLC-MS 
system, fitted with a C18 column (1.7 μm, 100 mm × 2.1 mm), photodiode array detector and a QTOF 
spectrometer. 
The initial biological studies entailed the measurement of GSK-3β inhibitory activity. The compounds 
with the lowest IC50 values were then further subjected to GSK-3β reversibility studies to determine 
the type of enzymatic inhibition (reversible vs. irreversible). Finally, the biological results were 
compared to the predictive modelling studies which were performed in this project (Chapter 3). 
6.1 Structure-activity relationships 
Table 6.1 summarises the GSK-3β inhibitory activity results of the reference compound, AR-A014418 
(3), and the final library of synthesised small-molecules. High inhibitory activity is highlighted in red in 
the table. 
Table 6.1: The GSK-3β inhibitory activity (IC50) of the library of synthesised compounds. 
 Compound IC50 (M) SD Compound IC50 (M) SD 
Reference: 
AR-A014418 
3 0.072 0.043    
Ring substituent Benzothiazoles Benzimidazoles 
Nitrile 4 0.11 0.04 6 0.086 0.023 
Acetyl 56 2.26 0.41 59 0.26 0.03 
HMK 7 0.77 0.04 8 0.13 0.06 
Vinyl ketone 9 4.05 0.39 10 1.82 0.22 
Ethynyl ketone 11 4.21 0.33 12 2.47 0.32 
Acrylamide 13 >10  14 >10  
IC50: The concentration of a substance that causes 50% inhibition of a given system1 
SD: Standard deviation 
     High inhibitory activity is highlighted in red 
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In comparison to the reference compound (3), which displayed an IC50 value of 0.072 ± 0.043 µM in 
the assay, a good inhibitory activity score was observed for 1-(6-cyano-1H-benzo[d]imidazol-2-yl)-3-
(4-methoxybenzyl)urea (6) with an IC50 value of 0.086 ± 0.023 µM, which was also the best IC50 value 
obtained in the library. The benzothiazole equivalent, nitrile 4, 
also displayed good inhibitory activity (IC50 = 0.11 ± 0.04 µM), 
but it should be noted that 4 has been synthesised in the 
literature before, and was one of the compounds that inspired 
our small-molecule library.2 
The results of Table 6.1 are further illustrated in Figure 6.1, to ease comparison. As already mentioned, 
the nitrile derivatives (4, 6) displayed the best inhibitory activity. Furthermore, the HMK derivatives 
(bromoacetyl electrophilic warheads) displayed good inhibitory concentrations, with 1-[6-(2-
bromoacetyl)-1H-benzo[d]imidazol-2-yl]-3-(4-methoxybenzyl)urea (8) having an IC50 value of 0.13 ± 
0.06 µM. The benzothiazole-derivative 7 showed lower activity with an IC50 of 0.77 ± 0.04 µM. In fact, 
over the whole range of biological results (Figure 6.1), a clear trend existed in which the benzimidazole 
equivalents always displayed better inhibitory activity than the benzothiazole equivalents, within each 
electrophilic moiety group. 
  
Figure 6.1: The variation in GSK-3β inhibitory activity (IC50) over different electrophilic moieties in 
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Figure 6.2: A comparison of pIC50 values over different electrophilic moieties in the benzothiazole- 
and benzimidazole urea compound sets (pIC50 = −log [IC50]) 
To further compare the activities of the different electrophilic warhead groups, the pIC50 values of the 
compounds were calculated (Figure 6.2). pIC50 is the negative logarithmic value of the IC50 value (in 
molar concentration). Thus, a larger pIC50 value illustrates higher inhibitory activity. 
The activity of bromoacetyl-derivative 7 (HMK) was higher in comparison to the acetyl-derivative 56, 
which suggested the bromine atom to have a structure-activity influence in HMKs which can increase 
inhibitory activity. The same structure-activity influence may apply for bromoacetyl-derivative 8 
(HMK) when compared to the benzimidazole-derived acetyl 59, but in our data these two compounds 
displayed similar activities within error (standard deviation). 
As further depicted in Figure 6.2, the inhibitory activities of the vinyl ketones (9, 10) and the ethynyl 
ketones (11, 12) were lower and in a pIC50 range of 5.3 – 5.8 (IC50 = 1.60 – 4.54 µM). The acrylamides 
did not show any significant inhibitory activity, with pIC50 values smaller than 5.0 (IC50 >10 µM). The 
larger size of the acrylamide warheads might complicate the entrance and positioning of the molecule 
in the ATP-binding site, and might no longer facilitate the binding of the electrophilic moiety in the 
deepest end of the GSK-3β ATP-binding pocket. 
In general, large variations in GSK-3β inhibitory activity were observed across the different 
electrophilic warhead groups. These variations necessitated reversibility studies to evaluate whether 
the electrophilic warheads were reacting with Cys199 through an irreversible binding mechanism. 
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which suggests that the size of electrophilic moieties might be a factor of consideration in the design 
of Cys199-targeted irreversible inhibitors for GSK-3β. 
6.2 Reversibility studies 
The reversibility studies entailed GSK-3β time-dependent studies, in which inhibition percentage was 
measured after different pre-incubation (GSK-3β enzyme + inhibitor) times. For irreversible inhibitors, 
a longer pre-incubation time with the enzyme is expected to increase the percentage of enzyme 
inhibition observed. Reversible inhibitors are not expected to increase the percentage of enzyme 
inhibition when longer pre-incubation times are applied. In the literature, these reversibility studies 
were applied by Martínez and co-workers3 to evaluate whether their GSK-3β inhibitors act through 
reversible or irreversible inhibition. 
Due to restricted funds, only the reference ligand (3) and two of the biologically potent, novel GSK-3 
inhibitors, cyano-substituted benzimidazole urea 6 and HMK-substituted benzimidazole urea 8, were 








Figure 6.3: GSK-3β time-dependent studies with reference inhibitor, 3, and the newly synthesised 
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The results of newly synthesised GSK-3β inhibitors, 6 and 8, appeared to indicate an irreversible 
binding mode with GSK-3β, facilitated by their electrophilic warheads. The increase in inhibition 
percentage with longer pre-incubation times, corresponded with the expected behaviour of an 
irreversible inhibitor. However, the result of the reference compound 3, was not as expected, and 
therefore, in our opinion, the reversibility results are inconclusive.  
The reference compound, AR-A014418 (3), is a well-known reversible GSK-3β inhibitor, as confirmed 
by X-ray crystallography. For a reversible binding mode, percentage GSK-3 inhibition is not expected 
to increase with longer pre-incubation times. The opposite was seen for 3 in Figure 6.3, and therefore 
the binding modes of the newly synthesised GSK-3 inhibitors are still unconfirmed. 
In future studies, the reversibility studies should be repeated, and the reversible GSK-3 inhibitor, 
alsterpaullone, which is the reference compound in the studies of Martínez and co-workers, should 
be included.3 It will also be of help to include the acetyl-substituted benzimidazole urea 59, to compare 
its binding mode with HMK-substituted benzimidazole urea 8. Additionally, covalent irreversible 
binding can be confirmed biophysically by MALDI-TOF MS analysis.4 If the inhibitor binds the GSK-3 
enzyme irreversibly, a mass peak corresponding to the combined mass of the enzyme and the inhibitor 
should be present in the mass spectrum.3 
6.3 A comparison: Molecular modelling scores and activity 
To evaluate the molecular modelling binding model which was used in Chapter 3, the biological activity 
results of the compound library were compared to the calculated irreversible and reversible docking 
scores recorded in the modelling study. 
The increased biological inhibitory activity of the benzimidazole-derivatives relative to the 
benzothiazole-derivatives was successfully predicted in the molecular modelling studies and was 
ascribed to the ability of the imidazole ring system to accommodate one additional hydrogen bond to 
the hinge region. This can be seen in Figure 6.4 (a, b), in which the benzimidazoles continuously 
displayed lower affinity/docking scores, which implied more favourable binding interactions.  
In Figure 6.4 it becomes clear that small differences in affinity scores (irreversible modelling) or 
docking scores (reversible modelling) did not correlate directly to increased or decreased IC50 values, 
i.e. there is no trend. However, in terms of the larger picture, all of the docked molecules displayed 
good affinity/docking scores (between −9.5 and −7.0 kcal/mol) which successfully predicted that these 
molecules have inhibitory ability, except for the acrylamides which did not display inhibitory activity. 
 




Figure 6.4: Molecular modelling affinity scores (irreversible docking) and docking scores (reversible 
docking) vs. actual biological inhibitory concentrations (IC50). 
A good correlation was observed when the Cys199 target distance (distance from the reactive atom 
of the electrophilic moiety to the sulfur atom of Cys199) obtained in the reversible docking stage was 
compared to the biological inhibitory activity (Figure 6.5). Compounds with a smaller Cys199 target 
distance displayed lower IC50 values, indicating higher inhibitory activity. 
 
Figure 6.5: A comparison of the Cys199 target distance in the reversible docking stage with 
biological activity (IC50) 
It can be concluded that the molecular docking model was sufficient to predict whether proposed 
compounds would have favourable binding interactions in the GSK-3β ATP-binding site, and to 
investigate possible binding modes. The model successfully predicted that the benzimidazole-derived 
ureas would display higher inhibitory activity than the benzothiazoles, and furthermore a direct 
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6.4 Concluding remarks 
To conclude, the GSK-3β inhibitory activity results were satisfying, with the nitrile derivatives (4, 6) 
and the benzimidazole HMK derivative (8) displaying the best IC50 values. In comparison to the 
reference compound (3), which displayed an IC50 value of 0.072 ± 0.043 µM in our assay, the best IC50 
value obtained in the library was 0.086 ± 0.023 µM, observed for 1-(6-cyano-1H-benzo[d]imidazol-2-
yl)-3-(4-methoxybenzyl)urea (6). Over the whole range of biological results, the benzimidazole 
derivatives always displayed better inhibitory activity than their benzothiazole counterparts. 
Reversibility studies were inconclusive, since the result of reference inhibitor 3 was not as expected 
in the pre-incubation time vs. inhibition percentage studies. 
The molecular docking model was evaluated and was found sufficient to predict whether proposed 
compounds would display GSK-3β inhibitory activity, except in the case of the acrylamides. The model 
successfully predicted that the benzimidazole-derived ureas would display higher inhibitory activity 
than their benzothiazole counterparts. It is further suggested that Cys199 target distance and the size 
of the electrophilic moieties might influence inhibitory activity. 
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Chapter 7: Conclusion 
The aim of this project was to design, synthesise, characterise and biologically test a proposed library 
of irreversible GSK-3 inhibitors as potential Alzheimer’s drug candidates. Due to the multifactorial role 
of GSK-3 in AD pathogenesis, GSK-3 is a promising CNS target. 
Our library included two sets of 1-aryl-3-(4-methoxybenzyl)ureas, wherein the incorporated aryl group 
was a benzimidazole or benzothiazole scaffold, respectively. These molecules contained different 
electrophilic warheads, with the potential to form a covalent, irreversible bond with nucleophilic 
Cys199 in the GSK-3 ATP binding pocket. The unique Cys199 residue was targeted covalently, with the 
hope of improving GSK-3 selectivity. 
In the molecular modelling studies, the modelled binding interactions, Cys199 target distances and 
docking scores in both the non-covalent and covalent docking stages were very promising for the 
proposed 1-aryl-3-(4-methoxybenzyl)urea series. Thus, the final compound library for synthesis 
included the nitrile, HMK, vinyl- and ethynyl ketone and acrylamide electrophilic warheads. 
The synthetic route commenced with the synthesis of the 6-substituted 2-aminobenzothiazole and 
6-substituted 2-aminobenzimidazole scaffolds in good yields. The 6-substituted 
2-aminobenzothiazoles (20 – 23) were synthesised from para-substituted anilines in a 
KSCN/AcOH/PTAB system, in which the first step entailed thiocyanation and the second step, 
cyclisation, when heated under reflux. The 6-substituted 2-aminobenzimidazoles (39 – 42) were 
synthesised from para-substituted anilines in a five-step procedure, in which the last step entailed 
cyclisation of the diamine using cyanogen bromide. 
The urea formation step entailed a CDI-mediated coupling and could be applied to both the 
benzothiazole and the benzimidazole scaffolds. CDI was reacted with the ammonium hydrochloride 
salt of 4-methoxybenzylamine, to form the electrophile, N-(4-methoxybenzyl) carbamoylimidazole 
(46). Carbamoylimidazole 46 was reacted with the 6-substituted 2-aminobenzothiazoles (20 – 23) in a 
NaH/DMF system to afford the 1-(6-substituted benzothiazol-2-yl)-3-(4-methoxybenzyl)ureas (4, 56 – 
58) in high to quantitative yields. The similar synthesis of the 1-(6-substituted benzimidazol-2-yl)-3-(4-
methoxybenzyl)ureas (6, 59 – 61) proved more challenging and afforded moderate yields. 
Ureas 56 – 58 and 59 – 61 were synthesised with modifiable substituents in the sixth position of their 
benzazole rings, which were further utilised to incorporate electrophilic warheads onto the 
compounds. Halomethylketones 7 and 8 were successfully prepared from their acetyl precursors, in 
low to moderate yields. The benzothiazole derivative required α-monobromination with a PTAB/THF 
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system, whereas the benzimidazole derivative was successfully α-monobrominated via a silyl enol 
ether intermediate. The vinyl- and the ethynyl ketones (9 – 12) were prepared from their ester 
precursors, which were converted into Weinreb amides in good yields and then reacted with Grignard 
reagents in low yields. Acrylamides 13 and 14 were synthesised in low to moderate yields by reduction 
of their 6-nitro precursors, and subsequent treatment of the amines with acryloyl chloride. 
The biological GSK-3β inhibitory results were satisfactory, except in the case of the acrylamides. The 
nitrile derivatives (4, 6) and the benzimidazole HMK derivative (8) displayed high inhibitory activity. 
The best IC50 value in the library was 0.086 ± 0.023 μM, observed for 1-(6-cyano-1H-benzo[d]imidazol-
2-yl)-3-(4-methoxybenzyl)urea (6), and is excellent in comparison to the reference compound (3), with 
an IC50 value of 0.072 ± 0.043 µM in our assay. The benzimidazole derivatives were generally better 
inhibitors than their benzothiazole equivalents, supposedly due to their ability to form one additional 
hydrogen bond with the hinge region of the GSK-3β ATP pocket. Structure-activity studies further 
proposed that Cys199 target distance and electrophilic warhead size might influence inhibitory 
activity. Unfortunately, the binding mode of the GSK-3 inhibitors (reversible vs. irreversible) could not 
be confirmed in this study. 
Highly active GSK-3β inhibitors, nitrile 6 and HMK 8, were successfully developed and may potentially 
contribute to the AD drug development pipeline as disease-modifying therapeutics (DMTs). The AD 
drug pipeline is in an urgent need of DMTs which will target the underlying mechanisms of the disease. 
 
Figure 7.1: The final library of compounds which was sent for GSK-3β biological testing 
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Chapter 8: Future work 
8.1 Future work: Chemistry 
8.1.1 CDI-coupling with the 2-aminobenzimidazoles 
In Chapter 4, the CDI-mediated urea formation step with the 2-aminobenzothiazoles and the 
2-aminobenzimidazoles were discussed, respectively. When the 2-aminobenzothiazoles were reacted 
with carbamoylimidazole 46, excellent yields were obtained. However, when the 
2-aminobenzimidazoles were reacted with 46, starting material remained in solution, which lowered 
the reaction yields. It was suggested that this might be due to 2-aminobenzimidazole’s weaker 
nucleophilic nature, due to the involvement of the primary amine’s electrons in tautomerism with the 
imidazole ring. 
An increase in the electrophilicity of carbamoylimidazole 46 could be explored as an alternative to 
drive the reactions with the 2-aminobenzimidazoles to completion.1 Methylation of the distal nitrogen 
in the imidazole ring of carbamoylimidazole 46 will form the resonance-stabilised 
carbamoylimidazolium salt 72 (Figure 8.1). Thus, compound 72 is activated at the carbonyl carbon 
centre and more susceptible to nucleophilic attack by 2-aminobenzimidazole (39 – 42). 
 
Figure 8.1: The proposed activation of carbamoylimidazole 46 with MeI, before the N-(4-
methoxybenzyl)-N’-(6-substituted benzimidazolyl)ureas (6, 59 – 61) are synthesised. 
8.1.2 α-Bromination via the silyl enol ether 
In Chapter 5, 1-(6-acetyl-1H-benzo[d]imidazol-2-yl)-3-(4-methoxybenzyl)urea (59) was successfully 
α-brominated via a silyl enol ether intermediate, in order to obtain regioselectivity and to prevent 
over-bromination. In the synthesis, the first step involved the generation of the silyl enol ether from 
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the acetyl with TMSOTf and DIPEA at 0 °C. This reaction was found to be incomplete, even after 
increasing the reaction temperature to 30 °C and increasing the reagent equivalents (TMSOTf, 7.8 
equiv, DIPEA, 10.4 equiv). TMSOTf is a powerful silylating agent which is usually used in stoichiometric 
quantities, and therefore a large excess of TMSOTf should not be necessary.2,3 In future studies, a 
stronger base should be considered, to drive the enolization reaction forward. 
1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU, pKa [BH+]= 12.0) is a slightly stronger base than DIPEA 
(pKa [BH+] = 10.5) and might be worth exploring.2,4 Otherwise, strong bases such as lithium diisopropyl 
amide (LDA) and lithium hexamethyldisilazide (LiHMDS) can be investigated. In the presence of a 
strong base, the acetyl will be deprotonated first to generate a highly reactive enolate, which is then 
trapped by a trimethylsilyl group. A powerful silylating reagent such as TMSOTf is no longer necessary 
and therefore trimethylsilyl chloride (TMSCl) can also be used as silylating reagent. The combination 
of strong bases with TMSCl is more common in the literature.5 
8.1.3 Improving the Grignard reactions 
In Chapter 5, the Weinreb amides 62 (81% yield) and 63 (78% yield) were successfully synthesised 
from their ester precursors. Next, the Weinreb amides were utilised in Grignard reactions to form the 
vinyl- and ethynyl ketones 9 – 12. Unfortunately, these reactions did not proceed well, irrespective of 
optimisation attempts, and the yields of the products were very low. These Grignard reactions can be 
improved in future work. However, it should be noted that the vinyl- and ethynyl ketones 9 – 12 
displayed low GSK-3β inhibitory activity in the biological studies, with IC50 values in the range of 1.60 
– 4.54 μM. Thus, the vinyl- and ethynyl ketones 9 – 12 and their synthetic pathways will not be 
developed any further. However, from a chemistry perspective, it may be of value to improve these 
Grignard reactions. 
The Grignard reactions required a large excess of the organomagnesium reagent to reach completion 
and it was suggested that these large quantities could have hindered the success of the reaction. It is 
therefore proposed that optimisation of the amount of organomagnesium reagent and higher 
reaction temperatures are explored as an alternative to drive reactions to completion. Nahm and 
Weinreb6 applied temperatures of up to 65 °C in their Grignard reactions with Weinreb amides. 
Organolithiums can also be investigated as alternative, more reactive, organometallic reagents. 
In the case of the vinyl ketones, a major by-product was formed during the quenching step, but the 
nature of the side-reaction could not be determined. The tetrahedral intermediate/product appears 
to be very sensitive to the quenching step, and alternative quenching solutions (e.g. 5% HCl in 
ethanol)6 or quenching procedures can be considered. To apply very mild quenching conditions, one 
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might consider diluting the reaction mixture with EtOAc first. Then, immediately after adding 1 M aq. 
NaHSO4 (quenching agent), the product will be able to partition into the organic layer. 
8.2 Future work: Biological studies and exploration 
8.2.1 Investigation of the binding mode: Irreversible vs. Reversible 
The most important future work, in order to conclude the outcomes of this project, is to investigate 
the binding mode of the newly synthesised GSK-3β inhibitors in the GSK-3β ATP binding pocket. It is 
important to determine whether the proposed electrophilic warheads are targeting the Cys199 
residue through an irreversible binding reaction. 
The reversibility study results were deemed inconclusive, since the results of our reference compound, 
AR-A014418 (3), were not as expected. There was no significant difference in efficacy in the time 
period of the experiment between the non-covalent reference and the new compounds with the 
electrophilic warhead. In future studies, the reversibility studies should be repeated, and the 
reversible GSK-3 inhibitor, alsterpaullone, which was used as reference compound in the reversibility 
studies of Martínez and co-workers, should also be included.7 Furthermore, covalent irreversible 
binding should be confirmed with MALDI-TOF MS analysis.8 If the inhibitor binds the enzyme 
irreversibly, a combined mass peak will be present in the MS spectrum. 
8.2.2 Investigation of alternative electrophilic warheads 
In the biological activity results, the compounds with smaller electrophilic warheads displayed better 
IC50 values. As seen from the molecular modelling studies, the ligands are positioned with the 
electrophilic moiety in the deepest end of the GSK-3β ATP pocket. Therefore, larger electrophilic 
moieties may push the ligand out of the binding pocket, or compromise the entrance and positioning 
of the ligand in the pocket. In future studies, alternative small electrophilic warheads can be 
investigated, for example, sulfonyl fluorides and vinyl sulfones (Figure 8.2). Sulfonyl fluorides are 
privileged electrophilic warheads, which can covalently modify various reactive residues, including 
cysteine residues.9 The potential of vinyl sulfones to mediate irreversible inhibition has also been  
 
Figure 8.2: Alternative electrophilic moieties which can be explored 
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recorded in the literature.10–12 
8.2.3 Investigation of alternative core structures 
In this project, the inhibitors with benzimidazole core-structures displayed better docking scores and 
higher inhibitory activities than their benzothiazole counterparts. Therefore, the effect of other core-
structures could be investigated in future studies. The benzoxazole core-structure (77) is the most 
obvious bioisostere to investigate (Figure 8.3). Smaller core-structures, such as imidazole (78) or 
triazole (79) are proposed to maintain the essential binding interactions with the GSK-3β hinge region, 
but additionally, these smaller structures may provide space for larger electrophilic warheads. 
 
Figure 8.3: Possible core-structures modifications that can be investigated 
It is important that compounds with new core-structures and electrophilic warheads are re-modelled 
in the GSK-3β ATP binding site, in order to investigate their feasibility, understand any potential 
binding interactions and to model the expected Cys199 target distances. 
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Chapter 9: Experimental Section 
9.1 General practices 
All reactions were performed in a fume hood. Unless carried out in water or if otherwise noted, all 
reactions were performed under a positive pressure of 5.0-grade nitrogen. Glassware was oven-dried 
(120 °C) and purged with nitrogen. Reagents were obtained from Sigma-Aldrich or Merck and were 
used without further purification, unless otherwise stated. Bulk solvents for chromatographic 
purposes were distilled by general distillation. Tetrahydrofuran was freshly distilled from sodium wire 
and benzophenone under nitrogen. Methanol and ethanol were freshly distilled from magnesium 
turnings and iodine. Dichloromethane was distilled from calcium hydride under nitrogen. 
Dimethylformamide was stirred over calcium hydride and filtered, whereafter it was distilled under 
nitrogen and stored over molecular sieves (4 Å). Any other reagents that required purification were 
purified according to standard protocol.1 
9.1.1 Chromatography 
Thin layer chromatography (TLC) was performed on Macherey Nagel aluminium TLC-plates, pre-
coated with 0.20 mm silica gel and fluorescent indicator UV254. Compounds were visualised with UV 
light (254 nm) and p-anisaldehyde stain. Stained TLC-plates required heating. Universal pH test paper 
strips were used to determine pH. Column chromatography was performed using 230 – 400 mesh 
silica (0.040 – 0.063 mm particle size). Automated flash column chromatography was carried out on 
the Teledyne ISCO Combiflash Rf 50, using 230 – 400 mesh silica. Mobile phase and Rf value solvent 
ratios are reported as v/v ratios. A rotary evaporator was used to remove solvents in vacuo. High 
vacuum (pressure less than 1 mm Hg) was used to dry products. 
9.1.2 Spectroscopic and physical analysis 
IR spectra were recorded on the Thermo Nicolet FT-IR, using an Attenuated Total Reflectance (ATR) 
attachment. OMNIC 7.0 software was used to analyse spectra. NMR spectra were recorded at 25 °C, 
on a 300 MHz Varian VNMRS (75 MHz for 13C NMR spectra), 400 MHz Varian Unity Inova (101 MHz for 
13C NMR spectra) or 600 MHz Varian Unity Inova (151 MHz for 13C NMR spectra) at the Central 
Analytical Facilities (CAF) of Stellenbosch University. Samples were dissolved in deuterated solvents. 
Chemical shifts (δ) are reported in ppm. Chemical shifts were referenced to the residual solvent signal 
in DMSO-d6 (δ 2.50 ppm in 1H NMR spectra; δ 39.5 ppm in 13C NMR spectra) or CDCl3 (δ 7.26 ppm in 
1H NMR spectra; δ 77.2 ppm in 13C NMR spectra). Notwithstanding that DMSO-d6 was dried over 4 Å 
molecular sieves, all 1H NMR spectra in DMSO-d6 displayed a water signal at δ 3.33 ppm. Spectra were 
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processed in MestreNova 6.0.2. Melting points were determined with Lasany Melting Point Apparatus. 
High-resolution mass spectrometry and purity analysis were conducted by CAF of Stellenbosch 
University, on a Waters Acquity UPLC system (fitted with a photodiode array detector) and a Waters 
SYNAPT G2 QTOF spectrometer, in ESI positive mode. A Waters BEH C18 column (1.7 μm, 100 mm × 
2.1 mm) were used for UPLC purity testing. 
9.1.3 Crystallography 
A single crystal of diffraction quality was selected, mounted in oil, and analysed at 100 K using a Bruker 
DUO Apex III X-ray diffractometer. An Oxford Cryostream cryostat (700 series Cryostream Plus) 
attached to the diffractometer was used to cool the sample. Data reduction and unit cell 
determinations were performed using the Bruker diffraction software SAINT,2 whereas absorption 
corrections were carried out in SADABS.3,4 Crystal structures were solved and refined with SHELXT-145 
and SHELXL-16,6 using the X-Seed7,8 graphical user interface. The positions of non-hydrogen atoms 
were refined anisotropically, and hydrogen atoms were placed on calculated positions. Electron 
density maps were used to locate the hydrogen atoms on nitrogen and oxygen atoms. POV-Ray was 
used to generate figures from the 3D crystal lattice.9 
9.1.4 Biological testing 
Inhibition of GSK-3 (Luminescent Assay):10 Human recombinant GSK-3β and the prephosphorylated 
polypeptide substrate were purchased from Millipore Iberica S.A.U. and the Kinase-Glo Luminescent 
Kinase Assay from Promega Biotech Ibérica (SL). ATP and all other reagents were obtained from Sigma-
Aldrich (St. Louis, MO). The assay buffer comprised of 50 mM HEPES (pH 7.5), 1 mM EDTA, 1 mM EGTA, 
and 15 mM magnesium acetate. The method of Baki et al.11 was followed to determine GSK-3β 
inhibitory activity. In the assay, 10 μL (10 μM) of test compound (dissolved to 1 mM concentration in 
DMSO, and further diluted with assay buffer to the desired concentration) and 10 μL (20 ng) of enzyme 
were added to each well, followed by 20 μL of assay buffer containing 25 μM substrate and 1 μM ATP. 
The final DMSO concentration did not exceed 1%. After 30 min of incubation at 30 °C, 40 μL of Kinase-
Glo reagent was added to stop the enzymatic reaction. After 10 min, the glow-type luminescence was 
recorded using a FLUOstar Optima multimode reader. Activity was determined from the difference in 
total ATP and ATP consumed. The inhibitory activity was then calculated by comparing with the 
maximal activity measured in the absence of an inhibitor. IC50 was defined as the concentration of 
compound that reduces the enzymatic activity by 50%. 
GSK-3β reversibility study:10 The enzyme was pre-incubated with the inhibitor for a certain 
pre-incubation time, before measuring the activity of the enzyme. GSK-3β inhibitory activities were 
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measured after several different pre-incubation times. A reversible inhibitor does not display 
increased levels of inhibition after longer pre-incubation times, whereas an irreversible inhibitor 
displays higher inhibition percentages with longer pre-incubation times. 
9.2 Procedures 
 4-Amino-3-thiocyanatobenzonitrile (24) 
4-Aminobenzonitrile (16, 0.500 g, 4.23 mmol, 1.0 equiv), glacial acetic acid (10 mL) and 
KSCN (1.33 g, 13.7 mmol, 3.2 equiv) were added to a 2-neck flask and stirred at 5 °C for 
10 min. Trimethylphenylammonium tribromide (2.15 g, 5.72 mmol, 1.4 eq.) was added 
to the reaction mixture in batches, at 5 °C, over 1 h. The reaction mixture was left to stir for 5 h at r.t. 
The yellow reaction mixture was quenched with H2O (70 mL) and was left overnight at 0 – 4 °C. The 
yellow precipitate was collected by filtration. The product was extracted from the yellow precipitate 
with EtOAc (7 × 30 mL) and the combined organic layers were dried over MgSO4, filtered and 
concentrated under reduced pressure. Column chromatography with 100% DCM afforded 24 as a 
white crystalline solid (0.553 g, 75% yield). 
Rf = 0.49 (100% DCM); 1H NMR (300 MHz, DMSO-d6) δ 7.95 (d, J = 2.0 Hz, 1H, ArH2), 7.57 (dd, J = 8.6, 
2.0 Hz, 1H, ArH6), 6.93 (br.s, 2H, NH2), 6.87 (d, J = 8.6 Hz, 1H, ArH5); 13C NMR (75 MHz, DMSO-d6) 
δ 153.6, 140.8, 135.6, 118.9, 115.6, 110.9, 103.8, 97.3; FT-IR (ATR mode) 3443 (N-H stretch), 3343 (N-H 
stretch), 3243, 3219, 2220 (C≡N stretch), 2158 (S-C≡N stretch), 1633, 1598, 1506, 836 cm-1; HRMS (ESI) 
m/z calcd for C8H5N3SNa, [M+Na]+: 198.0104, found 198.0104. 
1H NMR spectroscopic data correlated well with that in the literature.12 
2-Aminobenzo[d]thiazole-6-carbonitrile (20) 
To a stirred solution of 4-amino-3-thiocyanatobenzonitrile (24, 0.110 g, 0.628 
mmol, 1.0 equiv) in THF (5 mL) was added 60% NaH in mineral oil (0.035 g, 0.88 
mmol, 1.4 equiv) at r.t. The reaction mixture was heated under reflux for 2 h and 
then concentrated under reduced pressure. The product was purified by column chromatography 
(50% Hexane/EtOAc) to afford 20 as a white powder (0.093 g, 85% yield). 
Rf = 0.64 (50% DCM/EtOAc); mp = 198 – 202 °C (lit.13 mp 203 – 204 °C); 1H NMR (400 MHz, DMSO-d6) 
δ 8.17 (d, J = 1.7 Hz, 1H, ArH7), 8.03 (s, 2H, NH2), 7.60 (dd, J = 8.4, 1.7 Hz, 1H, ArH5), 7.41 (d, J = 8.4 Hz, 
1H, ArH4); 13C NMR (101 MHz, DMSO-d6) δ 170.0 (ArC2), 156.5 (ArC3a), 131.7 (ArC7a), 129.6 (ArC5), 125.3 
(ArC7), 119.7 (CN), 117.9 (ArC4), 102.0 (ArC6); FT-IR (ATR mode) 3412 (N-H stretch), 3288 (N-H stretch), 
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3064, 2935, 2215 (C≡N stretch), 1643, 1522, 1457, 1292, 1193, 809 cm-1; HRMS (ESI) m/z calcd for 
C8H6N3S, [M+H]+: 176.0283, found 176.0278. 
The signals in the 13C NMR spectrum were assigned in accordance with the results obtained in a 
13C NMR spectroscopic study on benzothiazoles, which was performed by Sawhney and Boykin.14 The 
13C NMR spectroscopic data correlated perfectly with their data. 
1-(2-Aminobenzo[d]thiazol-6-yl)ethanone (21) 
4-Aminoacetophenone (17, 0.300 g, 2.22 mmol, 1.0 equiv), glacial acetic acid 
(6 mL) and KSCN (0.669 g, 6.88 mmol, 3.1 equiv) were added to a 2-neck flask 
and stirred at 10 °C for 10 min. Trimethylphenylammonium tribromide (1.13 g, 
3.01 mmol, 1.4 equiv) was added to the reaction mixture in batches, at 10 °C, over 1 h. The reaction 
mixture was left to stir for 5 h at r.t., whereafter it was heated under reflux for 10 min to drive the 
internal cyclisation step to completion. The reaction was quenched with H2O (40 mL) and basified to 
pH = 10 with conc. NH4OH. The mixture was left overnight at 0 – 4 °C to allow precipitation and then 
the orange precipitate was collected by filtration. The product was extracted from the precipitate with 
EtOAc (7 × 30 mL), followed by acetone (4 × 30 mL). The combined organic layers were dried over 
MgSO4, filtered and concentrated under reduced pressure. Column chromatography with 50% 
DCM/EtOAc afforded 21 as a yellow solid (0.347 g, 81% yield). 
Rf = 0.43 (50% DCM/EtOAc); mp = > 200 °C decomp (lit.15 mp 257 – 258 °C); 1H NMR (300 MHz, 
DMSO-d6) δ 8.32 (d, J = 1.8 Hz, 1H, ArH7), 7.91 (s, 2H, NH2), 7.83 (dd, J = 8.4, 1.8 Hz, 1H, ArH5), 7.37 (d, 
J = 8.4 Hz, 1H, ArH4), 2.54 (s, 3H, CH3). 13C NMR (75 MHz, DMSO-d6) δ 196.2 (COCH3), 169.8 (ArC2), 
156.9 (ArC3a), 131.1 (ArC), 129.9 (ArC), 126.3 (ArC), 122.0 (ArC), 117.0 (ArC4), 26.5 (COCH3); FT-IR (ATR 
mode) 3351 (N-H stretch), 3322 (N-H stretch), 3042, 1644, 1586, 1513, 1417, 1354, 1293, 1276 (C-N 
stretch), 1231, 822 cm-1; HRMS (ESI) m/z calcd for C9H9N2OS, [M+H]+: 193.0436, found 193.0428. 
The NMR spectroscopic data of this compound compared well to literature data.16 The signals in the 
13C NMR spectrum were assigned in accordance with the trends obtained in a 13C NMR spectroscopic 
study on benzothiazoles, which was performed by Sawhney and Boykin.14 
6-Nitrobenzo[d]thiazole-2-amine (23) 
4-Nitroaniline (19, 0.500 g, 3.62 mmol, 1.0 equiv), glacial acetic acid (13 mL) and 
KSCN (1.09 g, 11.2 mmol, 3.1 equiv) were added to a 2-neck flask and cooled to 
10 °C. Trimethylphenylammonium tribromide (1.84 g, 4.89 mmol, 1.4 equiv) 
was added to the reaction mixture in batches, at 10 °C, over 1 h. The reaction mixture was left to stir 
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for 5 h at r.t., whereafter it was heated under reflux for 10 min and then quenched with H2O (40 mL). 
Conc. NH4OH was then used to basify the reaction mixture to pH = 8. The mixture was extracted with 
EtOAc (3 × 50 mL) and the combined organic phase was washed with brine (20 mL), dried over MgSO4, 
filtered and then concentrated in vacuo. The crude product was purified by column chromatography 
(5% MeOH/15% EtOAc/DCM) to afford 23 as a bright yellow solid (0.382 g, 54% yield). 
Rf = 0.44 (5% MeOH/15% EtOAc/DCM); 1H NMR (300 MHz, DMSO-d6) δ 8.68 (d, J = 2.5 Hz, 1H, ArH7), 
8.24 (s, 2H, NH2), 8.09 (dd, J = 8.9, 2.5 Hz, 1H, ArH5), 7.41 (d, J = 8.9 Hz, 1H, ArH4); 13C NMR (75 MHz, 
DMSO-d6) δ 171.8 (ArC2), 158.6 (ArC3a), 140.7 (ArC6), 131.6 (ArC7a), 122.0 (ArC5), 117.7 (ArC4), 116.8 
(ArC7); FT-IR (ATR mode) 3458 (N-H stretch), 3020, 2936, 1654, 1531, 1491 (N=O asym stretch), 1323 
(N=O sym stretch), 1289, 1122, 753 cm-1; HRMS (ESI) m/z calcd for C7H6N3O2S, [M+H]+: 196.0181, 
found 196.0181. 
The NMR spectroscopic data of this compound compared well to literature data.14,17 The signals in the 
13C NMR spectrum were assigned in accordance with the results obtained by Sawhney and Boykin.14  
Methyl 4-aminobenzoate (18)18  
A solution of 4-aminobenzoic acid (25, 2.00 g, 14.6 mmol, 1.0 equiv) and MeOH (15 mL) was 
cooled to 0 °C. Thionyl chloride (2.6 mL, 36 mmol, 2.5 equiv) was added slowly by dropwise 
addition, which resulted in a white suspension. The reaction mixture was heated under reflux 
for 19 h to yield a yellow solution. After cooling, the solution was concentrated under 
reduced pressure. After the addition of sat. aq. NaHCO3 (60 mL), the mixture was extracted 
with EtOAc (3 × 40 mL). The combined organic layers were dried over MgSO4, filtered and 
concentrated under reduced pressure. Column chromatography with 40% EtOAc/Hexane afforded 18 
as a cream-coloured solid (2.13 g, 97% yield). 
Rf = 0.66 (50% EtOAc/Hexane); 1H NMR (300 MHz, CDCl3) δ 7.84 (d, J = 8.6 Hz, 2H, 2 × ArH), 6.63 (d, J = 
8.6 Hz, 2H, 2 × ArH), 4.06 (br.s., 2H, NH2), 3.85 (s, 3H, CH3); 13C NMR (75 MHz, CDCl3) δ 167.3 (CO2CH3), 
151.0, 131.7, 119.8, 113.9, 51.7 (CH3). 
The NMR spectroscopy data collected for this compound compared well to literature data.18 
Methyl 2-aminobenzo[d]thiazole-6-carboxylate (22) 
Methyl 4-aminobenzoate (18, 0.750 g, 4.96 mmol, 1.0 equiv), glacial acetic 
acid (12 mL) and KSCN (1.49 g, 15.3 mmol, 3.1 equiv) were added to a 2-neck 
flask and cooled to 10 °C. Trimethylphenylammonium tribromide (2.52 g, 
6.70 mmol, 1.4 equiv) was added to the reaction mixture in batches, at 10 °C, 
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over 1 h. The reaction mixture was left to stir for 5 h at r.t., whereafter it was heated under reflux for 
40 min and then quenched with H2O (80 mL). Conc. NH4OH was used to basify the reaction mixture to 
pH = 10. The reaction mixture was left overnight at 0 – 4 °C to allow precipitation. The precipitate was 
collected by filtration and the colourless mother liquid discarded. The precipitate and H2O (50 mL) 
were transferred into a separatory funnel and the suspension was extracted with EtOAc (4 × 40 mL). 
The organic layers were combined and washed with brine (30 mL). The solvent was removed in vacuo 
and the crude product was purified by column chromatography (50% Hexane/EtOAc) to afford 22 as 
a yellow solid (0.761 g, 74% yield). 
Rf = 0.32 (50% Hexane/EtOAc); 1H NMR (300 MHz, DMSO-d6) δ 8.28 (d, J = 1.8 Hz, 1H, ArH7), 7.90 (s, 
2H, NH2), 7.81 (dd, J = 8.4, 1.8 Hz, 1H, ArH5), 7.37 (d, J = 8.4 Hz, 1H, ArH4), 3.82 (s, 3H, CH3); 13C NMR 
(75 MHz, DMSO-d6) δ 169.8 (ArC2), 166.1 (CO2CH3), 156.9 (ArC3a), 131.2 (ArC7a), 127.1 (ArC5), 122.6 
(ArC6/7), 121.7 (ArC6/7), 117.1 (ArC4), 51.8 (CO2CH3); FT-IR (ATR mode) 3357 (N-H stretch), 3298 (N-H 
stretch), 3084, 2948, 1691 (C=O), 1645, 1523, 1463, 1430, 1330, 1279, 1236, 1111, 765 cm-1; HRMS 
(ESI) m/z calcd for C9H9N2O2S, [M+H]+: 209.0385, found 209.0386. 
The signals in the 13C NMR spectrum were assigned in accordance with the results obtained for ethyl 
2-aminobenzo[d]thiazole-6-carboxylate in a 13C NMR spectroscopic study on benzothiazoles, which 
was performed by Sawhney and Boykin.14 
N-(4-methoxybenzyl)-1H-imidazole-1-carboxamide (46)19 
4-Methoxybenzylamine (15, 0.13 mL, 1.0 mmol, 1.0 equiv) was added to 
DCM (3 mL). The mixture was then treated with 4.0 M HCl in 1,4-dioxane 
(0.25 mL, 1.0 mmol, 1.0 equiv) while stirring at r.t. The resultant colour 
change from colourless to white, indicated the in situ formation of the ammonium hydrochloride salt. 
After stirring for 10 min, DMF (1.6 mL) was added and the reaction mixture was cooled to 0 °C. CDI 
(0.211 g, 1.30 mmol, 1.3 equiv) was added to the white suspension and the mixture was stirred for 
7 min at 0 °C. The colourless solution was concentrated immediately under reduced pressure, while 
maintaining a temperature of 30 °C on the rotary evaporator. After addition of EtOAc (30 mL), the 
mixture was washed with a saturated aqueous solution of NH4Cl (4 × 10 mL). The organic layer was 
dried over MgSO4, filtered and concentrated under reduced pressure. The product was purified by 
column chromatography (5% MeOH/DCM) to give 46 as a crystalline white solid (0.231 g, quant. yield). 
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Rf = 0.31 (5% MeOH/DCM); mp = 115 – 118 °C (lit.19 mp 113 – 114 °C); 1H NMR (300 MHz, CDCl3) δ 8.06 
(s, 1H, ArH), 7.57 (br.t†, 1H, NH), 7.41 (s, 1H, ArH), 7.23 (d, J = 8.7 Hz, 2H, 2 × ArH), 6.89 (s, 1H, ArH), 
6.85 (d, J = 8.7 Hz, 2H, 2 × ArH), 4.47 (d, J = 5.6 Hz†, 2H, CH2), 3.78 (s, 3H, OCH3); 13C NMR (75 MHz, 
CDCl3) δ 159.4, 149.1, 135.9, 129.9, 129.5, 129.3, 116.5, 114.3, 55.4, 44.5; FT-IR (ATR mode) 3204 (N-H 
stretch), 3001, 1715 (C=O stretch), 1545, 1509, 1483, 1473, 1447, 1331, 1286, 1251, 1231, 1212, 1174, 
1070, 1033 cm-1; HRMS (ESI) m/z calcd for C12H14N3O2, [M+H]+: 232.1086, found 232.1092. 
The 13C NMR spectroscopic data correlated well with that in the literature,19 whereas slight deviations 
were present in the rest of the spectroscopic data. 
1-(4-Methoxybenzyl)-3-(5-nitrothiazol-2-yl)urea (3)19 
60% NaH in mineral oil (0.0580 g, 1.45 mmol, 1.4 equiv) was added 
portion-wise to a solution of 2-amino-5-nitrothiazole (52, 0.150 g, 1.03 
mmol, 1.0 equiv) and N-(4-methoxybenzyl)-1H-imidazole-1-
carboxamide (46, 0.239 g, 1.03 mmol, 1.0 equiv) in DMF (7 mL). The 
reaction mixture was stirred for 15 h, whereafter the mixture was diluted with EtOAc (100 mL) and 
extracted with sat. aq. NH4Cl (3 × 35 mL). The organic layer was washed with brine (30 mL) and 
concentrated in vacuo. Purification of the crude product required two steps. First, column 
chromatography (3% MeOH, 97% DCM) was performed and the desired fractions were collected and 
concentrated in vacuo. Subsequently, trituration with DCM (3 × 7 mL) yielded the pure product 3 as a 
yellow solid (0.083 g, 26% yield). 
Rf = 0.26 (3% MeOH, 97% DCM); mp = > 190 °C decomp (lit.20 > 190 °C decomp); 1H NMR (300 MHz, 
DMSO-d6) δ 11.63 (br.s, 1H, NH), 8.50 (s, 1H, ArH), 7.25 – 7.22 (d imposed on a br.t. [app. d], J = 8.7 
Hz, 3H, 2 × ArH, NH), 6.90 (d, J = 8.7 Hz, 2H, 2 × ArH), 4.29 (d, J = 5.9 Hz, 2H, CH2), 3.73 (s, 3H, OCH3); 
13C NMR (75 MHz, DMSO-d6) δ 164.3, 158.4, 153.3, 143.3, 140.9, 130.8, 128.7, 113.8, 55.1, 42.6; FT-IR 
(ATR mode) 3313 (N-H stretch), 1673 (C=O stretch), 1516, 1480, 1440, 1352 (N=O sym stretch), 1315, 
1225, 1176, 1023, 821 cm-1; HRMS (ESI) m/z calcd for C12H13N4O4S, [M+H]+: 309.0658, found 309.0651; 
UPLC: Purity >95%, r.t = 6.02 min, acetonitrile/H2O (0.1% formic acid) 5/95. 
The spectroscopy data of this compound compared well to literature data.19 
                                                          
† The amide proton (NH) and the benzylic CH2 protons couple with one another. The J-coupling value measured 
for the NH triplet peak was not precise, due to the broadness of the signal. Therefore, only the J-coupling 
constant of the sharper CH2 signal is reported. This reporting method was applied throughout the experimental 
chapter, to all compounds displaying this particular NH to CH2 coupling. 
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General procedure for the synthesis of N-(4-methoxybenzyl) ureas (4, 56 – 58) from 
2-aminobenzothiazoles.19 
The amine (1.0 equiv) and N-(4-methoxybenzyl)-1H-imidazole-1-carboxamide (46, 1.3 equiv) were 
dissolved in DMF (3 – 6 mL). 60% NaH in mineral oil (1.4 equiv) was added in portions over 20 min and 
the solution was left to stir at r.t. for 22 h. After the addition of EtOAc (70 mL), the mixture was washed 
with a saturated aqueous solution of NH4Cl (4 × 20 mL) and then brine (1 × 20 mL). During the course 
of DMF removal, the organic layer changed from colourless to a white suspension. The organic layer 
was concentrated under reduced pressure. The crude product was purified by column 
chromatography to yield ureas 4, 56 – 58. 
1-(6-Cyanobenzo[d]thiazol-2-yl)-3-(4-methoxybenzyl)urea (4) 
Prepared according to the general procedure, with the following 
amounts: 2-Aminobenzo[d]thiazole-6-carbonitrile (20, 0.086 g, 
0.49 mmol), N-(4-methoxybenzyl)-1H-imidazole-1-carboxamide 
(46, 0.148 g, 0.640 mmol), 60% NaH in mineral oil (0.028 g, 0.70 
mmol). Column chromatography (5% MeOH/15% EtOAc/DCM) yielded 4 as a white solid (0.165 g, 99% 
yield). 
Rf = 0.53 (5% MeOH/DCM); mp = > 207 °C decomp; 1H NMR (300 MHz, DMSO-d6) δ 11.11 (s, 1H, NH), 
8.45 (s, 1H, ArH), 7.75 – 7.74 (m, 2H, 2 × ArH), 7.25 (d, J = 8.7 Hz, 2H, 2 × ArH), 7.20 (br.t, 1H, NH), 6.91 
(d, J = 8.7 Hz, 2H, 2 × ArH), 4.31 (d, J = 5.8 Hz, 2H, CH2), 3.73 (s, 3H, CH3); 13C NMR (75 MHz, DMSO-d6) 
δ 163.6, 158.4, 153.5, 152.5, 132.3, 131.0, 129.5, 128.7, 126.4, 120.2, 119.3, 113.8, 104.3, 55.1, 42.5; 
FT-IR (ATR mode) 3314 (N-H stretch), 2226 (C≡N stretch), 1667 (C=O stretch), 1557, 1547, 1514, 1446, 
1274, 1257, 1227, 1174, 1033, 824 cm-1; HRMS (ESI) m/z calcd for C17H15N4O2S, [M+H]+: 339.0916, 
found 339.0915; UPLC: Purity 99%, r.t = 6.71 min, acetonitrile/H2O (0.1% formic acid) 2/98. 
The spectroscopy data of this compound compared well to literature data.21 
1-(6-Acetylbenzo[d]thiazol-2-yl)-3-(4-methoxybenzyl)urea (56) 
Prepared according to the general procedure, with the following 
amounts: 1-(2-Aminobenzo[d]thiazol-6-yl)ethanone (21, 0.150 g, 
0.780 mmol), N-(4-methoxybenzyl)-1H-imidazole-1-carboxamide 
(46, 0.230 g, 0.995 mmol), 60% NaH in mineral oil (0.045 g, 1.1 
mmol). Column chromatography (5% MeOH/25% EtOAc/DCM) 
yielded 56 as a light yellow solid (0.228 g, 82% yield). 
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Rf = 0.61 (5% MeOH/25% EtOAc/DCM); mp = > 214 °C decomp; 1H NMR (300 MHz, DMSO-d6) δ 11.02 
(s, 1H, NH), 8.57 (d, J = 1.5 Hz, 1H, ArH7), 7.95 (dd, J = 8.5, 1.5 Hz, 1H, ArH5), 7.67 (d, J = 8.5 Hz, 1H, 
ArH4), 7.26 (d, J = 8.6 Hz, 2H, 2 × ArH), 7.20 (br.t, 1H, NH), 6.91 (d, J = 8.6 Hz, 2H, 2 × ArH), 4.31 (d, J = 
5.8 Hz, 2H, CH2), 3.73 (s, 3H, OCH3), 2.60 (s, 3H, COCH3); 13C NMR (75 MHz, DMSO-d6) δ 196.7 (COCH3), 
163.2, 158.4, 153.6, 152.8, 131.7, 131.5, 131.1, 128.7, 126.0, 122.8, 119.3, 113.8, 55.1, 42.5, 26.7 
(COCH3); FT-IR (ATR mode) 3312 (N-H stretch), 1685 (C=O stretch), 1673 (C=O stretch), 1557, 1527, 
1510, 1268, 1233 cm-1; HRMS (ESI) m/z calcd for C18H18N3O3S, [M+H]+: 356.1070, found 356.1057; 
UPLC: Purity 95%, r.t = 5.88 min, acetonitrile/H2O (0.1% formic acid) 5/95. 
Methyl 2-[3-(4-methoxybenzyl)ureido]benzo[d]thiazole-6-carboxylate (57) 
Prepared according to the general procedure, with the following 
amounts: Methyl 2-aminobenzo[d]thiazole-6-carboxylate (22, 
0.200 g, 0.960 mmol), N-(4-methoxybenzyl)-1H-imidazole-1-
carboxamide (46, 0.289 g, 1.25 mmol), 60% NaH in mineral oil 
(0.0540 g, 1.35 mmol). The crude product was purified by column 
chromatography (5% MeOH/25% EtOAc/DCM) to afford 57 as a white solid (0.265 g, 74%). 
Rf = 0.69 (5% MeOH/25% EtOAc/DCM); mp = > 220 °C decomp; 1H NMR (300 MHz, DMSO-d6) δ 11.04 
(br.s, 1H, NH), 8.53 (d, J = 1.7 Hz, 1H, ArH7), 7.94 (dd, J = 8.5, 1.7 Hz, 1H, ArH5), 7.67 (d, J = 8.5 Hz, 1H, 
ArH4), 7.26 (d, J = 8.7 Hz, 2H, 2 × ArH), 7.18 (br.t, 1H, NH) , 6.91 (d, J = 8.7 Hz, 2H, 2 × ArH), 4.31 (d, J = 
5.8 Hz, 2H, CH2), 3.86 (s, 3H, CO2CH3), 3.73 (s, 3H, PhOCH3); 13C NMR (75 MHz, DMSO-d6) δ 166.1, 
163.3, 158.4, 153.7, 152.9, 131.8, 131.1, 128.7, 126.9, 123.6, 123.3, 119.3, 113.8, 55.1, 52.1 (CO2CH3), 
42.5; FT-IR (ATR mode) 3291 (N-H stretch), 1720 (C=O stretch), 1668 (C=O stretch), 1555, 1536, 1510, 
1434, 1296, 1271, 1235, 1112, 1030, 770 cm-1; HRMS (ESI) m/z calcd for C18H18N3O4S, [M+H]+: 
372.1019, found 372.1001. 
1-(4-Methoxybenzyl)-3-(6-nitrobenzo[d]thiazol-2-yl)urea (58) 
Prepared according to the general procedure, with the following 
amounts: 6-Nitrobenzo[d]thiazol-2-amine (23, 0.130 g, 0.666 
mmol), N-(4-methoxybenzyl)-1H-imidazole-1-carboxamide (46, 
0.200 g, 0.865 mmol), 60% NaH in mineral oil (0.037 g, 0.93 mmol). 
Column chromatography (5% MeOH/25% EtOAc/DCM) yielded 58 as a white solid (0.24 g, quant. 
yield). 
Rf = 0.61 (5% MeOH/25% EtOAc/DCM); 1H NMR (300 MHz, DMSO-d6) δ 11.25 (s, 1H, NH), 8.94 (d, J = 
2.4 Hz, 1H, ArH7), 8.21 (dd, J = 8.9, 2.4 Hz, 1H, ArH5), 7.74 (d, J = 8.9 Hz, 1H, ArH4), 7.27 – 7.21 (m, 3H, 
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2 × ArH, NH), 6.91 (d, J = 8.7 Hz, 2H, 2 × ArH), 4.32 (d, J = 5.8 Hz, 2H, CH2), 3.73 (s, 3H, OCH3); 13C NMR 
(75 MHz, DMSO-d6) δ 165.3, 158.4, 154.3, 153.6, 142.3, 132.2, 131.0, 128.7, 121.6, 119.5, 118.5, 113.8, 
55.1, 42.6; FT-IR (ATR mode) 3290 (N-H stretch), 1668 (C=O stretch), 1551, 1508, 1445, 1332 (N=O 
sym stretch), 1276, 1257, 1231, 1179, 1129, 1025, 821 cm-1; HRMS (ESI) m/z calcd for C16H15N4O4S, 
[M+H]+: 359.0815, found 359.0805. 
The spectroscopy data of this compound compared well to literature data.21 
N-(4-cyanophenyl)acetamide (26)22 
4-Aminobenzonitrile (16, 1.00 g, 8.46 mmol) was added portion-wise to acetic anhydride 
(12 mL) over 1 h, while stirring and maintaining the temperature at 35 – 45 °C. While 
keeping the flask on ice, ice water (20 mL) was added to the white suspension. The mixture 
was left at 0 – 4 °C for 1 h. The product was collected by filtration and was washed with cold 
H2O (3 × 30 mL). The product was dried in the oven at 120 °C to give 26 as a white solid 
(1.13 g, 83% yield). 
Rf = 0.07 (100% DCM); 1H NMR (300 MHz, CDCl3) δ 7.67 – 7.59 (m, 4H, 4 × ArH), 7.44 (br.s, 1H, NH), 
2.22 (s, 3H, CH3); 13C NMR (75 MHz, CDCl3) δ 168.7, 142.0, 133.5, 119.6, 118.9, 107.3, 24.9. FT-IR (ATR 
mode) 3298, 3256, 3184, 3111, 2221 (C≡N stretch), 1666 (C=O stretch), 1596, 1538, 1531, 1505, 1403, 
1360, 1320, 1264, 1175, 833 cm-1. 
The spectroscopic data correlated well with that in the literature.23 
N-(4-acetylphenyl)acetamide (27)22 
4-Aminoacetophenone (17, 2.00 g, 14.8 mmol) was added portion-wise, over 30 minutes, 
to an acetic anhydride (20 mL) and DCM (40 mL) mixture at 10 °C. The reaction mixture was 
left to stir at r.t. for 1.5 h, whereafter the DCM was removed in vacuo. While keeping the 
flask on ice, ice water (100 mL) was added to the mixture. The mixture was left at 0 – 4 °C 
overnight. The product, a white precipitate, was collected by filtration and washed with 
cold H2O (3 × 30 mL). It became evident that the mother liquid still contained product, therefore it was 
neutralised with conc. NH4OH and extracted with EtOAc (3 × 40 mL). The organic layers and the white 
precipitate were combined and washed with brine (20 mL). Column chromatography (60% 
EtOAc/Hexane → 80% EtOAc/Hexane) afforded 27 as a white solid (2.53 g, 97% yield). 
Rf = 0.44 (80% EtOAc/Hexane); 1H NMR (400 MHz, DMSO-d6) δ 10.30 (s, 1H, NH), 7.91 (d, J = 8.7 Hz, 
2H, 2 × ArH), 7.71 (d, J = 8.7 Hz, 2H, 2 × ArH), 2.51 (s, 3H, CH3), 2.08 (s, 3H, CH3); 13C NMR (101 MHz, 
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DMSO-d6) δ 196.4 (COCH3), 168.9 (HNCOCH3), 143.6, 131.5, 129.4, 118.1, 26.4, 24.2; FT-IR (ATR mode) 
3291, 3265, 1673 (C=O stretch), 1591, 1528, 1510, 1408, 1369, 1358, 1317, 1263, 1182, 853, 839 cm-1. 
The spectroscopy data collected for this compound compared well to literature data.24,25 
Methyl 4-acetamidobenzoate (28)22 
Methyl 4-aminobenzoate (18, 0.583 g, 3.86 mmol) was added portion-wise, over 30 
minutes, to an acetic anhydride (6 mL) and DCM (10 mL) mixture at 10 °C. The reaction 
mixture was left to stir at r.t. for 1 h. The DCM was removed in vacuo, whereafter the 
orange solution was diluted with H2O (40 mL) and extracted with EtOAc (3 × 30 mL). The 
combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. 
Automated column chromatography (20 – 60% EtOAc/Hexane) gave 28 as a white solid (0.704 g, 94% 
yield). 
Rf = 0.44 (50% EtOAc/Hexane); 1H NMR (300 MHz, DMSO-d6) δ 10.27 (s, 1H, NH), 7.90 (d, J = 8.7 Hz, 
2H, 2 × ArH), 7.71 (d, J = 8.7 Hz, 2H, 2 × ArH), 3.81 (s, 3H, CO2CH3), 2.08 (s, 3H, HNCOCH3); 13C NMR (75 
MHz, DMSO-d6) δ 168.9, 165.8, 143.7, 130.3, 123.7, 118.3, 51.8, 24.2;  
The NMR spectroscopy data collected for this compound compared well to literature data.26 
N-(4-cyano-2-nitrophenyl)acetamide (29)22 
A solution of potassium nitrate (0.663 g, 6.56 mmol, 1.5 equiv) in conc. H2SO4 (4 mL) was 
cooled to −15 °C. N-(4-cyanophenyl)acetamide (26, 0.700 g, 4.37 mmol, 1.0 equiv) was 
added to the mixture in a slow, batch-wise manner, while maintaining the temperature 
below −15 °C. The temperature was kept below −10 °C, while the reaction mixture was 
stirred for 3.5 h. The reaction was quenched with ice water (35 mL) to form a bright 
yellow precipitate. The flask was left overnight at 0 – 4 °C and then the yellow product was collected 
by filtration. The product was purified by automated column chromatography (0-20% EtOAc/Hexane 
→ 20% EtOAc/Hexane → 30% EtOAc/Hexane) to afford 29 as a bright yellow solid (0.615 g, 69% yield).  
Rf = 0.63 (100% DCM); mp = 125 – 127 °C (lit.27 mp 130 – 131 °C in MeOH); 1H NMR (300 MHz, CDCl3) 
δ 10.54 (s, 1H, NH), 9.02 (d, J = 8.9 Hz, 1H, ArH6), 8.55 (d, J = 2.0 Hz, 1H, ArH3), 7.87 (dd, J = 8.9, 2.0 Hz, 
1H, ArH5), 2.34 (s, 3H, CH3); FT-IR (ATR mode) 3341 (N-H stretch), 3139, 3099, 2231 (C≡N stretch), 1712 
(C=O stretch), 1616, 1570, 1538, 1499 (N=O asym stretch), 1441, 1396, 1371, 1345 (N=O sym stretch), 
1263, 1215, 1191, 1142, 858, 762 cm-1. 
The NMR spectroscopic data of this compound compared well to the literature.28 
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General nitration procedure to yield compounds 30 – 31. 
A stirred mixture of 65% HNO3 and the N-(4-substituted phenyl)acetamide were cooled to 0 °C and 
then treated, dropwise, with conc. H2SO4 (1:1 v/v; 65% HNO3/ conc. H2SO4). While maintaining a 
temperature of 0 °C, the bright yellow solution was stirred for 1 h and then quenched with H2O 
(40 mL). The mixture was basified with conc. NH4OH to pH = 8 and extracted with EtOAc (4 × 30 mL). 
The combined organic layer was washed with brine (25 mL), dried over MgSO4, filtered and 
concentrated in vacuo. The pure product was isolated by automated column chromatography (0 – 30% 
EtOAc/Hexane → 30% EtOAc/Hexane). 
N-(4-acetyl-2-nitrophenyl)acetamide (30) 
Prepared according to the general procedure with N-(4-acetylphenyl)acetamide (27, 
0.150 g, 0.847 mmol), 65% HNO3 (2 mL) and conc. H2SO4 (2 mL). 30 was obtained as a 
bright yellow solid (0.130 g, 69% yield). 
Rf = 0.29 (30% EtOAc/Hexane); 1H NMR (400 MHz, CDCl3) δ 10.54 (br.s, 1H, NH), 8.93 (d, 
J = 8.9 Hz, 1H, ArH6), 8.79 (d, J = 2.1 Hz, 1H, ArH3), 8.20 (dd, J = 8.9, 2.1 Hz, 1H, ArH5), 2.63 (s, 3H, CH3), 
2.33 (s, 3H, CH3); 13C NMR (101 MHz, CDCl3) δ 194.8 (COCH3), 169.2 (HNCOCH3), 138.5, 135.7, 135.3, 
131.8, 126.4, 121.9, 26.5, 25.9; FT-IR (ATR mode) 3345 (N-H stretch), 1716 (C=O stretch), 1682 (C=O 
stretch), 1610, 1569, 1539, 1502 (N=O asym stretch), 1448, 1396, 1360, 1340 (N=O sym stretch), 1305, 
1259, 1233, 1219, 1140, 853 cm-1. 
The NMR spectroscopy data collected for this compound compared well to literature data.29 
Methyl 4-acetamido-3-nitrobenzoate (31) 
Prepared according to the general procedure with methyl 4-acetamidobenzoate (28, 
0.681 g, 3.52 mmol), 65% HNO3 (8 mL) and conc. H2SO4 (8 mL). 31 was obtained as a 
bright yellow solid (0.758 g, 90% yield). 
Rf = 0.47 (30% EtOAc/Hexane); 1H NMR (300 MHz, DMSO-d6) δ 10.55 (s, 1H, NH), 8.38 (d, 
J = 1.9 Hz, 1H, ArH2), 8.20 (dd, J = 8.6, 1.9 Hz, 1H, ArH6), 7.86 (d, J = 8.6 Hz, 1H, ArH5), 3.88 (s, 3H, 
CO2CH3), 2.12 (s, 3H, HNCOCH3); 13C NMR (75 MHz, DMSO-d6) δ 168.8, 164.3, 141.1, 135.4, 134.1, 
125.9, 125.4, 124.6, 52.6 (COOCH3), 23.7 (HNCOCH3); FT-IR (ATR mode) 3351 (N-H stretch), 1716 (C=O 
stretch), 1617, 1579, 1505 (N=O asym stretch), 1439, 1380, 1340 (N=O sym stretch), 1290, 1257, 1211, 
1146, 1128, 1073, 1003, 984, 861, 751 cm-1. 
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General deacetylation procedure (32 – 34).27 
The acetamide and 1 M H2SO4 were heated under reflux for 2 h. The reaction mixture was left to cool, 
whereafter it was neutralised with sat. aq. NaHCO3. The yellow product was extracted from the 
mixture with EtOAc (4 × 30 mL). The combined organic layers were dried over MgSO4, filtered and 
concentrated under reduced pressure. Column chromatography was used to isolate the pure 
compound. 
4-Amino-3-nitrobenzonitrile (32) 
Prepared according to the general procedure with N-(4-cyano-2-nitrophenyl)acetamide 
(29, 0.746 g, 3.64 mmol) and 1 M H2SO4 (45 mL). Column chromatography with 100% 
DCM afforded 32 as a bright yellow powder (0.567 g, 95% yield).  
Rf = 0.54 (100% DCM); 1H NMR (300 MHz, CDCl3) δ 8.48 (d, J = 1.9 Hz, 1H, ArH2), 7.54 (dd, J = 8.8, 1.9 
Hz, 1H, ArH6), 6.89 (d, J = 8.8 Hz, 1H, ArH5), 6.54 (br.s, 2H, NH2); 13C NMR (75 MHz, CDCl3) δ 147.1, 
137.3, 132.0, 119.8, 117.8, 100.1, one quaternary carbon missing; FT-IR (ATR mode) 3494, 3468, 3381, 
3338, 2227 (C≡N stretch), 1630, 1597, 1555, 1519 (N=O asym stretch), 1482, 1423, 1355 (N=O sym 
stretch), 1286, 1271, 1203, 1174, 1086, 918, 829, 822 cm-1. 
The spectroscopy data collected for this compound compared well to literature data.27,28,30 
1-(4-Amino-3-nitrophenyl)ethanone (33)  
Prepared according to the general procedure with N-(4-acetyl-2-nitrophenyl)acetamide 
(30, 0.124 g, 0.558 mmol) and 1 M H2SO4 (9 mL). Column chromatography with 5% 
EtOAc/DCM afforded 33 as a dark yellow solid (0.097 g, 96% yield). 
Rf = 0.56 (5% EtOAc/DCM); 1H NMR (400 MHz, CDCl3) δ 8.74 (d, J = 2.0 Hz, 1H, ArH2), 8.00 (dd, J = 8.8, 
2.0 Hz, 1H, ArH6), 6.86 (d, J = 8.8 Hz, 1H, ArH5), 6.52 (br.s, 2H, NH2), 2.57 (s, 3H, CH3); 13C NMR (101 
MHz, CDCl3) δ 195.1 (COCH3), 147.7, 134.7, 131.1, 128.5, 126.9, 119.0, 26.2 (COCH3); FT-IR (ATR mode) 
3444 (N-H stretch), 3325 (N-H stretch), 1665, 1626, 1555, 1475, 1358, 1346, 1297, 1248, 1156, 1091, 
1071, 1022, 952, 900, 831 cm-1; 
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Methyl 4-amino-3-nitrobenzoate (34) 
Prepared according to the general procedure with methyl 4-acetamido-3-nitrobenzoate 
(31, 0.729 g, 3.06 mmol) and 1 M H2SO4 (24 mL). Automated column chromatography 
with 30% EtOAc/Hexane afforded 34 as a yellow solid (0.491 g, 82% yield). 
Rf = 0.40 (30% EtOAc/Hexane); 1H NMR (300 MHz, DMSO-d6) δ 8.54 (d, J = 1.9 Hz, 1H, ArH2), 7.98 (br.s, 
2H, NH2), 7.85 (dd, J = 8.9, 1.9 Hz, 1H, ArH6), 7.06 (d, J = 8.9 Hz, 1H, ArH5), 3.81 (s, 3H, OCH3); 13C NMR 
(75 MHz, DMSO-d6) δ 164.9 (COOCH3), 148.9, 134.8, 129.6, 128.0, 119.4, 116.1, 51.9 (OCH3). 
The NMR spectroscopy data collected for this compound compared well to literature data.32 
General hydrogenation procedure to form the diamines 35 – 37.33 
The 4-amino-3-nitro compound was dissolved in EtOAc and MeOH. The solution was treated with 10% 
palladium on carbon (10% w/w) and hydrogenated with a H2 balloon at r.t. The reaction mixture was 
monitored by TLC and by a complete colour change from bright yellow to a transparent orange or red. 
When judged to be complete, the reaction mixture was filtered through a bed of celite and 
concentrated in vacuo. The product was purified by column chromatography. 
3,4-Diaminobenzonitrile (35) 
Prepared according to the general procedure with 4-amino-3-nitrobenzonitrile (32, 0.150 
g, 0.920 mmol) dissolved in a 4:1 mixture of EtOAc (6.4 mL) and MeOH (1.6 mL). The 
product was purified by column chromatography (50% EtOAc/Hexane) to give 35 as an 
orange-cream coloured solid (0.121 g, 99% yield). 
Rf = 0.12 (100% DCM); 1H NMR (400 MHz, CDCl3) δ 7.04 (dd, J = 8.1, 1.8 Hz, 1H, ArH6), 6.94 (d, J = 1.8 
Hz, 1H, ArH2), 6.68 (d, J = 8.1 Hz, 1H, ArH5), 3.81 (br.s, 2H, NH2), 3.39 (br.s, 2H, NH2); 13C NMR (101 
MHz, CDCl3) δ 140.1, 134.0, 125.8, 120.1, 119.9, 115.7, 102.0; FT-IR (ATR mode) 3436, 3360, 3186, 
2211 (C≡N stretch), 1625, 1593, 1578, 1509, 1440, 1307, 1270, 1149, 863, 810 cm-1. 
The spectroscopy data collected for this compound compared well to literature data.34 
1-(3,4-Diaminophenyl)ethanone (36) 
Prepared according to the general procedure with 1-(4-amino-3-nitrophenyl)ethanone 
(33, 0.076 g, 0.42 mmol) dissolved in a 2:1 mixture of EtOAc (4 mL) and MeOH (2 mL). 
The product was purified by column chromatography (70% EtOAc/DCM) to yield 36 as 
an orange solid (0.057 g, 90% yield). 
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Rf = 0.42 (70% EtOAc/DCM); 1H NMR (300 MHz, DMSO-d6) δ 7.13 – 7.10 (m, 2H, ArH2,6), 6.50 (d, J = 
8.7 Hz, 1H, ArH5), 5.36 (s, 2H, NH2), 4.63 (s, 2H, NH2), 2.35 (s, 3H, CH3); 13C NMR (75 MHz, DMSO-d6) 
δ 195.4 (COCH3), 141.0, 133.7, 126.2, 120.4, 113.6, 112.3, 25.9 (CH3); FT-IR (ATR mode) 3437 (N-H 
stretch), 3395 (N-H stretch), 3360 (N-H stretch), 3286 (N-H stretch), 1665, 1637, 1621, 1567, 1432, 
1363, 1324, 1291, 1228, 1150, 1054, 965, 930, 878, 832 cm-1; HRMS (ESI) m/z calcd for C8H11N2O, 
[M+H]+: 151.0871, found 151.0864. 
Methyl 3,4-diaminobenzoate (37) 
Prepared according to the general procedure with methyl 4-amino-3-nitrobenzoate (34, 
0.485 g, 2.47 mmol) dissolved in a 2:1 mixture of EtOAc (24 mL) and MeOH (12 mL). The 
product was purified by column chromatography (50% EtOAc/Hexane) to yield 37 as a 
red-orange solid (0.374 g, 91% yield). 
Rf = 0.35 (50% EtOAc/Hexane); 1H NMR (400 MHz, DMSO-d6) δ 7.15 (d, J = 1.8 Hz, 1H, ArH2), 7.09 (dd, 
J = 8.1, 1.8 Hz, 1H, ArH6), 6.50 (d, J = 8.1 Hz, 1H, ArH5), 5.27 (s, 2H, NH2), 4.65 (s, 2H, NH2), 3.71 (s, 3H, 
OCH3); 13C NMR (101 MHz, DMSO-d6) δ 166.8 (CO2CH3), 140.5, 133.8, 120.2, 117.2, 114.9, 112.6, 51.0 
(OCH3). 
The NMR spectroscopy data collected for this compound compared well to literature data.35  
General cyclisation procedure to form 2-aminobenzimidazoles 39 – 42.36 
Cyanogen bromide (1.3 equiv) in CH3CN was added to a solution of diamine (1.0 equiv) in H2O/MeOH 
(1:1). The reaction mixture was stirred at r.t. for 18 h. Conc. NH4OH was used to basify the reaction 
mixture to pH = 8, whereafter MeOH and CH3CH were removed under reduced pressure. H2O was 
added to the residual mixture and the mixture was extracted with EtOAc. The combined organic layers 
were dried over MgSO4, filtered and concentrated under reduced pressure. Column chromatography 
afforded a pure product. 
2-Amino-1H-benzo[d]imidazole-6-carbonitrile (39) 
Prepared according to the general procedure, with the following amounts: 
Cyanogen bromide (0.665 g, 6.28 mmol), CH3CN (0.8 mL), 3,4-
diaminobenzonitrile (35, 0.643 g, 4.83 mmol), H2O (8.5 mL) and MeOH (8.5 mL). 
H2O (10 mL) and EtOAc (3 × 25 mL) were used in the work-up procedure. Column chromatography 
(2% MeOH/EtOAc → 3% MeOH/EtOAc) afforded 39 as a cream-coloured solid (0.682 g, 89% yield). 
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Rf = 0.21 (100% EtOAc); mp = 215 – 218 °C (lit.36 mp 213 – 215 °C); 1H NMR (300 MHz, DMSO-d6) 
δ 11.14 (br.s, 1H, NH), 7.46 (d, J = 1.6 Hz, 1H, ArH7), 7.26 (dd, J = 8.1, 1.6 Hz, 1H, ArH5), 7.20 (d, J = 
8.1 Hz, 1H, ArH4), 6.65 (s, 2H, NH2); 13C NMR (101 MHz, DMSO-d6) δ 157.7 (ArC2), 144.0 (weak br.s), 
138.0 (weak br.s), 123.9, 120.9, 114.4 (weak br.s), 112.4 (weak br.s), 100.0; FT-IR (ATR mode) 3421 
(N-H stretch), 3324 (N-H stretch), 2213 (C≡N stretch), 1643, 1618, 1548, 1469, 1441, 1284, 823 cm-1; 
HRMS (ESI) m/z calcd for C8H7N4, [M+H]+: 159.0671, found 159.0666. 
The 1H NMR spectroscopic data correlated with the literature data,36 however small chemical shift 
differences were seen since the literature values were internally referenced to tetramethylsilane. 
1-(2-Amino-1H-benzo[d]imidazol-6-yl)ethanone (40) 
Prepared according to the general procedure, with the following amounts: 
Cyanogen bromide (0.347 g, 3.28 mmol), CH3CN (0.7 mL), 1-(3,4-
diaminophenyl)ethanone (36, 0.379 g, 2.52 mmol), H2O (5 mL) and MeOH 
(5 mL). H2O (60 mL) and EtOAc (6 × 40 mL) were used in the work-up procedure. Column 
chromatography (10% MeOH/DCM) afforded 40 as a yellow solid (0.383 g, 87% yield). 
Rf = 0.28 (10% MeOH/DCM); mp = > 198 °C decomp, mp 205 – 207 °C; 1H NMR (400 MHz, DMSO-d6) 
δ 7.71 (d, J = 1.6 Hz, 1H, ArH7), 7.60 (dd, J = 8.3, 1.6 Hz, 1H, ArH5), 7.14 (d, J = 8.3 Hz, 1H, ArH4), 6.61 (s, 
2H, NH2), 2.52 (s, 3H, CH3), NH signal not visible due to tautomerism; 13C NMR (101 MHz, DMSO-d6) 
δ 196.8 (COCH3), 157.6 (ArC2), 145.1, 137.1, 128.5, 121.4, 111.6, 110.7, 26.5 (CH3); FT-IR (ATR mode) 
3328 (N-H stretch), 3139 (N-H stretch), 1649, 1621, 1558, 1453, 1358, 1280, 1233, 1194, 1099, 1020, 
812 cm-1; HRMS (ESI) m/z calcd for C9H10N3O, [M+H]+: 176.0824, found 176.0816. 
6-Nitro-1H-benzo[d]imidazol-2-amine (42) 
Prepared according to the general procedure, with the following amounts: 
Cyanogen bromide (0.225 g, 2.12 mmol, 1.6 equiv), CH3CN (0.4 mL), 
4-nitrobenzene-1,2-diamine (38, 0.200 g, 1.31 mmol), H2O (3.5 mL) and MeOH 
(3.5 mL). The reaction mixture was stirred one additional day. H2O (30 mL) and EtOAc (4 × 30 mL) were 
used in the work-up procedure. Automated column chromatography (EtOAc → 5% MeOH/EtOAc) 
afforded 42 as a bright yellow solid (0.24 g, quant. yield). 
Rf = 0.12 (100% EtOAc); 1H NMR (300 MHz, DMSO-d6) δ 11.25 (br.s, 1H, NH), 7.95 (d, J = 2.3 Hz, 1H, 
ArH7), 7.87 (dd, J = 8.7, 2.3 Hz, 1H, ArH5), 7.18 (d, J = 8.7 Hz, 1H, ArH4), 6.93 (br.s, 2H, NH2); 13C NMR 
(75 MHz, DMSO-d6) 159.1 (ArC2), 150.3 (weak br.s), 139.5, 133.9 (weak br.s), 116.8, 112.2 (weak br.s), 
105.4 (weak br.s); HRMS (ESI) m/z calcd for C7H7N4O2, [M+H]+: 179.0569, found 179.0569. The carbon 
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signals were barely visible and were seen as very weak and broad signals, even after running the 
13C NMR spectroscopic analysis overnight.  
The 1H NMR spectroscopy data collected for this compound fitted the literature perfectly. The 13C NMR 
data corresponded well to the literature, but small deviations were seen due to the broadness of some 
signals.37 
Methyl 2-amino-1H-benzo[d]imidazole-6-carboxylate (41) 
Prepared according to the general procedure, with the following amounts: 
Cyanogen bromide (0.307 g, 2.90 mmol), CH3CN (0.7 mL), methyl 3,4-
diaminobenzoate (37, 0.370 g, 2.23 mmol), H2O (6 mL) and MeOH (6 mL). H2O 
(15 mL) and EtOAc (6 × 30 mL) were used in the work-up procedure. Column 
chromatography (10% MeOH/DCM) afforded 41 as an orange-cream coloured solid (0.400 g, 94% 
yield). 
Rf = 0.32 (10% MeOH/DCM); mp = 184 – 186 °C; 1H NMR (600 MHz, DMSO-d6) δ 7.71 (d, J = 1.6 Hz, 1H, 
ArH7), 7.58 (dd, J = 8.2, 1.6 Hz, 1H, ArH5), 7.14 (d, J = 8.2 Hz, 1H, ArH4), 6.55 (s, 2H, NH2), 3.80 (s, 3H, 
OCH3), NH signal not visible due to tautomerism; 13C NMR (151 MHz, DMSO-d6) δ 167.2 (CO2CH3), 
157.4 (ArC2), 144.9 (weak br.s, ArC3a), 137.2 (weak br.s, ArC7a*), 121.6 (ArC5H), 119.8 (ArC6*), 111.7 
(ArC4+7H), 51.5 (OCH3); FT-IR (ATR mode) 3101 (N-H stretch), 1667 (C=O stretch), 1624, 1566, 1433, 
1293, 1235, 1207, 1119, 1092, 771, 744 cm-1; HRMS (ESI) m/z calcd for C9H10N3O2, [M+H]+: 192.0773, 
found 192.0779. 
1H,13C gHSQC NMR (600/600 MHz, DMSO-d6) δ 1H/ δ 13C 7.71/111.7 (ArH7/ArC7H), 7.58/121.6 (ArH5/ 
ArC5H), 7.14/111.7 (ArH4/ArC4H), 3.80/51.5 (OCH3/OCH3); 1H,13C gHMBC NMR (600/600 MHz, 
DMSO-d6) δ 1H/ δ 13C 7.71/ 167.2, 144.9, 121.6 (ArH7/ CO2CH3, ArC3a, ArC5H), 7.58/ 167.2, 144.9, 111.7 
(ArH5/CO2CH3, ArC3a, ArC7H), 7.14/ 137.2, 119.8 (ArH4/ ArC7a+6), 3.80/167.2 (OCH3/ CO2CH3). 
*ArC7a and ArC6 may be reversed. The signals were assigned based on the assumption that ArC7a and 
ArC3a have a similar chemical environment. 
The 1H NMR spectroscopy data collected for this compound corresponded well to the available 
literature.38 
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Table 9.1: The 2D NMR spectra assignments (gHSQC and gHMBC) for methyl 2-amino-1H-
benzo[d]imidazole-6-carboxylate (41) 
13C (δ ppm) gHSQC (δ ppm) gHMBC (δ ppm) Carbon assignment 
51.5 3.80  OCH3 
111.7 7.14, 7.71 7.58 ArC4+7H 
119.8 – 7.14 ArC7a/6 
121.6 7.58 (dd) 7.71 ArC5H 
137.2 – 7.14 ArC7a/6 
144.9 – 7.71, 7.58 ArC3a 
157.4 – – ArC2 
167.2 – 7.71, 7.58, 3.80 CO2CH3 
 
General procedure for the synthesis of N-(4-methoxybenzyl) ureas (6, 59 – 61) from 
2-aminobenzimidazoles.19 
To a solution of the amine (1.0 equiv) and N-(4-methoxybenzyl)-1H-imidazole-1-carboxamide (46, 1.3 
equiv) in DMF (3.5 – 9 mL) were added 60% NaH in mineral oil (1.4 equiv) in portions over 20 min. The 
reaction mixture was left to stir for 20 h at r.t. Thereafter, another portion of 60% NaH in mineral oil 
(0.4 equiv) was added to the reaction mixture to ensure that all N-(4-methoxybenzyl)-1H-imidazole-
1-carboxamide react and the reaction mixture was left to stir for 1 h. After the addition of EtOAc (35 
– 100 mL), the reaction mixture was washed with a sat. aq. NH4Cl (4 × 30 mL). The organic layer was 
then washed with 1 M HCl (30 mL) to remove the remaining starting material and was kept aside. The 
combined aqueous layers were extracted with EtOAc (2 × 30 mL) and the resultant organic portion 
(60 mL) was washed with sat. aq. NH4Cl (2 × 30 mL). All of the organic layers were combined and dried 
over MgSO4, filtered and concentrated in vacuo. The crude product was purified by column 
chromatography to yield ureas 6, 59 – 61. 
1-(6-Cyano-1H-benzo[d]imidazol-2-yl)-3-(4-methoxybenzyl)urea (6) 
Prepared according to the general procedure, with the following 
amounts: 2-Amino-1H-benzo[d]imidazole-6-carbonitrile (39, 0.060 
g, 0.38 mmol), N-(4-methoxybenzyl)-1H-imidazole-1-carboxamide 
(46, 0.13 g, 0.56 mmol, 1.5 equiv), 60% NaH in mineral oil (0.022 g 
+ 0.020 g, 1.1 mmol, 2.9 equiv). The product was purified by column chromatography (5% MeOH/15% 
EtOAc/DCM) to yield 6 as a white solid (0.060 g, 49% yield). 
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Rf = 0.30 (5% MeOH/15% EtOAc/DCM); mp = > 230 °C decomp; 1H NMR (400 MHz, DMSO-d6) δ 12.09 
(br.s, 1H, NH), 10.21 (br.s, 1H, NH), 7.76 (s, 1H, ArH7), 7.48 (br.t, 1H, NH), 7.44 – 7.41 (m, 2H, 2 × ArH), 
7.26 (d, J = 8.7 Hz, 2H, 2 × ArH), 6.91 (d, J = 8.7 Hz, 2H, 2 × ArH), 4.32 (d, J = 5.8 Hz, 2H, CH2), 3.73 (s, 
3H, OCH3); 13C NMR (101 MHz, DMSO-d6) δ 158.3, 153.9, 150.5, 131.3, 128.6, 124.6, 120.4, 113.8, 55.1, 
42.4; five carbon signals were not visible in the spectrum; FT-IR (ATR mode) 3398 (N-H stretch), 3309 
(N-H stretch), 2219 (C≡N stretch), 1668, 1649, 1588, 1506, 1463, 1249, 1223, 1174, 1027, 827, 812, 
741 cm-1; HRMS (ESI) m/z calcd for C17H16N5O2, [M+H]+: 322.1304, found 322.1309; UPLC: Purity 99%, 
r.t = 5.77 min, acetonitrile/H2O (0.1% formic acid) 2/98. 
1-(6-Acetyl-1H-benzo[d]imidazol-2-yl)-3-(4-methoxybenzyl)urea (59) 
Prepared according to the general procedure, with the following 
amounts: 1-(2-Amino-1H-benzo[d]imidazol-6-yl)ethanone (40, 
0.383 g, 2.19 mmol), N-(4-methoxybenzyl)-1H-imidazole-1-
carboxamide (46, 0.650 g, 2.81 mmol), 60% NaH in mineral oil 
(0.123 g + 0.0350 g, 3.95 mmol). The product was purified by 
column chromatography (3% MeOH/15% EtOAc/DCM) to yield 59 as a yellow solid (0.554 g, 75% 
yield). 
Rf = 0.25 (3% MeOH/15% EtOAc/DCM); mp = > 200 °C decomp; 1H NMR (300 MHz, DMSO-d6) δ 11.91 
(br.s, 1H, NH), 10.18 (br.s, 1H, NH), 8.00 (s, 1H, ArH7), 7.72 (dd, J = 8.3, 1.5 Hz, 1H, ArH5), 7.55 (br.t, 1H, 
NH), 7.42 (d, J = 8.3 Hz, 1H, ArH4), 7.27 (d, J = 8.6 Hz, 2H, 2 × ArH), 6.91 (d, J = 8.6 Hz, 2H, 2 × ArH), 4.34 
(d, J = 5.8 Hz, 2H, CH2), 3.73 (s, 3H, OCH3), 2.56 (s, 3H, COCH3); 13C NMR (75 MHz, DMSO-d6) δ 197.1 
(COCH3), 158.4, 154.1, 150.4, 131.5, 130.1, 128.6, 121.8, 113.8, 55.1, 42.4, 26.7 (COCH3); four carbon 
signals were not visible in the spectrum; FT-IR (ATR mode) 3305 (N-H stretch), 1666, 1651, 1579, 1501, 
1461, 1304, 1244, 1180, 1110, 818, 806, 743 cm-1; HRMS (ESI) m/z calcd for C18H19N4O3, [M+H]+: 
339.1457, found 339.1443; UPLC: Purity 99%, r.t = 4.43 min, acetonitrile/H2O (0.1% formic acid) 5/95. 
Methyl 2-[3-(4-methoxybenzyl)ureido]-1H-benzo[d]imidazole-6-carboxylate (60) 
Prepared according to the general procedure, with the following 
amounts: Methyl 2-amino-1H-benzo[d]imidazole-6-carboxylate 
(41, 0.400 g, 2.09 mmol), N-(4-methoxybenzyl)-1H-imidazole-1-
carboxamide (46, 0.629 g, 2.72 mmol), 60% NaH in mineral oil 
(0.117 g + 0.033 g, 3.75 mmol). The product was purified by 
column chromatography (2% MeOH/15% EtOAc/DCM) to afford 60 as a white solid (0.450 g, 61% 
yield). 
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Rf = 0.18 (3% MeOH/15% EtOAc/DCM); mp = > 260 °C decomp; 1H NMR (300 MHz, DMSO-d6) δ 11.94 
(br.s, 1H, NH), 10.17 (br.s, 1H, NH), 8.00 (br.s, 1H, ArH7), 7.70 (dd, J = 8.3, 1.6 Hz, 1H, ArH5), 7.50 (br.t, 
1H, NH), 7.41 (d, J = 8.3 Hz, 1H, ArH4), 7.27 (d, J = 8.6 Hz, 2H, 2 × ArH), 6.91 (d, J = 8.6 Hz, 2H, 2 × ArH), 
4.33 (d, J = 5.8 Hz, 2H, CH2), 3.83 (s, 3H, CO2CH3), 3.73 (s, 3H, PhOCH3); 13C NMR (75 MHz, DMSO-d6) 
δ 166.9 (CO2CH3), 158.3, 154.0, 150.2, 131.4, 128.6, 122.3, 113.8, 55.1, 51.8 (CO2CH3), 42.4; five carbon 
signals were not visible in the spectrum; FT-IR (ATR mode) 3374 (N-H stretch), 3325 (N-H stretch), 
1710 (C=O stretch), 1668, 1653, 1598, 1581, 1501, 1466, 1300, 1246, 1225, 1197, 1180, 1115, 1036, 
817, 769, 742 cm-1; HRMS (ESI) m/z calcd for C18H19N4O4, [M+H]+: 355.1406, found 355.1406. 
1-(4-Methoxybenzyl)-3-(6-nitro-1H-benzo[d]imidazol-2-yl)urea (61) 
Prepared according to the general procedure, with the following 
amounts: 6-Nitro-1H-benzo[d]imidazol-2-amine (42, 0.400 g, 2.25 
mmol), N-(4-methoxybenzyl)-1H-imidazole-1-carboxamide (46, 
0.670 g, 2.90 mmol), 60% NaH in mineral oil (0.126 g + 0.036 g, 
4.05 mmol). The product was purified by column chromatography (2.5% MeOH/25% EtOAc/DCM) to 
yield 61 as a yellow solid (0.438 g, 57% yield). 
Rf = 0.22 (2.5% MeOH/25% EtOAc/DCM); mp = > 280 °C decomp; 1H NMR (300 MHz, DMSO-d6) δ 12.28 
(br.s, 1H, NH), 10.37 (br.s, 1H, NH), 8.25 (br.s, 1H, ArH), 7.99 (dd, J = 8.8, 2.3 Hz, 1H, ArH5), 7.49 (br.s, 
1H, ArH), 7.39 (br.t, 1H, NH), 7.27 (d, J = 8.6 Hz, 2H, 2 × ArH), 6.90 (d, J = 8.6 Hz, 2H, 2 × ArH), 4.33 (d, 
J = 5.8 Hz, 2H, CH2), 3.73 (s, 3H, OCH3); 13C NMR (75 MHz, DMSO-d6) δ 158.4, 153.8, 131.3, 128.7, 
113.8, 55.1, 42.4; seven carbon signals were not visible in the spectrum; FT-IR (ATR mode) 3344 (N-H 
stretch), 3300 (N-H stretch), 1673, 1658, 1588, 1493, 1464, 1327 (N=O sym stretch), 1293, 1242, 1223, 
1175, 1056, 1027, 817, 740 cm-1; HRMS (ESI) m/z calcd for C16H16N5O4, [M+H]+: 342.1202, found 
342.1189. 
Very weak, broad signals were present on the baseline of the 13C NMR spectra, which could represent 
some quaternary carbons. Due to the low S/N ratio, these signals could not be selected 









Trimethylphenylammonium tribromide (0.098 g, 0.26 mmol, 1.1 
equiv) was added to a stirred suspension of 1-(6-
acetylbenzo[d]thiazol-2-yl)-3-(4-methoxybenzyl)urea (56, 0.084 
g, 0.24, 1.0 equiv) in THF (4 mL), over 20 minutes. The reaction 
mixture was stirred at 30 °C for 64 h, whereafter the solvent was 
removed in vacuo, at 30 °C. The crude product was resuspended into EtOAc (60 mL) and washed with 
sat. aq. NaHCO3 (20 mL) and brine (20 mL). The organic layer was concentrated in vacuo. Column 
chromatography (20% EtOAc/DCM) was used to obtain the pure product 7 as an off-white solid 
(0.036 g, 35% yield). 
Rf = 0.41 (20% EtOAc/DCM); mp = > 182 °C decomp; 1H NMR (300 MHz, DMSO-d6) δ 11.08 (br.s, 1H, 
NH), 8.62 (d, J = 1.7 Hz, 1H, ArH7), 7.99 (dd, J = 8.5, 1.7 Hz, 1H, ArH5), 7.70 (d, J = 8.5 Hz, 1H, ArH4), 7.26 
(d, J = 8.7 Hz, 2H, 2 × ArH), 7.21 (br.t, 1H, NH), 6.91 (d, J = 8.7 Hz, 2H, 2 × ArH), 4.93 (s, 2H, CH2Br), 4.31 
(d, J = 5.8 Hz, 2H, NHCH2), 3.73 (s, 3H, OCH3); 13C NMR (75 MHz, DMSO-d6) δ 190.5 (COCH2Br), 163.7, 
158.4, 153.7, 153.2, 131.8, 131.0, 128.7, 128.4, 126.7, 123.3, 119.4, 113.8, 55.1, 42.5, 34.0 (CH2Br); FT-
IR (ATR mode) 3282 (N-H stretch), 1678 (C=O stretch), 1667 (C=O stretch), 1551, 1531, 1513, 1274, 
1251, 1236 cm-1; HRMS (ESI) m/z calcd for C18H17N3O3S79Br, [M+H]+: 434.0174, found 434.0178, m/z 
calcd for C18H17N3O3S81Br, [M+H]+: 436.0174, found 436.0162; UPLC: Purity >95%, r.t = 6.77 min, 
acetonitrile/H2O (0.1% formic acid) 5/95. 
1-[6-(2-Bromoacetyl)-1H-benzo[d]imidazol-2-yl]-3-(4-methoxybenzyl)urea (8)40 
Trimethylsilyl trifluoromethanesulfonate (0.28 mL, 1.5 mmol, 3.9 
equiv) and N,N-diisopropylethylamine (0.35 mL, 2.0 mmol, 5,2 
equiv) were added to a suspension of 1-(6-acetyl-1H-
benzo[d]imidazol-2-yl)-3-(4-methoxybenzyl)urea (59, 0.130 g, 
0.384 mmol, 1.0 equiv) in DCM (4 mL) at 0 °C. The reaction 
mixture was stirred at 0 °C for 1.5 h, whereafter it was stirred at r.t. for 40 min and then at 30 °C for 
40 min. The reaction was monitored by TLC and was judged to be incomplete. The solution was treated 
with additional equivalents of trimethylsilyl trifluoromethanesulfonate (0.28 mL, 1.5 mmol, 3.9 equiv) 
and N,N-diisopropylethylamine (0.35 mL, 2.0 mmol, 5,2 equiv) at 0 °C and was left to stir at r.t. for 
20 h.‡ The orange solution was diluted with DCM (35 mL) and washed with cold sat. aq. NaHCO3 
                                                          
‡ After increasing the equivalents and stirring overnight, the reaction was still incomplete, as judged by the 
presence of remaining starting material on the TLC plate. However a significant amount of silyl enol ether was 
present in the reaction mixture and the crude mixture could be utilised further to perform the bromination step. 
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(25 mL). The organic layer was dried over MgSO4, filtered and concentrated in vacuo to yield the crude 
silyl enol ether intermediate; Rf = 0.74 (100% EtOAc). The crude intermediate was dissolved in THF 
(4 mL) and treated with N-bromosuccinimide (0.051 g, 0.29 mmol, 0.76 equiv) and NaHCO3 powder 
(0.048 g, 0.57 mmol, 1.5 equiv) at −78 °C. The reaction was stirred at −78°C for 1.5 h, after which TLC 
indicated that the majority of silyl enol ether had been consumed. The solution was partitioned 
between EtOAc (25 mL) and cold sat. aq. NaHCO3 (25 mL). The organic layer was dried over MgSO4, 
filtered and concentrated in vacuo. The product was purified by column chromatography (50 – 70% 
EtOAc/DCM) to yield 8 as a light yellow solid (0.077 g, 48% yield). 
Rf = 0.50 (100% EtOAc); mp = > 200 °C decomp; 1H NMR (400 MHz, DMSO-d6) δ 8.05 (s, 1H, ArH7), 7.77 
(dd, J = 8.4, 1.1 Hz, 1H, ArH5), 7.54 (br.t, 1H, NH), 7.45 (d, J = 8.4 Hz, 1H, ArH4), 7.27 (d, J = 8.6 Hz, 2H, 
2 × ArH), 6.91 (d, J = 8.6 Hz, 2H, 2 × ArH), 4.88 (s, 2H, BrCH2), 4.34 (d, J = 5.7 Hz, 2H, HNCH2), 3.73 (s, 
3H, OCH3), two NH signals not visible due to tautomerism; 13C NMR (101 MHz, DMSO-d6) δ 191.0 
(COCH2Br), 158.4, 153.8, 150.3, 131.4, 128.6, 127.1, 122.5, 113.8, 55.1, 42.4, 34.0 (Br-CH2), four carbon 
signals were not visible in the spectrum; FT-IR (ATR mode) 3356 (N-H stretch), 3307 (N-H stretch), 
1647, 1571, 1504, 1463, 1300, 1246, 1224, 1176, 1097, 1037, 812, 743 cm-1; HRMS (ESI) m/z calcd for 
C18H18N4O379Br, [M+H]+: 417.0562, found 417.0565, m/z calcd for C18H18N4O381Br, [M+H]+: 419.0562, 
found 419.0545; UPLC: Purity 98%, r.t = 3.81 min, acetonitrile/H2O (0.1% formic acid) 5/95. 
General reduction procedure to synthesise the aminobenzazole ureas 64 – 65.41,42 
The nitrobenzazole urea was dissolved in DMF (5 mL), whereafter MeOH (15 mL) and 10% palladium 
on carbon (10% w/w) were added to the stirred solution. The mixture was hydrogenated at 60 °C for 
4.5 h, by employing a H2 balloon. The mixture was filtered through a bed consisting of celite and cotton 
wool and concentrated under reduced pressure. The crude product was diluted with EtOAc (80 mL) 
and washed with H2O (4 × 20 mL). The organic layer was dried over MgSO4, filtered and concentrated 
in vacuo. The pure product was isolated by column chromatography. 
1-(6-Aminobenzo[d]thiazol-2-yl)-3-(4-methoxybenzyl)urea (64) 
Prepared according to the general procedure with 1-(4-
methoxybenzyl)-3-(6-nitrobenzo[d]thiazol-2-yl)urea (58, 0.150 g, 
0.419 mmol). Column chromatography (5% MeOH/15% 
EtOAc/DCM) yielded a light yellow solid (64, 0.055 g, 40% yield). 
Rf = 0.34 (5% MeOH/15% EtOAc/DCM); mp = 190 – 191 °C; 1H NMR (300 MHz, DMSO-d6) δ 10.36 (s, 
1H, NH), 7.29 (d, J = 8.5 Hz, 1H, ArH4), 7.24 (d, J = 8.5 Hz, 2H, 2 × ArH), 7.11 (br.t, 1H, NH), 6.95 (d, J = 
1.9 Hz, 1H, ArH7), 6.90 (d, J = 8.5 Hz, 2H, 2 × ArH), 6.64 (dd, J = 8.5, 1.9 Hz, 1H, ArH5), 5.02 (s, 2H, NH2), 
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4.28 (d, J = 5.7 Hz, 2H, CH2), 3.73 (s, 3H, OCH3); 13C NMR (75 MHz, DMSO-d6) δ 158.3, 155.2, 153.9, 
145.0, 140.2, 132.6, 131.4, 128.6, 120.0, 113.9, 113.8, 104.4, 55.1, 42.4; FT-IR (ATR mode) 3319 (N-H 
stretch), 1666 (C=O stretch), 1579, 1562, 1512, 1456, 1269, 1228, 1177, 1029, 823, 803, 718 cm-1; 
HRMS (ESI) m/z calcd for C16H17N4O2S, [M+H]+: 329.1072, found 329.1065. 
1-(6-Amino-1H-benzo[d]imidazol-2-yl)-3-(4-methoxybenzyl)urea (65) 
Prepared according to the general procedure with 
1-(4-methoxybenzyl)-3-(6-nitro-1H-benzo[d]imidazol-2-yl)urea 
(61, 0.120 g, 0.352 mmol). Column chromatography (5 – 7 % 
MeOH/DCM) yielded a pink-white solid (65, 0.094 g, 85% yield). 
Rf = 0.33 (5% MeOH/DCM); mp = 184 – 186 °C; 1H NMR (300 MHz, DMSO-d6) δ 11.69 – 8.81 (br.s, 2H, 
2 × NH), 7.91 (br.s, 1H, NH), 7.25 (d, J = 8.6 Hz, 2H, 2 × ArH), 7.00 (d, J = 8.3 Hz, 1H, ArH4), 6.90 (d, J = 
8.6 Hz, 2H, 2 × ArH), 6.57 (d, J = 2.0 Hz, 1H, ArH7), 6.35 (dd, J = 8.3, 2.0 Hz, 1H, ArH5), 5.01 – 4.32 (br.s, 
2H, NH2), 4.32 (d, J = 5.8 Hz, 2H, CH2), 3.73 (s, 3H, OCH3); 13C NMR (101 MHz, DMSO-d6) δ 158.3, 154.7, 
147.1, 143.2, 136.2 (weak br.s), 131.8, 128.5, 113.8, 109.3, 97.8, 55.1, 42.3; two carbon signals were 
not visible in the spectrum; FT-IR (ATR mode) 3388 (N-H stretch), 3338 (N-H stretch), 1647, 1604, 1506, 
1483, 1242, 1221, 1175, 1030, 830, 816, 736 cm-1; HRMS (ESI) m/z calcd for C16H18N5O2, [M+H]+: 
312.1460, found 312.1457. 
X-ray crystal structure determination (65) 
Table 9.2: Selected crystallographic data of compound 65 
Molecular formula (dimer) C32H30N10O4 § 
Mr/ g.mol-1 618.66 § 
Temperature/ K 100 
Crystal system Monoclinic 






                                                          
§ Four hydrogens are absent in the molecular formula and molar mass of the dimer in the asymmetric unit, since 
the location of the primary amine protons could not be located in the electron density map. 




V / 3 1426.7(5) 
Z 2 
/mm-1 0.10 
R1 [I > 2(I)] 0.037 
wR2 (F2) 0.183 
 
Table 9.3: Hydrogen-bond geometry (Å, °) for 65 
D—H···A D—H H···A D···A D—H···A 
N6—H6···O3i 0.87 2.32 3.125 154 
N1—H1···O1ii 0.93 2.21 3.137 174 
N2—H2···N8 0.91 1.96 2.862 170 
N3—H3···O1 0.95 2.09 2.715 122 
C25—H25A···N10iii 0.96 2.53 3.471 165.6 
N4—H10···N7 1.15 1.70 2.837 170 
Symmetry codes: (i) x+1, y, z; (ii) x−1, y, z; (iii) −x+1, y−1/2, −z. 
General procedure for the synthesis of acrylamides 13 – 14 from their amine precursors. 
THF and NEt3 (1.1 equiv) were added to a stirred solution of the aminobenzazole urea (1.0 equiv) in 
DMF. The mixture was cooled to 0 °C before the dropwise addition of acryloyl chloride (1.1 equiv). The 
reaction mixture was left to stir at 0 °C for 30 min and then at r.t. for 45 min. The mixture was 
quenched with H2O (10 mL) and concentrated in vacuo. The crude product was diluted with EtOAc 
(60 mL) and washed with H2O (4 × 20 mL). A small amount of product remained in the aqueous layer, 
therefore the combined aqueous layer was extracted with EtOAc (3 × 30 mL) and the newly formed 
organic layer (90 mL) was washed with H2O (3 × 20 mL). All organic layers were combined, dried over 
MgSO4, filtered and concentrated in vacuo. The pure product was isolated by column chromatography. 
N-{2-[3-(4-methoxybenzyl)ureido]benzo[d]thiazol-6-yl}acrylamide (13) 
Prepared according to the general procedure, utilising THF (2 
mL), DMF (1 mL), 1-(6-aminobenzo[d]thiazol-2-yl)-3-(4-
methoxybenzyl)urea (64, 0.100 g, 0.305 mmol), NEt3 (0.05 mL, 
0.34 mmol) and acryloyl chloride (0.030 g, 0.33 mmol). 
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Column chromatography (5% MeOH/DCM) afforded 13 as a white solid (0.063 g, 54% yield). 
Rf = 0.22 (5% MeOH/DCM); mp = 192 – 195 °C; 1H NMR (300 MHz, DMSO-d6) δ 10.67 (br.s, 1H, NH), 
10.23 (s, 1H, NHCOCHCH2), 8.30 (d, J = 1.8 Hz, 1H, ArH7), 7.56 (d, J = 8.7 Hz, 1H, ArH4), 7.51 (dd, J = 8.7, 
1.8 Hz, 1H, ArH5), 7.25 (d, J = 8.7 Hz, 2H, ArH2’+6’), 7.13 (br.t, 1H, HNCH2), 6.91 (d, J = 8.7 Hz, 2H, ArH3’+5’), 
6.45 (dd, 3Jtrans = 17.0, 3Jcis = 10.0 Hz, 1H, NHCOCHCH2), 6.26 (dd, 3Jtrans = 17.0, 2Jgem = 2.2 Hz, 1H, 
NHCOCHCH2), 5.75 (dd, 3Jcis = 10.0, 2Jgem = 2.2 Hz, 1H, NHCOCHCH2), 4.30 (d, J = 5.8 Hz, 2H, HNCH2), 
3.73 (s, 3H, OCH3); 13C NMR (75 MHz, DMSO-d6) δ 163.0 (NHCOCHCH2), 159.0 (ArC2), 158.4 (ArC4’), 
153.8 (HNCONH), 145.3 (ArC3a), 134.3 (ArC6), 131.9 (NHCOCHCH2), 131.3 (ArC1’), 128.7 (ArC2’+6’H), 
126.7 (NHCOCHCH2), 119.6 (ArC4H), 118.3 (ArC5H), 113.8 (ArC3’+5’H), 111.7 (ArC7H), 55.1 (OCH3), 42.5 
(HNCH2), one quaternary carbon signal was not visible in the spectrum; FT-IR (ATR mode) 3267 (N-H 
stretch), 1678 (C=O stretch), 1656 (C=O stretch), 1612, 1536, 1513, 1455, 1408, 1269, 1240, 1225, 
1196, 1176, 826 cm-1; HRMS (ESI) m/z calcd for C19H19N4O3S, [M+H]+: 383.1178, found 383.1180; UPLC: 
Purity 94%, r.t = 5.43 min, acetonitrile/H2O (0.1% formic acid) 5/95. 
1H,13C gHSQC NMR (300/300 MHz, DMSO-d6) δ 1H/ δ 13C 8.30/111.7 (ArH7/ ArC7H), 7.56/119.6 (ArH4/ 
ArC4H), 7.51/118.3 (ArH5/ ArC5H), 7.25/128.7 (ArH2’+6’/ArC2’+6’H), 6.91/113.8 (ArH3’+5’/ArC3’+5’H), 
6.45/131.9 (NHCOCHCH2/NHCOCHCH2), 6.26/126.7 (NHCOCHCHtrans/NHCOCHCH2), 5.75/126.7 
(NHCOCHCHcis/NHCOCHCH2), 4.30/42.5 (HNCH2/ HNCH2), 3.73/55.1 (OCH3/OCH3); 
1H,13C gHMBC NMR (300/300 MHz, DMSO-d6) δ 1H/ δ 13C 10.23/ 163.0, 134.3, 118.3, 111.7 
(NHCOCHCH2/ NHCOCHCH2, ArC6, ArC5H, ArC7H), 8.30/ 145.3, 134.3, 118.3 (ArH7/ ArC3a, ArC6, ArC5H), 
7.56/ 134.3, (ArH4/ ArC6), 7.51/ 145.3, 111.7 (ArH5/ ArC3a, ArC7H), 7.25/ 158.4, 128.7, 113.8, 42.5 
(ArH2’+6’/ ArC4’, ArC2’+6’H, ArC3’+5’H, HNCH2), 7.13/ 153.8 (HNCH2/ HNCONH), 6.91/ 158.4, 131.3, 113.8  
(ArH3’+5’/ ArC4’, ArC1’, ArC3’+5’H), 6.45/ 163.0, 126.7 (NHCOCHCH2/ NHCOCHCH2, NHCOCHCH2), 6.26/ 
163.0, 131.9 (NHCOCHCHtrans/ NHCOCHCH2, NHCOCHCH2), 5.75/ 163.0 (NHCOCHCHcis/ NHCOCHCH2), 
4.30/ 153.8, 131.3, 128.7 (HNCH2/ HNCONH, ArC1’, ArC2’+6’H), 3.73/ 158.4 (OCH3/ ArC4’). 
The 2D NMR spectra assignments (gHSQC and gHMBC) for N-{2-[3-(4-
methoxybenzyl)ureido]benzo[d]thiazol-6-yl}acrylamide (13) 
13C (δ ppm) gHSQC (δ ppm) gHMBC (δ ppm) Carbon assignment 
42.5 4.30 7.25 HNCH2 
55.1 3.73 – OCH3 
111.7 8.30 10.23, 7.51 ArC7H 
113.8 6.91 7.25, 6.91 ArC3’+5’H 
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118.3 7.51 (dd) 10.23, 8.30 ArC5H 
119.6 7.56 – ArC4H 
126.7 6.26, 5.75 6.45 NHCOCHCH2 
128.7 7.25 7.25, 4.30 ArC2’+6’H 
131.3 – 6.91, 4.30 ArC1’ 
131.9 6.45 6.26 NHCOCHCH2 
134.3 – 10.23, 8.30, 7.56 ArC6 
145.3 – 8.30, 7.51 ArC3a 
153.8 – 7.13, 4.30 HNCONH 
158.4 – 7.25, 6.91, 3.73 ArC4’ 
159.0 – – ArC2 
163.0 – 10.23, 6.45, 6.26, 5.75 NHCOCHCH2 
 
N-{2-[3-(4-methoxybenzyl)ureido]-1H-benzo[d]imidazol-6-yl}acrylamide (14) 
Prepared according to the general procedure, utilising THF (4 
mL), DMF (2 mL), 1-(6-amino-1H-benzo[d]imidazol-2-yl)-3-(4-
methoxybenzyl)urea (65, 0.230 g, 0.739 mmol), NEt3 (0.11 mL, 
0.79 mmol) and acryloyl chloride (0.070 g, 0.77 mmol). 
Column chromatography (7% MeOH/30% EtOAc/DCM) 
afforded 14 as a white solid (0.109 g, 40% yield). 
Rf = 0.24 (7% MeOH/30% EtOAc/DCM); mp = 188 – 192 °C; 1H NMR (400 MHz, DMSO-d6) δ 11.49 (br.s, 
1H, NH), 10.01 (s, 1H, NHCOCHCH2), 9.92 (br.s, 1H, NH), 7.86 (s, 1H, ArH7), 7.72 (br.s, 1H, NH), 7.27 – 
7.25 (m, 3H, ArH2’+6’, ArH4), 7.22 (dd, J = 8.6, 1.2 Hz, 1H, ArH5), 6.91 (d, J = 8.7 Hz, 2H, ArH3’+5’), 6.45 (dd, 
3Jtrans = 17.0, 3Jcis = 10.1 Hz, 1H, NHCOCHCH2), 6.23 (dd, 3Jtrans = 17.0, 2Jgem = 2.1 Hz, 1H, NHCOCHCH2), 
5.70 (dd, 3Jcis = 10.1, 2Jgem = 2.1 Hz, 1H, NHCOCHCH2), 4.33 (d, J = 5.8 Hz, 2H, HNCH2), 3.73 (s, 3H, OCH3); 
13C NMR (101 MHz, DMSO-d6) δ 162.7 (NHCOCHCH2), 158.3 (ArC4’), 154.3 (HNCONH), 148.6, 132.7 
(ArC3a/6/7a), 132.3 (NHCOCHCH2), 131.6 (ArC1’), 128.6 (ArC2’+6’H), 126.0 (NHCOCHCH2), 113.8 (ArC3’+5’H), 
113.4 (ArC5H), 104.3 (weak br.s), 55.1 (OCH3), 42.3 (HNCH2); three carbon signals were not visible in 
the spectrum; FT-IR (ATR mode) 3281 (N-H stretch), 1653, 1548, 1510, 1483, 1218, 1176, 803, 741 
cm-1; HRMS (ESI) m/z calcd for C19H20N5O3, [M+H]+: 366.1566, found 366.1569; UPLC: Purity 95%, r.t = 
3.73 min, acetonitrile/H2O (0.1% formic acid) 5/95. 
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1H,13C gHSQC NMR (400/400 MHz, DMSO-d6) δ 1H/ δ 13C 7.27 – 7.25 (m)/128.6 (ArH2’+6’/ ArC2’+6’H), 
7.22/113.4 (ArCH5/ArC5H), 6.91/113.8 (ArC3’+5’H/ ArC3’+5’H), 6.45/132.3 (NHCOCHCH2/ NHCOCHCH2), 
6.23/126.0 (NHCOCHCHtrans/ NHCOCHCH2), 5.70/126.0 (NHCOCHCHcis/ NHCOCHCH2), 4.33/42.3 
(HNCH2/ HNCH2), 3.73/55.1 (OCH3/OCH3); 
1H,13C gHMBC NMR (400/400 MHz, DMSO-d6) δ 1H/ δ 13C 10.01/ 162.7, 132.3, 113.4 (NHCOCHCH2/ 
NHCOCHCH2, NHCOCHCH2, ArC5H), 7.86/ 132.7, 113.4 (ArH7/ ArC3a/6/7a , ArC5H), 7.27 – 7.25/ 158.3, 
132.7, 128.6, 113.8, 42.3 (ArH2’+6’, ArH4 / ArC4’, ArC3a/6/7a , ArC2’+6’H, ArC3’+5’H, HNCH2), 6.91/ 158.3, 
131.6, 128.6, 113.8 (ArH3’+5’/ ArC4’, ArC1’, ArC2’+6’H, ArC3’+5’H), 6.45/ 162.7, 126.0 (NHCOCHCH2/ 
NHCOCHCH2, NHCOCHCH2), 6.23/ 162.7, 132.3 (NHCOCHCH2/ NHCOCHCH2, NHCOCHCH2), 5.70/ 162.7, 
132.3 (NHCOCHCH2/ NHCOCHCH2, NHCOCHCH2), 4.33/154.3, 131.6, 128.6 (HNCH2/ HNCONH, ArC1’, 
ArC2’+6’H), 3.73/158.3 (OCH3/ArC4’). 
Table 9.4: The 2D NMR spectra assignments (gHSQC and gHMBC) for N-{2-[3-(4-
methoxybenzyl)ureido]-1H-benzo[d]imidazol-6-yl}acrylamide (14) 
13C (δ ppm) gHSQC (δ ppm) gHMBC (δ ppm) Carbon assignment 
42.3 4.33 7.27 – 7.25 (2 × ArH) HNCH2 
55.1 3.73 – OCH3 
104.3 – – unknown 
113.4 7.22 10.01, 7.86 ArC5H 
113.8 6.91 7.27 – 7.25, 6.91 ArC3’+5’H 
126.0 5.70, 6.23 6.45 NHCOCHCH2 
128.6 7.27 – 7.25 (m) 7.27 – 7.25, 6.91, 4.33 ArC2’+6’H 
131.6 – 6.91, 4.33 ArC1’ 
132.3 6.45 10.01, 6.23, 5.70 NHCOCHCH2 
132.7 – 7.86, 7.27 – 7.25 (ArH4) ArC3a/6/7a 
148.6 – – unknown 
154.3 – 4.33 HNCONH 
158.3 – 7.27 – 7.25, 6.91, 3.73 ArC4’ 
162.7 – 10.01, 6.45, 6.23, 5.70 NHCOCHCH2 
 
ArC5H is the only carbon in the benzimidazole ring that could be assigned. The other carbons (C2, C3a, 
C4, C6, C7, C7a) were either absent from the 13C NMR spectrum or could not be assigned with the use of 
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the available 2D NMR results. A total of three carbon signals were missing from the 13C NMR spectrum, 
and three carbon signals (δ 104.3, 132.7, 148.6 ppm) could not be assigned. 
 
General procedure for the synthesis of the Weinreb amides (62 – 63).43–45 
Reactions were performed under argon, using glassware that was oven-dried overnight. 
2-Bromopropane was freshly distilled from calcium hydride under argon. N,O-Dimethylhydroxylamine 
hydrochloride was dried overnight under vacuum, in a 40 °C oil bath. Mg turnings were dried in the 
oven (120 °C) overnight. 
Preparation of the Grignard reagent, isopropylmagnesium bromide 
Mg turnings (1.50 g, 61.7 mmol, 1.5 equiv) and THF (20 mL) were placed in a 2-neck flask with a rubber 
septum. In order to initiate the reaction, a small allocate (1 mL) of the required 2-bromopropane 
(3.8 mL, 40 mmol, 1.0 equiv) was added to the stirred solution at r.t. and then the reaction flask was 
warmed by hand. When the reaction mixture started to dissipate heat, the rest of the 
2-bromopropane was added by slow dropwise addition. The mixture was left to stir for 30 min or until 
the reaction mixture had cooled down. 
The Grignard reagent was titrated at r.t., by the dropwise addition of isopropylmagnesium bromide to 
a stirred solution of menthol (0.239 g, 1.53 mmol, 1.0 equiv) and 1,10 phenanthroline (5 mg, 
0.03 mmol, 0.02 equiv) in THF (10 mL). The end-point was characterised by a distinct pink colour that 
persisted for longer than a minute. 
Conversion of the ester to the Weinreb amide 
The ester (1.0 equiv) and N,O-Dimethylhydroxylamine hydrochloride (2.0 equiv) were suspended in 
THF. The suspension was cooled to −20 °C with an acetonitrile/dry ice bath, before the dropwise 
addition of isopropylmagnesium bromide solution. The reaction mixture was left to stir for 1 h, 
allowing it to reach −5 °C. The bright yellow solution was quenched with sat. aq. NH4Cl (15 mL), 
extracted with a mixture of 10% MeOH/DCM (3 × 35 mL) and washed with brine (30 mL). The organic 
layer was dried over MgSO4, filtered and concentrated under reduced pressure. The crude product 
was purified by column chromatography to yield the Weinreb amides 62 – 63. 
 
 




Prepared according to the general procedure, with the following 
amounts: Methyl 2-[3-(4-
methoxybenzyl)ureido]benzo[d]thiazole-6-carboxylate (57, 
0.988 g, 2.66 mmol), N,O-dimethylhydroxylamine hydrochloride 
(0.519 g, 5.32 mmol), THF (26 mL) and  isopropylmagnesium 
bromide (1.3 M in THF, 11.8 mL, 15 mmol, 5.6 equiv). The crude product was purified by column 
chromatography (2% MeOH/30% EtOAc/DCM) to afford 62 as a white solid (0.863 g, 81% yield). 
Rf = 0.25 (40% EtOAc/DCM); mp = 190 – 193 °C; 1H NMR (400 MHz, DMSO-d6) δ 10.90 (br.s, 1H, NH), 
8.18 (s, 1H, ArH7) 7.65 – 7.60 (m, 2H, ArH4,5), 7.26 (d, J = 8.7 Hz, 2H, 2 × ArH), 7.17 (br.t, 1H, NH), 6.91 
(d, J = 8.7 Hz, 2H, 2 × ArH), 4.31 (d, J = 5.8 Hz, 2H, CH2), 3.73 (s, 3H, Ph-OCH3), 3.56 (s, 3H, NOCH3), 3.27 
(s, 3H, NCH3); 13C NMR (101 MHz, DMSO-d6) δ 168.8, 161.9, 158.4, 153.7, 150.7, 131.1, 128.7, 128.3, 
125.9, 121.7, 118.8, 113.8, 60.6, 55.1, 42.5, 33.6, one quaternary carbon missing in the spectrum; 
FT-IR (ATR mode) 3311 (N-H stretch), 1668 (C=O stretch), 1604, 1560, 1513, 1447, 1271, 1236, 1177, 
1035, 832, 806, 753, 716 cm-1; HRMS (ESI) m/z calcd for C19H21N4O4S, [M+H]+: 401.1284, found 
401.1284. 
N-methoxy-2-[3-(4-methoxybenzyl)ureido]-N-methyl-1H-benzo[d]imidazole-6-carboxamide (63) 
Prepared according to the general procedure, with the following 
amounts: Methyl 2-[3-(4-methoxybenzyl)ureido]-1H-
benzo[d]imidazole-6-carboxylate (60, 0.450 g, 1.27 mmol), N,O-
dimethylhydroxylamine hydrochloride (0.248 g, 2.54 mmol), THF 
(15 mL) and isopropylmagnesium bromide (1.4 M in THF, 6.4 mL, 
9.0 mmol, 7.1 equiv). The pure product was isolated by column chromatography (2% MeOH/60% 
EtOAc/DCM) to yield a white solid (63, 0.381 g, 78% yield). 
Rf = 0.14 (60% EtOAc/DCM), mp = 158 – 160 °C; 1H NMR (300 MHz, DMSO-d6) δ 11.79 (br.s, 1H, NH), 
10.07 (br.s, 1H, NH), 7.68 (s, 1H, ArH7), 7.58 (br.t, 1H, NH), 7.39 – 7.32 (m, 2H, ArH4,5), 7.27 (d, J = 
8.7 Hz, 2H, 2 × ArH), 6.91 (d, J = 8.7 Hz, 2H, 2 × ArH), 4.33 (d, J = 5.8 Hz, 2H, CH2), 3.73 (s, 3H, Ph-OCH3), 
3.55 (s, 3H, NOCH3), 3.25 (s, 3H, NCH3); 13C NMR (75 MHz, DMSO-d6) δ 169.9, 158.3, 154.1, 149.6, 
131.5, 128.6, 126.0, 121.2, 113.1, 60.4, 55.1, 42.3, 33.8, four carbon signals missing in the spectrum; 
FT-IR (ATR mode) 3392 (N-H stretch), 3319 (N-H stretch), 1672 (C=O stretch), 1650, 1628, 1594, 1509, 
1245, 1223, 1174, 1030, 993, 835, 816 cm-1; HRMS (ESI) m/z calcd for C19H22N5O4, [M+H]+: 384.1672, 
found 384.1671. 
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General Grignard reaction procedure to synthesise ketones 9 – 12.46 
The Weinreb amide (1.0 equiv) was suspended in THF (4 mL) and was cooled to −20 °C with an 
acetonitrile/dry ice bath, before the dropwise addition of the Grignard reagent. The reaction mixture 
was monitored by TLC to determine the amount of Grignard reagent to be added. The reaction mixture 
was left to stir 45 min in between portions of Grignard reagent. Finally, the reaction mixture was 
stirred for 20 h, wherein the mixture was allowed to reach 15 °C. The transparent yellow solution was 
transferred dropwise into a stirred solution of 1 M aq. NaHSO4 (30 mL) at 0 °C and was left to stir for 
1 h at 0 °C. The mixture was allowed to reach r.t. and was extracted with EtOAc (3 × 25 mL). The organic 
layer was washed with brine (20 mL), dried over MgSO4, filtered and concentrated in vacuo. The pure 
product was obtained by column chromatography. 
1-(6-Acryloylbenzo[d]thiazol-2-yl)-3-(4-methoxybenzyl)urea (9) 
Prepared according to the general procedure with Weinreb 
amide 62 (0.110 g, 0.275 mmol) and vinylmagnesium bromide 
(1 M in THF, 2.6 mL, 2.6 mmol, 9.5 equiv). A major by-product 
formed which was only visible when the TLC plate was stained 
with p-anisaldehyde stain. The product was purified by column 
chromatography (1% MeOH/10% Hexane/30% EtOAc/DCM) to yield 9 as a white solid (0.026 g, 26% 
yield). 
Rf = 0.47 (40% EtOAc/DCM); mp = > 150 °C decomp; 1H NMR (400 MHz, DMSO-d6) δ 11.05 (br.s, 1H, 
NH), 8.65 (s, 1H, ArH7), 8.02 (dd, J = 8.5, 1.5 Hz, 1H, ArH5), 7.70 (d, J = 8.5 Hz, 1H, ArH4), 7.50 (dd, 3Jtrans 
= 16.9, 3Jcis = 10.4 Hz, 1H, COCHCH2), 7.26 (d, J = 8.5 Hz, 2H, 2 × ArH), 7.20 (br.s, 1H, NH), 6.91 (d, J = 
8.5 Hz, 2H, 2 × ArH), 6.36 (dd, 3Jtrans = 16.9, 2Jgem = 1.7 Hz, 1H, COCHCH2), 5.96 (dd, 3Jcis = 10.4, 2Jgem = 
1.7 Hz, 1H, COCHCH2), 4.31 (d, J = 5.8 Hz, 2H, HNCH2), 3.73 (s, 3H, OCH3); 13C NMR (101 MHz, DMSO-d6) 
δ 188.4 (COCHCH2), 163.5, 158.4, 153.6, 153.0, 132.3, 131.9, 131.3, 131.1, 129.7, 128.7, 126.6, 123.1, 
119.5, 113.8, 55.1, 42.5; FT-IR (ATR mode) 3295 (N-H stretch), 1672 (C=O stretch), 1608, 1555, 1512, 
1454, 1275, 1229, 1177, 1032, 785 cm-1; HRMS (ESI) m/z calcd for C19H18N3O3S, [M+H]+: 368.1069, 









Prepared according to the general procedure with Weinreb 
amide 62 (0.100 g, 0.250 mmol) and ethynylmagnesium bromide 
(0.5 M in THF, 6.5 mL, 3.3 mmol, 13 equiv). Column 
chromatography (1% MeOH/10% Hexane/30% EtOAc/DCM) 
afforded 11 as a light yellow solid (0.069 g, 76% yield). 
Rf = 0.62 (40% EtOAc/DCM); mp = > 185 °C decomp; 1H NMR (300 MHz, DMSO-d6) δ 11.15 (br.s, 1H, 
NH), 8.69 (d, J = 1.7 Hz, 1H, ArH7), 8.06 (dd, J = 8.5, 1.7 Hz, 1H, ArH5), 7.73 (d, J = 8.5 Hz, 1H, ArH4), 7.27 
– 7.21 (m, 3H, 2 × ArH, NH), 6.91 (d, J = 8.7 Hz, 2H, 2 × ArH), 5.06 (s, 1H, COCCH), 4.31 (d, J = 5.8 Hz, 
2H, HNCH2), 3.73 (s, 3H, OCH3); 13C NMR (75 MHz, DMSO-d6) δ 175.8 (COCCH), 164.5, 158.4, 154.3, 
153.6, 132.2, 131.0, 130.5, 128.7, 127.1, 124.1, 119.6, 113.9, 84.9 (C≡C), 80.5 (C≡C), 55.1, 42.6; FT-IR 
(ATR mode) 3291 (N-H stretch), 3252 (N-H stretch), 2096 (C≡C stretch), 1672 (C=O stretch), 1642, 1603, 
1554, 1535, 1511, 1450, 1269, 1242, 1225, 1028, 757 cm-1; HRMS (ESI) m/z calcd for C19H16N3O3S, 
[M+H]+: 366.0912, found 366.0910; UPLC: Purity 96%, r.t = 5.59 min, acetonitrile/H2O (0.1% formic 
acid) 0/100. 
1-(6-Acryloyl-1H-benzo[d]imidazol-2-yl)-3-(4-methoxybenzyl)urea (10) 
Prepared according to the general procedure with Weinreb amide 
63 (0.100 g, 0.261 mmol) and vinylmagnesium bromide (1 M in 
THF, 2.9 mL, 2.9 mmol, 11 equiv). A major by-product formed 
which was only visible when the TLC plate was stained with 
p-anisaldehyde stain. The product was purified by column 
chromatography (1% MeOH/20% DCM/60% EtOAc/Hexane) to yield 10 as a light yellow solid (0.010 g, 
11% yield). 
Rf = 0.38 (60% EtOAc/DCM), 1H NMR (400 MHz, DMSO-d6) δ 11.95 (br.s, 1H, NH), 10.17 (br.s, 1H, NH), 
8.05 (s, 1H, ArH7), 7.78 (d, J = 8.0 Hz, 1H, ArH), 7.51 – 7.44 (m, 3H, COCHCH2, NH, ArH), 7.27 (d, J = 
8.5 Hz, 2H, 2 × ArH), 6.91 (d, J = 8.5 Hz, 2H, 2 × ArH), 6.31 (dd, 3Jtrans = 16.9, 2Jgem = 1.8 Hz, 1H, COCHCH2), 
5.91 (d, 3Jcis = 11.3 Hz, 1H, COCHCH2), 4.33 (d, J = 5.7 Hz, 2H, HNCH2), 3.73 (s, 3H, OCH3); HRMS (ESI) 








Prepared according to the general procedure with Weinreb 
amide 63 (0.100 g, 0.261 mmol) and ethynylmagnesium bromide 
(0.5 M in THF, 10.4 mL, 5.20 mmol, 20 equiv). The reaction 
mixture was stirred at 40 °C during the 20 h period in the general 
procedure. Column chromatography (1% MeOH/10% 
Hexane/50% EtOAc/DCM) afforded 12 as a light yellow solid (0.014 g, 15% yield). 
Rf = 0.50 (60% EtOAc/DCM), mp = > 160 °C decomp, mp 208 – 210 °C; 1H NMR (400 MHz, DMSO-d6) 
δ 12.08 (br.s, 1H, NH), 10.28 (br.s, 1H, NH), 8.18 (br.s, 1H, ArH), 7.85 (d, J = 8.2 Hz, 1H, ArH), 7.33 – 
7.60 (br.s, 2H, ArH, NH), 7.27 (d, J = 8.6 Hz, 2H, 2 × ArH), 6.91 (d, J = 8.6 Hz, 2H, 2 × ArH), 4.95 (s, 1H, 
COCCH), 4.33 (d, J = 5.8 Hz, 2H, HNCH2), 3.73 (s, 3H, OCH3); 13C NMR (101 MHz, DMSO-d6) δ 176.3 
(COCCH), 158.3, 153.9, 151.5, 131.4, 128.6, 123.4, 115.9, 113.8, 112.9, 83.8 (C≡C), 80.9 (C≡C), 55.1, 
42.4; three carbon signals were not visible in the spectrum; HRMS (ESI) m/z calcd for C19H17N4O3, 
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